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Abstract
This thesis is divided into two main chapters. The first chapter relates to studies
undertaken to gain insights into the mechanism of action on liver growth by the
peroxisome proliferator (PP) ciprofibrate and the chemical cyproterone acetate
(CPA) in rodents. Peroxisome proliferators are a class of chemicals that have diverse
effects in rats and mice including increased DNA synthesis and peroxisome
proliferation. Peroxisome proliferators include herbicides, plasticisers, hypolipidemic
drugs and synthetic fatty acids. These chemicals act through ligand activation of
nuclear membrane receptors termed ‘peroxisome-proliferator-activated receptors’
(PPARs), which ultimately activate nuclear transcription.
PPs induce a cellular process in liver characterised by dramatic increases in the size
and number of peroxisomes, correlated with both hepatocyte hypertrophy (i.e. an
increase in the size of liver cells) and hyperplasia (i.e. an increase in the number of
liver cells during replicative DNA synthesis and cell division). However, the
mechanism of action of increased hepatocyte growth is not currently understood.
Understanding the mechanism by which increased liver growth is induced by PPs in
rodents will hopefully provide insights into how natural liver growth occurs and
might have medical benefits for human health if the mechanism of PP toxicity can be
overcome. Knowledge gained from the mechanism of PP activation might also then
be applied to other chemical carcinogens. Therefore, firstly the mode of action of the
peroxisome proliferator ciprofibrate was investigated. Previous work had indicated
that two successive doses of ciprofibrate treatment separated by 24hr led to two
rounds of liver cell replication, but it was not clear whether the same or different
hepatocytes were involved in this growth response. To study this phenomenon,
histochemical experimental work was undertaken to assess whether the same or
different hepatocyte cells were stained during the two rounds of cell division
following ciprofibrate treatment. The two histochemical stains used were EdU and
BrdU, which are both base-pair analogues that stain nuclei undergoing DNA
replication. It was hypothesized that if EdU was used to stain cells at 24 hr and then
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BrdU at 48 hr, that if the same cells were responding to ciprofibrate treatment then
cells would be co-stained by both dyes, whereas if different cells were responding
then there would be little or no double staining of hepatocyte cells. It was found that
different cells were stained by the two dyes, indicating that ciprofibrate treatment
was targeting different cells. Secondly, the mode of action of the carcinogen
cyproterone acetate (CPA) on hepatocyte growth was investigated. Previous work
had investigated the effects of CPA on hepatocyte growth in male and female rats
and had suggested differences in response between the sexes. In the present study
female rats were treated with CPA, to assess whether differences in labelling indices
were present compared to previous male results. Female F-344/NHsd rats, aged 14-
15 weeks, were treated with CPA and then injected with BrdU at 22 hr, and rats were
killed 2 hr later. Results confirmed that the female rats had a considerably higher
labelling index (50%) compared to male rats (6%). This suggested that upregulation
of gene expression in female rats was much higher, which might provide an exciting
opportunity to identify sets of genes involved in carcinogenic responses. To
investigate whether there was any overlap between genes induced by ciprofibrate and
CPA treatment a preliminary study was designed where female rats were gavaged
with CPA and then killed 3 hr later. Real-time PCR analysis of a small number of
target genes showed no consistent changes in expression between the present CPA
and previous ciprofibrate treatment results, suggesting largely different modes of
action of these chemicals.
The second chapter of this thesis relates to studies undertaken to gain insights into
neurodegenerative disorders. Neurodegeneration is a gradual loss of structure or
function of neurons, which may lead to neuronal death. Neurodegenerative diseases
including Parkinson’s, Alzheimer’s, and Huntington’s occur as a result of
neurodegenerative changes. Several studies have suggested that PPARs have critical
roles in reducing the brain inflammation which in turn might have a significant effect
on reducing the fundamental processes involved. Work was performed using a
mouse model of dementia with lewy body disease (Psmc1fl/fl &D0.,,Į&UH WR
represent neurodegenerative disorder, and involved parallel, in vivo and in vitro
investigations to determine whether the development of neurodegenerative diseases
occurs at the same rate in vitro and in vivo i.e. a comparison of rapidity of
Vpathogenicity progression was made. Astrocytes were used to track the development
of disease, given that these play a key role in neurological disorders, using an
LPPXQRKLVWRFKHPLVWU\ DSSURDFK $ 33$5Ȗ DQDORJXH ZDV XVHG WR LQYHVWLJDWH WKH
role of PPARs in reducing astrocytes proliferation. To optimise the validity of the
results, four controls were used including an antagonist T0070907 which abolished
WKH HIIHFW RI URVLJOLWD]RQH WUHDWPHQW DORQH 7KH UHVXOWV RQ WKH HIIHFW RI 33$5Ȗ
DJRQLVWDQGURVLJOLWD]RQHDIWHUDZHHNRIWUHDWPHQWVKRZHGWKDWWKH33$5ȖDJRQLVW
inhibited astrocytes activation in both the cortex and hippocampus of the mutant
mice organotypic slice culture. The number of GFAP +ve astrocytes was significantly
decreased in mutant mice with 100 µM rosiglitazone in both areas, whereas 50 µM
rosiglitazone showed a decrease in the number of astrocytes in the cortex, but the
effect was less in the region of the hippocampus. This finding suggests that PPs such
as rosiglitazone may have potential uses as therapeutic drugs to inhibit
neurodegeneration.
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General Introduction
Peroxisome proliferators (PPs) are non-genotoxic carcinogens known for their ability
to cause hepatocarcinogensis in laboratory rodents. These chemicals act through
nuclear receptors known as peroxisome proliferator-activated receptors (PPARs)
(Gill, James et al. 1998). The mechanism by which non-genotoxic peroxisome
proliferators induce hepatic tumours is not fully understood.
Three isoforms of peroxisome proliferator-activated receptors (PPARs) have been
LGHQWLILHGĮȖDQGȕ $OO WKH33$5VLVRIRUPVKHWHURGLPHULVHZLWKWKHUHWLQRLG;
receptor (RXR) and bind to specific regions on the DNA of target genes called
peroxisome proliferator hormone response elements (PPREs) (IJpenberg, Jeannin et
al. 1997, Mandard, Müller et al. 2004). These receptors have a strong binding affinity
for both saturated and unsaturated fatty acids.
Humans are exposed to peroxisome proliferators including hypolipidemic agents,
herbicides, plasticizers, industrial solvents and natural products. Some studies have
reported that long-term administration of peroxisome proliferators results in liver
cells being subjected to persistent oxidative stress resulting from marked
proliferation of peroxisomes and a consequent differential increase in the levels of
H2O2 (over a 20-fold increase) and increased activity of certain degradative enzymes
(a two-fold increase) (Dhaunsi, Singh et al. 1994, O'Brien, Spear et al. 2005).
This study follows on from a previous study at Nottingham (Amer 2011) on the
mechanism of action of liver growth by peroxisome proliferators. It also addresses
the role of these peroxisome proliferators in nervous system degeneration.
The study aims to investigate the role of PP and PPARs in two systems; the liver and
the brain. On this basis the thesis has been divided into two main parts investigating
the role of peroxisome proliferators: firstly a part focusing on liver growth, and
secondly a part focuses on neurodegenerative disorders.
The first part is devoted to the non-genotoxic carcinogenic peroxisome proliferator
‘ciprofibrate’ and the steroidal genotoxic carcinogen cyproterone acetate (CPA) in a
liver system. This follows on from previous studies by Amer (2011) where many
XXX
genes were identified which were upregulated at early time points of acute response
to ciprofibrate or CPA. Some interesting genes were chosen for follow up work in
this study because microarray analysis and the RNA sequences work suggested that
some genes were jointly highly expressed in response to dosing with ciprofibrate.
This allowed a comparison of expression to be made between ciprofibrate and CPA
in the present study using the real time PCR technique. In particular, investigations
were made to gain insights into whether these whether these chosen genes might be
part of a shared pathway(s), and if so to consider the implications for shared or
different mechanisms of action of CPA and ciprofibrate. Also the previous CPA
study was conducted using male rats, whereas the present study used female rats,
since there was a suggestion from previous work (Amer 2011) that levels of DNA
synthesis and genes induction were much higher in female rats but this had to be
confirmed.
The second part of the study was dedicated to a study of the role of peroxisome
SUROLIHUDWRUDFWLYDWHGUHFHSWRUȖ33$5ȖLQDQHXURGHJHQHUDWLYHGLVRUGHU$PRXVH
model of Parkinson's disease (PD) was used. Neurodegeneration refers to the
pathological changes in the brain resulting from loss of neuron leading to
deterioration of brain function. At a cellular level, neurodegeneration is seen as a
gradual loss of structure or function of neurons which predominantly leads to
neuronal death.
3HUR[LVRPHSUROLIHUDWRUDFWLYDWHGUHFHSWRUȖ33$5ȖLVH[SUHVVHGE\PDFURSKDJHV
endothelial cells, and vascular smooth muscle cells. It regulates gene expression of
proteins involved in lipid metabolism, vascular inflammation, and proliferation
contributing to atherogenesis and post-angioplasty restenosis (Nagy, Tontonoz et al.
&KLQHWWL)UXFKDUWHWDO7KHGLVFRYHU\RIV\QWKHWLFOLJDQGVIRU33$5Ȗ
has led to significant enhancement of understanding of the mechanism of their
ligand-dependent activation and subsequent biological effects, particularly with
UHVSHFWWRWKHUROHRI33$5ȖLQQHXURSURWHFWLYHDFWLYLW\E\33$5ȖDJRQLVW
3HUR[LVRPHSUROLIHUDWRUDFWLYDWHGUHFHSWRUJDPPD33$5ȖKDVEHHQLPSOLFDWHGLQ
neurodegeneration in a mouse model. It has been reported that peroxisome
proliferators may be considered as potential therapeutic agents against
XXXI
neurodegenerative disorders (Hirsch, Breidert et al. 2003, Aggarwal and Harikumar
2009). They were found to reduce memory impairment in a transgenic mouse model
RI $' VLJQLILFDQWO\ 8QGHUVWDQGLQJ WKH UROH RI 33$5Ȗ PD\ KHOS HOXFLGDWH WKLV
receptor’s influence in the reduction of neuronal cell death in the CNS. This nuclear
receptor may convey its neuroprotective effects via inhibition of astrocytes
proliferation.
It was reported in the literature that the peroxisome proliferator-activated receptor
JDPPD 33$5Ȗ KDV EHHQ VKRZQ WR EH LQYROYHG LQ LPPXQH GLIIHUHQWLDWLRQ DQG
playing a key role in the immune response during the inhibition of the inflammatory
UHVSRQVH&XUUHQWHYLGHQFHKDVIRFXVHGRQDWWHPSWVWRHOXFLGDWHWKHUROHRI33$5Ȗ
agonist in an in vivo and in vitro model of neurodegenerative disease.
Recent evidence suggests neuroglia-mediated inflammatory mechanisms may
stimulate disorders in the mouse brain. From this standpoint, astrocytes were used as
a tool to monitor neurodegenerative disorder using an organotypic slice culture
system of PD mouse model.
,Q WKLV VWXG\ URVLJOLWD]RQH D 33$5Ȗ DJRQLVW ZDV XVHG DW WKUHH GLIIHUHQW
concentrations) since previous results indicated a positive effect of this drug on
neurodegenerative processes through PPs activity. For example Sun Hong and
FROOHDJXHVVWXGLHGWKHLPSDFWRID33$5ȖDJRQLVWRQFRJQLWLYHLPSDLUPHQW
in epilepsy, revealing its inhibitory effect on astrocytic activity as a measure of brain
inflammation.
Therefore, this thesis brings together two aspects of the activity of peroxisome
proliferators namely (a) as effector molecules, and (b) their receptor function.
Part 1
The role of peroxisome
proliferators in liver
growth
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Introduction - Review of Literature1.
1.1The Liver
The liver is a large mass of glandular tissue located in the upper right of the
abdomen, and most of its mass is found in the right lobe. It comprises about 4% of
the body weight in rats and 2% in humans (Kamath, Wiesner et al. 2003). The liver
has the ability to regulate its growth in animals and is the main detoxifying organ of
the body and therefore may be injured by ingested toxins. When the liver is exposed
to chemical injury, it triggers a mechanism by which hepatocytes begin to divide
(Sherlock and Dooley 2002). This is mediated via activation of several genes. Given
their medical importance the present study aims to identify some of the genes
involved with the control and replication of hepatocyte cells.
1.1.1 Liver cells
The two main cells in liver are parenchymal and non- parenchymal. The
parenchymal cells (hepatocytes) represent about 90% of the liver whilst non-
parenchymal cells comprising mostly sinusoidal lining cells as well as hemopoietic,
bile duct and blood vessels wall cells (Figure 1-1), account for the other 10%. The
parenchymal cells are the largest cells in the liver which can vary in size but on
DYHUDJH KDYH D GLDPHWHU RI  ȝP 0RUHRYHU WKH\ KDYH D KLJK FRQFHQWUDWLRQ RI
deoxyribonucleic acid. The hepatocytes have many functions such as bile secretion,
phosphorylation, haem synthesis, protein synthesis and beta oxidation
(Krishnamurthy and Krishnamurthy 2009).
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Figure 1-1 Illustration of the arrangement of liver cells in a lobule:
The figure shows hepatocyte cells (in light brown) present on the surface, the central vein (light blue),
the bile canaliculus (a thin tube that merges and forms bile ductules), sinusoids (dark blue), and
Kupffer cells (yellow; also known as stellate macrophages).
http://www.thestudentroom.co.uk/showthread.php?t=1059551&page=210
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1.1.2 The liver cell cycle
As with many other eukaryotic cell types, the cycle of proliferating liver cells can be
divided into four stages: G1, S, G2, and M phase (Figure 1-2). The S phase is
characterised by a period of DNA synthesis leading to a doubling in the amount of
DNA in the cell. At the end of the S-phase, the number of chromosomes has been
replicated to 4n in diploid organisms. Hepatocytes are in general in the G0 phase, or
quiescent phase, of the cell cycle (Seidman, Hogan et al. 2001). However, when
induced to regenerate, hepatocytes are able to enter G1 phase and continue through
the cell cycle (G1-S-G2-M), and at the end of M phase cell division occurs (Yoshida,
Arii et al. 1992). Generally, hepatocytes may have one or two nuclei which contain
2n, 4n, 8n and even greater DNA amounts. In rat liver, the rate of DNA synthesis in
hepatocytes increases after about 12 hr and peaks around 24 hr. This contrasts with
non-parenchymal cells such as biliary epithelial cells or Kupffer cells, in which
synthesis is slower - beginning around 48 hours and approximately 96 hr in
endothelial cells. DNA synthesis starts in rat hepatocytes around the portal zone of
the liver lobule and then proceeds towards the central vein. This contrasts with mice,
in which DNA synthesis occurs around the central vein first and then extends to the
portal zone (Al Kholaifi, Amer et al. 2008).
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Figure 1-2 Cartoon illustration of cell cycle:
The cycle of proliferating cells is divided into four stages G1, S, G2, and M phase. The hepatocytes
enter G1 phase and then DNA synthesis starts at S phase stage. Cell division occurs at the end of M
phase. http://www.biologymad.com
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1.1.3 Liver growth and its regeneration
Liver cells (hepatocytes) have a natural ability to proliferate by replication of the
DNA during cell division. Given this regenerative ability, hepatocytes have a major
role to play in reacting to damage to the liver. Biologically, in normal circumstances
hepatocytes of adult rats seldom divide and proliferate. However, in instances of
partial hepatectomy or tissue injury, hepatocytes can undergo DNA replication
followed by cell division, with histological studies in rats revealing a high capacity to
regain damaged liver cells (Grisham 1962, Fausto 2000). It has been reported that
DNA synthesis in rat hepatocytes starts at 14 hr and reaches a peak at 24 hr. At 36 hr
the liver may have doubled in size, and within a week the normal liver mass is fully
restored(Widmann and Fahimi 1975). A full review of liver growth is beyond the
scope of the present study.
1.1.4 Control of liver growth
The liver is the main detoxifying organ in the body and plays a major role in
metabolism. It also has several other functions in the body including plasma protein
synthesis, glycogen storage, decomposition of red blood cells, and hormone
production (Taub 2004). Liver cell numbers may decrease as a result of chemical
injury or viral infection. This can trigger a mechanism by which hepatocytes start to
divide. The genes c-fos, c-jun and c-myc are known to be involved with activation of
FHOO GLYLVLRQ  DQG LQKLELWLRQ E\ RWKHU IDFWRUV VXFK DV 7*)ȕ )DXVWR DQG :HEEHU
1993). Hepatocytes are relatively long lived and generally do not divide unless
exposed to toxic injury or infection. As a result of liver injury some new hepatocytes
are required to restore liver function, showing that hepatocytes have replicative
capacity (Taub 2004).
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1.2 Peroxisome proliferation
1.2.1 Peroxisomes
Peroxisomes are cytoplasmic sub-cellular organelles found in all eukaryotic cells,
and comprise around 2% of the total cytoplasm and cellular protein content. They are
characterized by a single membrane and have a metabolic role involved with lipid
breakdown (Tabak, Murk et al. 2003). In 1954 Rhodin identified the peroxisomes
naming them microbodies, because their function was at that point unknown (Singh
1997). It has been suggested that peroxisomes are not discrete organelles but actually
exist in continuum with the endoplasmic reticulum (Matheson, Hanton et al. 2006).
In the liver they are usually round and measure about 0.5-1.0 µm diameter. In
rodents they contain a prominent central crystalloid part, but this may be absent in
newly formed rodent peroxisomes as well as in human peroxisomes. Originally it
was thought that rat liver peroxisomes contain hydrogen peroxide which generated
oxidase enzymes and catalases. However, it was later revealed that they contain a
FRPSOHWHIDWW\DFLGȕR[LGDWLRQF\FOH)DKO/DOZDQLHWDO3HUR[LVRPHVKDYHD
main metabolic role in the breakdown of long-chain fatty acids, thereby
complementing mitochondrial fatty-acid metabolism.
1.2.2 Peroxisome proliferators
Many chemicals are known to increase the numbers of peroxisomes in rat and mouse
hepatocytes. This phenomenon of ‘peroxisome proliferation’ coincides with
replicative DNA synthesis and liver cancer in rodents (Holden and Tugwood 1999).
Many of these peroxisome proliferator (PP) chemicals can modulate fatty acid
metabolism (Heuvel 1999) and some xenobiotic and anabolic pathways such as
cholesterol synthesis and dolichol synthesis (Latruffe, Pacot et al. 1995). The PP
group of chemicals is especially significant to human health because they are potent
carcinogens able to induce, for example, 100% multifocal liver cancer in rodents up
to 1 year after exposure (Cattley, Marsman et al. 1991). However, they also have
potential beneficial properties such as cellular receptor for a class of drugs used in
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the treatment of dyslipidemia, also considered a treatment of non-alcoholic fatty liver
disease.
Peroxisome proliferators are a diverse group of chemicals which differ slightly in
structure but all induce characteristic effects in the liver of treated rats and mice
(Mannaerts and Van Veldhoven 1993). Peroxisome proliferators include several
chemicals which are unrelated structurally such as hypolipidemic drugs, plasticizers
and organic solvents (which are used in the chemical industry and in herbicides), all
of which cause liver carcinogenesis in laboratory rodents by a non-genotoxic
mechanism (Ashby, Brady et al. 1994, Passilly, Schohn et al. 1999).
PPs have an effect both on lipid metabolism and carcinogenesis through binding to
peroxisome proliferator activated receptors (PPARs). These receptors are found
intracellularly on the nuclear envelope and can detach from here and themselves
function as transcription factors regulating the expression of genes (Lee, Pineau et al.
1995). The peroxisome proliferator response has gained considerable interest due to
its association with metastatic hepatocellular carcinomas in laboratory rodents.
Peroxisome proliferators are non-genotoxic hepatocarcinogens that cause cell
proliferation and ultimately liver enlargement (Roberts, James et al. 2001). The
mechanism of action by which peroxisome proliferators cause cancer is not
understood (Cattley 2003). Some scientists have suggested that PPs promote liver
growth by an increase in cellular oxidative stress via H2O2 production, leading to
increased peroxisomal fatty acyl CoA (Kobliakov 2010). Peroxisome proliferators
are considered "non-genotoxic" (i.e. not involving direct damage to DNA itself) and
are classified as a novel class of epigenetic chemical carcinogens. It is believed that a
major contributing factor to cancer formation by non-genotoxic carcinogens,
including peroxisome proliferators, is altered gene expression.
7KHSHUR[LVRPHSUROLIHUDWRUDFWLYDWHGUHFHSWRUDOSKD33$5ĮLVDQHVVHQWLDOIDFWRU
LQ SHUR[LVRPH SUROLIHUDWLRQ LQ URGHQW KHSDWRF\WHV 33$5Į VHUYHV DV D UHFHSWRU IRU
diverse compounds, of particular interest are the family of fibrate chemicals due to
their wide range of effects, which include induction of hepatic peroxisome
proliferation, hepatomegaly, hepatocarcinogenesis, and activation of expression of
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several enzymes such as CYP4A in rodents. In the present study efforts will be
IRFXVVHGRQ WKH33µFLSURILEUDWH¶ )LJXUH VHH ODWHU VHFWLRQ33$5ĮKDV
an influence on fatty acid metabolism and it is thought that this results in regulation
of cell cycle control and apoptosis (Issemann and Green 1990, Koves, Ussher et al.
 33$5Į IRUPV D KHWHURGLPHU ZLWK D VHSDUDWH SURWHLQ µUHWLQRLG ; UHFHSWRU¶
5;5 ZLWK DFWLYDWLRQ E\ SHUR[LVRPH SUROLIHUDWRUV OHDGLQJ WR 33$5Į ELQGLQJ WR
DNA regions termed peroxisome proliferator hormone response elements (PPREs).
+XPDQ 33$5ĮV VKDUH PDQ\ IXQFWLRQDO FKDUDFWHULVWLFV ZLWK WKH URGHQW UHFHSWRUV
However, humans appear to be refractory to the adverse effects to peroxisome
proliferation (Roberts 1999).
1.2.3 Cyproterone acetate
Other classes of chemicals (i.e. independent of PPs) are also able to cause
enlargement of the liver, but in contrast can act as genotoxic carcinogens (i.e.
causing damage to DNA). One example is cyproterone acetate (CPA) (Figure 1.3),
which is a steroidal anti-androgen (Siddique, Ara et al. 2008). It suppresses the
action of testosterone and its metabolite dihydrotestosterone. It acts by blocking
androgen receptors, thereby preventing androgens from binding to them which in
turn reduces testosterone levels (Dehm and Tindall 2005). Cyproterone acetate has
been used in animal experimentation to investigate the actions of androgens in fetal
sexual differentiation.
It is worth mentioning that initial stages of CPA action have a completely different
mechanism to the PP ciprofibrate mentioned above (Hasmall and Roberts 1999).
Cyproterone acetate can be used as a drug as a gestagen and anti-androgen, and is a
potent inducer of drug-metabolizing enzymes in female rat liver. CPA has the ability
to stimulate liver enlargement in rats and laboratory mice. Administration of high
doses of CPA over a long-term period may lead to liver tumour formation. It is
hoped that a better understanding of how cell enlargement and division occurs in
induced liver cells, as a result of CPA treatment, will help to better understand the
relationship between induction of liver growth and hepatpoma formation.
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The initiating activity of CPA in vivo in the rat liver shows that it not only promotes
but may be sufficient to induce complete carcinogenesis in rat liver. A key aspect of
the initial stages of CPA action is that it binds to and activates the receptor protein
Pregnane X Receptor (PXR), increasing reporter levels more than 7-fold. PXR serves
as a regular of CYP3A expression (Deml, Schwarz et al. 1993). Similar to PPAR,
PXR is located in the nucleus and plays a major role in regulating lipid homeostasis
as well as hepatic detoxification (Handschin and Meyer 2005).
In previous studies, the effect on liver growth following treatment with CPA was
observed in Wistar rats. Effects were less pronounced in male Wistar compared to
female Wistar rats. Administration with 5-10 mg/ CPA for 3 days showed a peak in
DNA synthesis after 18-24 hr (Schulte-Hermann, Hoffman et al. 1980).
Systematic *IUPAC
Name
3D** Structure Structure
Ciprofibrate
2-[4-(2,2-dichlorocyclopro-
pyl) phenoxy] 2-methylpro-
panic acid
Cyproterone acetate
(CPA)
Chloro-6-hydroxy-17 alpha
methylene-1 alpha, 2 alpha
pregnadiene-4,6 dione-3, 20
acetate
*IUPAC (International Union of Pure and Applied Chemistry).
**Blue= oxygen, Red= carbon, Pink= hydrogen, Green= chlorine
Figure 1-3 Chemical formula and structure of cyproterone acetate.
http://www.google.co.uk/search?newwindow=1&hl=en&tbm=isch&q=Cyproterone+acetate+CPA+3
D+and+chemical+structure&spell=1&sa=X&ei=IgkJUpefHsru0gWnpoD4Bw&ved=0CFEQvwUoA
A&biw=1366&bih=632
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As mentioned above, PXR is a nuclear hormone receptor which is linked to the
induction and regulation of expression of cytochrome P450 3A monooxygenase
(CYP3A) genes. PXR is initially expressed in the liver and intestine, and binds to a
variety of drugs and xenobiotics, together with the retinoid X receptor (RXR) to form
a heterodimer. This then binds to certain xenobiotic response elements that have been
identified in CYP3A gene promoters to induce CYP3A gene transcription (Kliewer,
Goodwin et al. 2002). PXR stimulates expression of several genes involved in
metabolic elimination of unusual compounds and toxic endogenous substances
(Guzelian, Barwick et al. 2006).
1.2.4 Ciprofibrate (peroxisome proliferators) compared to
Cyproterone acetate (CPA)
Ciprofibrate is a potent PP that has tumour promoting activity in rodent liver
.ODXQLJ%DELFKHW DO &LSURILEUDWHELQGV WRDQGDFWLYDWHV33$5Į%QJHU
+RRLYHOG HW DO  33$5Į IRUPV D KHWHURGLPHU ZLWK WKH UHWLQRLG ; UHFHSWRU
(RXR), before then binding to specific regions of DNA called PPREs.
By contrast, cyproterone acetate (CPA) binds to and activates PXR. It has been
reported that CPA induces cell proliferation and apoptosis and then ultimately causes
liver cancer. CPA is a tumour promoting agent and a genotoxic carcinogenic
chemical, in contrast to ciprofibrate which is considered a non-genotoxic carcinogen
(Rotroff, Beam et al. 2010).
Thus a comparison can be made between the chemical classes to be studied in the
present thesis. PPs are non genotoxic carcinogens (i.e. are non-mutagenic) (Roberts
1996), whereas the steroidal CPA is a genotoxic carcinogenic chemical.
The mechanism of action of non genotoxic carcinogenic may cause damage to the
DNA structure indirectly. During carcinogenesis, PPs promote liver tumours by
increasing oxidative stress in liver as a result of the creation of H2O2, whilst
genotoxic chemicals such as CPA can stimulate the DNA directly to cause changes
in the genome (Cavalieri, Frenkel et al. 2000).
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However, there are also some similarities in PP and CPA activity in that both have a
role in mediating the induction of hepatic CYP450, and both involve binding with
the RXR family of proteins (Figure 1.4) (see section 1.2.6).
1.2.5 Induction of hepatic DNA synthesis by cyproterone acetate
It has reported that the treatment to rats with cyproterone acetate (CPA) or
peroxisome proliferators (e.g. nafenopin) can cause DNA synthesis at 18 to 24 hr
post treatment (Menegazzi, CarcereriǦDe Prati et al. 1997). Previous work at
Nottingham by Amer (2011) had studied the effects of CPA on the induction of DNA
synthesis at four different time points 1, 3, 5 and 24 hr as will be described below,
(section 1.3).
1.2.6 Inducing the expression of hepatic Cytochrome P450
The cytochrome P450 (CYP450) superfamily of proteins includes a broad range of
enzymes (Thomas 2007). These enzymes generally stimulate the oxidation of organic
substances. Evidence has increasingly indicated that orphan nuclear receptors such as
PPARs, PXR and CAR have a role in mediating the induction of hepatic CYP450 (see
Figure; 1-5) (Waxman and Booth 2003, Finn, Henderson et al. 2009). It is important
to understand the mechanisms through which xenochemicals induce the expression
of hepatic P450 enzymes. It is known that both the constitutive androstane receptor
(CAR) and PXR category of receptors are present within the cytoplasm of cells and
both have the ability to bind different chemicals, which might enter the body either
through ingestion of food or being produced as the products of metabolism e.g. by
incorporation of one hydroxyl group into substrates in metabolic pathways
(Lehmann, McKee et al. 1998, Kodama, Koike et al. 2004, Kapitulnik, Pelkonen et
al. 2009). It is critical to mention that oxidative metabolism of several endogenous
xenobiotics, including numerous toxins and carcinogens, might lead to production of
ligands binding to such receptors (Brown, Reisfeld et al. 2008).
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In the case of the receptor PXR, this is activated by a wide group of steroids and
GLYHUVLW\ RI [HQRELRWLFV 3;5 WKHQ ELQGV ZLWK D VHSDUDWH SURWHLQ 5;5Į WR IRUP D
heterodimer. This can then bind to the regulatory regions of CYP3A and induce the
Cyp3A family genes which in mice are called Cyp3A1 (compared to Cyp3A4 in
humans) (Wan, An et al. 2000, Goodwin, Redinbo et al. 2002). It is worthwhile
noting that most studies of CYPA3 regulation have been carried out using rabbit and
rats, while less studies have been performed in human both vivo and in vitro (Jones,
Moore et al. 2000). Indeed, induction by CPA has shown differences in induction of
CYP3A gene expression between species. The mouse and human pregnane X
receptors (PXR) were shown to be consistently activated by compounds that induced
CYP3A expression, consistent with a role of PXR in CYP3A regulation. However,
human and rabbit PXR show a stronger transcriptional response than that seen in
mouse and rats. The pregnane 16a-carbonitrile is one of the potent stimuli that are
usually used in the rat PXR than the human receptor. It has been demonstrated that
many of the compounds that induce CYP3A expression bind directly to human PXR
(Bulera, Eddy et al. 2001). It is also noteworthy that metabolic pathways in the liver
mediated by RXR heterodimerization with PXR is compromised in the absence of
RXR. The ligand activated nuclear receptors CAR, PXR and PPAR bind to their
cognate DNA elements as heterodimers with RXR (Figure 1.4) (Jacobs, Dickins et
al. 2003).
Figure 1-4; Diagram showing the mechanism of action of various P450 transcription factors
(Jacobs 2004).
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1.2.7 Effect of CPA (PXR) ligands on hepatic DNA synthesis
It is hoped that an improved understanding of the mechanisms of liver cell division
and growth will pave the way to providing insights into the mystery of the basis of
liver cancer. Using different chemicals such as ciprofibrate as a non-genotoxic
carcinogen or CPA, as a genotoxic carcinogen, which both cause liver growth is
anticipated to provide some clues as to how cell division and liver growth occur.
However, CPA has a completely different mechanism from ciprofibrate (Crunkhorn,
3ODQW HW DO  /LNH 33$5Į WKH 3;5 LV D QXFOHDU UHFHSWRU WKDW UHTXLUHV
heterodimerization with retinoid X receptors (RXRs) (Figure 1.5). CAP (PXR) binds
ZLWK5;5ĮZKLOVW33$5ĮELQGVZLWK5;5Į. There are three isoforms of the retinoid
;UHFHSWRU5;55;5ĮȕDQGȖ,WLVEHOLHYHGWKDW5;5ĮLVWKHPRVWDEXQGDQWLQ
liver of adult mammals (Cullingford, Bhakoo et al. 1998).
Figure 1-5 Schematic diagram of PXR binding to DNA as a heterodimer with RXR:
The diagram shows an example of PXR- induced detoxification of xenobiotics. PXR is an orphan
nuclear receptor known to mediate the effects of xenobiotics. PXR requires heterodimerization with
RXR for DNA binding. The downstream processes are mediated by CYPs belonging to the CYP1A,
CYP2B, and CYP3A families. Their gene expression is affected by chemical inducers and stimulates
the transcription of genes encoding CYP450. The super-gene family of cytochrome P450 is expressed
mainly in the liver and is able to identify a tremendous diversity of xenobiotics, and catalyse the
metabolic conversion of these xeno-chemicals to polar derivatives that are then eliminated from the
body. Thus, PXR functions to regulate expression of several genes, with CYP3A being the most
responsive (Goodwin, Redinbo et al. 2002, Yano, Hsu et al. 2005)
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1.2.8 Hepatic CYP450 gene expression by Peroxisome
proliferators and cyproterone acetate
Both PP and PXR inducers have the ability to stimulate transcription of an enormous
number of genes. However, there is some commonality in that both can induce
expression of hepatic CYP450 genes. PPs in particular can induce the transcription of
CYP4A1gene. For example, the effect of PPs on early gene expression has been
studied in vivo in rats, revealing a significant induction of CYP4A1 after 6 hr
(Woodyatt, Lambe et al. 1999).
By contrast, pregnane X receptors (PXR) play a key role in the regulation of CYP3A
genes. Related to this, PXR regulates a large number of genes involved in xenobiotic
metabolism, including oxidative processes (Kliewer, Goodwin et al. 2002). PXR
binds to and activates transcription from specific response elements found in the
CYP3A gene promoter from multiple species including human and rodents
(LeCluyse 2001).
Considering the specific chemicals to be investigated in the present study,
ciprofibrate and CPA are believed to induce an almost completely different set of
genes by and large. However, this study follows on from a previous study carried out
by Amer (2011) at Nottingham which identified several genes that interestingly
appeared to be jointly induced by either PPs or CPA. This work will be explained in
more detail in the following section.
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1.3 Previous Work Leading to the Present Study
Despite their medical importance the mechanism by which PPs induce hepatocyte
hypertrophy and hyperplasia is not currently well understood. Understanding the
mechanism by which liver growth is induced by PPs in rodents will hopefully
provide insights into how natural liver growth occurs and have medical benefits for
human health if the mechanism of PP toxicity can be understood and remediated.
Knowledge gained from the mechanism of PP activation might also then be applied
to other chemical carcinogens.
Given their medical importance the PP group of chemicals have been the subject of
ongoing research at Nottingham. Previous work, leading up to the present study, was
undertaken by Amer (2011) who investigated aspects of the mode of action of the PP
chemical ciprofibrate. Both histochemical and molecular biology studies were made.
Firstly, histochemical studies found that treating rats during a time course with two
separate doses of ciprofibrate (50 mg/kg body weight) at Ø and 24hr resulted in a
subsequent biphasic pattern of DNA synthesis of cell division, with increased DNA
labelling evident at 24 hr and at 48 hr following treatment (Figure 1.6). However, it
was not clear if the same or different groups of cells were responding to the
treatment. This is a significant question as it might suggest that certain liver cells
might be particularly sensitive to PP induction. Identifying particular cells, and the
genes activated in these cells, might provide valuable insights into the basis of PP
induction. Secondly, microarray, real-time PCR and RNA seq work was undertaken
to identify genes that were up-regulated following treatment with ciprofibrate. This
led to the identification of a series of at least 1000 genes that were up-regulated at
early time points (1, 3 and 5 hr) after treatment in male rats (Amer 2011). Of
particular interest genes were identified that were related to the cell cycle (e.g. Gos2,
Ccnd1 and Scd1).
Meanwhile, previous parallel work at Nottingham studied the effects of CPA
activation of liver cell growth and division (Amer 2011). The fact that other chemical
factors such as CPA also lead to cell division and carcinogenicity in liver cells
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suggests that some common genetic mechanisms regulating DNA replication and cell
division might be activated by both PPs, such as ciprofibrate, and chemicals such as
CPA. It is therefore of great fundamental and medical interest to try to identify any
such common genetic pathways. Again, both histochemical and molecular biology
studies were made of the mode of action of CPA. Firstly, histochemical studies were
made to investigate the effects of CPA on the induction of DNA synthesis at four
different time points 1, 3, 5 and 24 hr. Male and female Fisher rats were used to
study the induction of DNA synthesis at a dose of 100 mg/kg CPA. A labelling index
involving staining of cells with the histochemical BrdU was used to assess DNA
synthesis. It was found that male rats yielded low labelling index values of
approximately only 6 % (as a percentage of all cells) at 24 hr compared to female
rats which showed much higher labelling, with values of approximately 50%
detected (Amer 2011). This was a very interesting finding, suggesting that female
rats exhibited much higher peaks in the DNA synthesis than males, under CPA
treatment, under the same conditions (age and dose) i.e. the genes involved in
signalling were most likely induced much more in female than male rats. These
finding will be investigated further in the present study, using two time points at 3
and 24 hr and also using real-time PCR methodology rather than the microarray
technique used in the previous study (see section 1.4). Secondly, preliminary
microarray and real-time PCR work was undertaken to identify genes that were up-
regulated following treatment with CPA. This led to the identification of a series of a
1377 genes that were up-regulated at early time points (1, 3 and 5 hr) after treatment
in male rats. For example the Ccnd1 gene showed a 2.9 fold change, Scd1 showed a
13.2 fold change and Scd4 showed a15.6 fold change at 3 hr. (Amer 2011).
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Figure 1-6 Time course showing change in labelling index following treatment with 50 mg/kg/day
ciprofibrate compared to labelling index of control corn oil treatment.
Graph shows the induction of hepatic DNA synthesis, as judged by a DNA labelling index, in male F-
344/NHsd rats aged 14-15 weeks. A biphasic pattern of DNA synthesis was evident, one peak of
labelling being observed at 24 hr and the other at 48 hr following ciprofibrate treatment. The rats were
gavaged with either corn oil or with ciprofibrate at time Ø and at 24 hr. The animals injected i.p with
BrdU were then killed, and visualization of BrdU-stained hepatocyte nuclei undertaken. The same
procedure was performed at 30, 36 and 48 hr (n=6). The data showed significant differences in the
percentage of cells labelled between the test and the control treated for 24 hr and 48 hr (P<0.0001)
(Amer, 2011).
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1.4 The hypotheses and aims of the first part of the current project: liver
cell growth
Work undertaken in the first part of current thesis focussed on gaining an
understanding of the effects of non-genotoxic and genotoxic carcinogens on liver
DNA synthesis and cell division. Non-genotoxic and carcinogenic drugs have been
shown to have some beneficial properties, being able to improve the outcome of
specific medical conditions, related to their ability to signal through transcriptional
factors. However, they can also have detrimental affects on the liver, for example
they might cause cancer through mechanisms that do not involve direct DNA
damage.
Ciprofibrate and cyproterone acetate (CPA) were used in the present study as
examples of non-genotoxic and genotoxic carcinogens, respectively. Insights into
their mode of action have come from prior research by Amer (2011) who
demonstrated firstly that two rounds of ciprofibrate treatment resulted in a
subsequent biphasic pattern of liver DNA synthesis in rodents, Secondly, these
earlier studies suggested that a gender difference, in terms of degree of response of
DNA synthesis, occurred in male and female rodents treated with CPA. Finally, the
earlier work had identified a series of genes which showed altered expression as a
result of ciprofibrate treatment.
The hypotheses
I. That there are two distinct hepatocyte cell populations that respond to ciprofibrate
treatment in a time dependent fashion, rather than a particular subset of cells that are
the only cells responding to treatment.
II. That there is gender differences, in terms of resulting gene expression and level of
DNA synthesis, in rodents treated with cyproterone acetate (CPA).
III. That the mechanism of action of CPA and ciprofibrate are completely different
and they do not share common pathways of action.
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The aims
1. To characterise DNA synthesis in rodents following two rounds of ciprofibrate
treatment in order to determine whether the hepatocytes responding over time are the
same or distinct cell populations. To do this it will first be determined if two base-
pair analogues, namely EdU and BrdU, can be used to stain nuclei undergoing DNA
replication at the two rounds of liver cell replication at 24 hr and 48 hr.
2. To examine the effect of cyproterone acetate (CPA) on hepatic growth in female
F-344/NHsd rats, to find out if differences in response occur between rats of different
genders. This will be achieved by determining labelling indices at 24 hr after
induction and comparing results to previous data from male rats.
3. To determine levels of mRNA expression of the G0s2, Ccnd1, and Scd1 genes
following CPA treatment by real-time PCR methodology. These genes, which are
associated with DNA synthesis, had previously been identified as being upregulated
in response to ciprofibrate and/or CPA treatment. It was therefore of relevance to use
RT-PCR to confirm if the same genes showed a response to CPA treatment., as this
would give insights into whether the chemicals have similar or different pathways of
action.
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Materials and methods2.
2.1Materials
2.1.1 Animals
Male and female Fisher (F-344/NHsd) rats were purchased from Harlan UK limited
(Bicester, UK). Two groups of rats were purchased, one group aged 8-9 weeks and
other aged 14-15 weeks, which were all housed 6 rats per cage. The experiments
were performed in accordance with protocols from Scientific Procedures (Act 1986).
All animals were given human care handling and husbandry. They were housed in
plastic cages in biologically clean rooms with filtered air. Temperature and relative
humidity were held at 22 ± 2 0C and 50 ± 5% respectively and were maintained on a
12-hr light/dark cycle. Rats were maintained on a standard lab diet and purified water
with addition of libitum. For CPA experiments female F-344/NHsd (Fisher) rats at
13-14 weeks of age (187.0 ± 18 g) were used. The animals were housed 4 rats per
cage to the group of 3 hr at killing (to study effects of CPA treatment) and 6 rats per
cage for 24 hr at killing (for labelling index experiments). Treated animals were
given 100 mg/kg CPA at time Ø and BrdU 2 hr prior of sacrifice. The animals were
treated, anaesthetised and killed according to a Schedule 1 method, at the designated
establishment (BMSU, QMC at the University of Nottingham) recognized by project
and personal licenses.
2.1.2 Chemicals
2.1.2.1 Immunohistochemistry materials
All chemicals were obtained at highest grade possible. Ultrapure Tris Base was
obtained from Melford. Acetic acid (glacial), xylene, ethanol, methanol, sodium
phosphate and haematoxylin stain were purchased from BDH (UK). 3,3’
diaminobenzidine tetrahydrochloride (Adabi Mohazab, Javadi-Paydar et al.),
polyoxyethylene sorbitane monolaureate (Tween-20), bovine serum albumin (BSA)
and formalin solution, 10% formalin (approx. 4% formaldehyde) were obtained from
Sigma (UK). Hydrochloric acid and 30% hydrogen peroxide (H2O2) and cobaltous
Chapter 2 Materials
53
chloride were obtained from Fischer scientific (UK), ammonium hydroxide from
Aldrich (UK). Hoechst dye 33258, which binds specifically to DNA (nuclei), and
poly-L-lysine-coated slides (PolysineTM) were obtained from Fischer UK), whilst
pure paraffin wax (MP 56deg c) were obtained from Lottbrige Drove (Eastbourne,
UK). Pure water was produced in the Nottingham laboratory. BrdU (5-bromo-2'-
deoxyuridine), and cell proliferation kits were purchased from Amersham TM (UK).
Anti-BrdU (Bromodeoxyuridine) antibody, used as the primary antibody, and Goat
Anti-mouse HRP conjugate, used a the secondary antibody, were obtained from Bio-
Rad laboratories (UK)
The immunohistochemistry technique of BrdU was optimised to gain efficient
results. Hepatic cell which have been labelled with BrdU antibody can be used as
evidence that a cell has divided (Figure 2-1) (Boenisch 2001).
Figure 2-1 Enzyme-labelled secondary antibody reacion with primary antibody bound to tissue
antigen.
BrdU (shown in blue) that is given to the animal i.p should bind to replicating DNA. The primary
antibody in green (anti-BrdU mouse monoclonal antibody) then binds to the BrdU. A peroxidase anti-
mouse IgG secondary antibody (in orange) is next directed against the primary antibody, followed by
the (HRP) Horse Radish Peroxidase enzyme (in pink). Details of immunochemical staining methods
as described by (Boenisch, Farmilo et al. 2001).
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2.1.3 EdU chemistry materials
Phosphate buffered saline (PBS), 3% Bovine serum albumin (BSA) in PBS (3% BSA
in PBS) were prepared using pH 7.4, deionised water from the Nottingham
laboratory. An EdU (5-ethynyl-2’-deoxyuridine) Cell Proliferation Assay (Click-iT®
EdU Alexa Fluor ® 594 Imaging) kit with 50 coverslips (cat#10084) was obtained
from Invitrogen TM. The latter contains 12 reagents named component A to L.
Components A, B, C, D, F, G and H are required. Component A, EdU; B, Alexa
Fluor ® 594 azide; C, DMSO solvent solution; D, EdU reaction buffer (1X); F, EdU
reaction buffer (10X); G, reaction buffer; H, copper sulphate. 5-ethynyl-2´-
deoxyuridine (EdU) incorporation into DNA was detected using this kit, and all the
reaction steps were performed at room temperature to keep the samples moist. In the
EdU reaction a thymidine analogue, in which a terminal group replaces the methyl
group, is incorporated into cellular DNA during DNA synthesis. The terminal alkyne
group is then detected via its reaction with fluorescent azides, in a Cu (I)-catalyzed
covalent reaction between an azide and an alkyne. The EdU contains the alkyne and
the Alexa Fluor dye contains the azide (Figure 2.2).
Figure 2-2 Schematic of the click reaction for detecting EdU incorporated into cellular DNA.
(A) The Cu (1) catalysed 1,3-dipolar cyloaddition reaction of organic azides (R1 –N3) with terminal
acetylenes (R2-=). (B) 1: Use of 5-ethynyl-2-deoxyuridine (EdU), a thymidine analogue that carries a
terminal alkyne group to label DNA in cells as a result of incorporation into cellular DNA during
DNA replication. A copper catalyzed covalent reaction subsequently occurs between an azide and an
alkyne. EdU, a thymidine analogue in which a terminal alkyne group replace the methyl group, with a
suitable fluorescent probe (Salic and Mitchison 2008).
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2.1.4 Total RNA isolation
1 ml of Tri reagent solution from Sigma (UK) was used to isolate total RNA from
samples that had been treated with CPA at 3 hr, according to manufacturer’s
instructions. Frozen liver tissue (80-90 mg) from each animal was placed in a 1.5 ml
Eppendorf tube and RNA extracted using the Tris reagent. 200 µl (1-bromo-3-
chloro-propane) from Sigma (B9673)- 600 µl of isopropanol- 75% ice cold ethanol
were used for washing the RNA pellet which was re-suspended in DEPC water
(diethyl pyro carbonate) and the RNA stored at – 80oC until use. Concentrations of
RNA were determined as in section 2.1.4.1. and using 2% agarose gels See appendix
page 274.
2.1.4.1 Quantifying the RNA
Two methods were used to check if the samples were pure without significant
amount of contaminants such as proteins, phenol, agarose or other nucleic acids.
These were as follows.
1-Spectrophotometer determination of amount of RNA or DNA. For quantifying the
amount of DNA or RNA reads were taken at wavelengths of 260 nm and 280 nm.
2-Thermo-scientific Nanodrop 1000 spectrophotometer: a nanodrop machine was
used and the quantity of RNA was determined according to the manufacturer’s
schedule (Table 2.1).
Table 2-1 Quantification of RNA from Fisher rats.
RNA sample Measure ng/ml
C
o
n
tr
o
l
G
ro
u
p
GI R1 077.2
GI R2 159.9
GI R3 121.1
GI R4 116.2
T
re
at
ed
G
ro
u
p
GII R1 106.4
GII R2 097.6
GII R3 044.2
GII R4 122.4
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2.1.5 Other chemicals and instruments
The peroxisome proliferator -2-[4-(2, 2-dichlorocyclopropyl) phenoxy]-2-
methylpropanoic acid (ciprofibrate) was obtained from Hangzhou BM Chemical
&KLQD&KORURȕȕGLK\GURK\GUR[\ƍ+F\FORSURSD>@SUHJQDGLHQH
3, 20-Dione (cyproterone acetate: CPA) was obtained from Sigma (UK). These
chemicals were dissolved in corn oil before use. Polysine slides have an advantage
that they are not affected by chemicals, enzyme predigestion or heating, making
them ideal for immunohistochemical or tissue sections. Slides were purchased from
Thermo Scientific (UK). LucaEM Camera DL-604mtvp was used to capture the
images of tissues which were detected by using DAPI and mCharry filters and white
light. The camera was purchased from ANDOR Technology (UK), which was
attached to a Leitz WetzlarTM light microscope.
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2.2 Methods
2.2.1 Experimental Design
Animal experiments were designed to reduce the number of animals as much as
possible, whilst bearing in mind that the number of animals in each group must be at
least 6 to produce meaningful statistical analysis. The least stressful procedures
possible were employed to reduce suffering, distress and lasting harm to the animals
in accordance with Home Office (UK) regulations. The animals were housed on the
basis of body weight into appropriate number of groups to minimise random
variation and allow suitable statistical analyses. The animals age 7-8 weeks were
used for the optimisation experiments. The animals age 14-15 weeks were used to
perform time courses assays.
2.2.1.1 Initial optimisation of staining techniques
Before main experiments were performed to study the effects of PP action, it was
first necessary to perform control experiments to ensure that satisfactory staining
could be achieved with the base analogues EdU and BrdU, and also that Hoescht dye
could be used to identify nuclei of the rat liver cells under study. The concept behind
this work was that Hoescht staining could be used to identify all cell nuclei in the
field of scoring, and then EdU and BrdU staining could be used to identify those cell
nuclei undergoing division, which could be expressed as a cell labelling percentage
index value. Previous studies had already determined an optimum concentration for
BrdU usage (Amer 2011) but optimum concentrations for EdU had not been
determined. Therefore, in initial work the effects of staining using three different
concentrations of EdU were investigated. Eight male F-344/NHsd rats aged 7-8
weeks were grouped into 4 groups of two rats. Each group was injected
intraperitoneal (i.p) as follows (Figure 2-3): 2 rats were injected i.p with 100 mg/kg
BrdU in 10 ml/kg PBS 2 hrs before the killing of the animals. 2 rats were injected i.p
with 2mg/kg EdU in 5ml/kg in PBS, 2 rats were injected i.p with 5mg/kg EdU in
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5ml/kg PBS and 2 rats were injected i.p with 25mg/kg EdU in 5ml/kg PBS. The
injections were conducted 2 hr before the killing of the animals.
Figure 2-3 Schematic showing different injection treatments, either BrdU or EdU, and relative time of
killing of animals.
The animals were anaesthetised and killed by a schedule 1 method at the designated establishment
(BMSU, QMC, University of Nottingham) recognised by the project and personal license. Three
different concentrations of EdU were investigated.
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2.2.2 Time course protocol of effects of 50 mg/kg/day ciprofibrate
After initial optimisation of the staining protocols, main experimental work was then
performed to determine the effects of ciprofibrate treatment, together with control
experiments to allow gavage and animal exposure to the experimental procedures.
Experiments were designed to serve several objectives. After determining the
optimal concentration of EdU, the design was devised taking into account the legal
obligation to reduce the number of animals according to Home Office regulations.
This study follows a pervious study which has been performed by Amer (2011). This
research found two peaks of labelling index at 24 hr and 48 hr when rats were treated
with 50 mg/kg/day ciprofibrate. This study will focus on those two peaks. The same
conditions that were used in the previous study with regard to age, concentration of
ciprofibrate, number and time of dosage (Figures 2-4 to 2-7). Six animals were used
in each of the three control and treated groups. As recommended by the Home Office
regarding the administration of substances to laboratory animals, each animal
received an amount of 2.0-2.4 ml for gavaging (Table 2.2). The treated animals were
anaesthetised and killed according to a schedule 1 method at the designated
establishment (BMSU, QMC at the University of Nottingham).
Two complementary time course protocols were undertaken. First, the effects of
staining with BrdU or EdU alone after 22 hr were determined in animals (sacrificed
at 24 hr) that were either treated with ciprofibrate or corn oil (control) at time zero
(Figures 2-4 A, B; Figure 2-6 A,B). This served as a control to confirm the staining
protocol and provide background labelling index data. Second, animals were stained
with EdU after 22 hr and then with BrdU after 46 hr (before being sacrificed at 48
hr), with animals either treated with ciprofibrate or corn oil (control) at both zero and
24 hr stages (Figures 2-5 and 2-7). The latter experiment was especially significant
for assessing the possible dual labelling of cells (section 2.2.3).
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Table 2-2 The maximum recommended volumes of chemical substances for rats dosage
2.2.2.1 The control vehicle groups
ĻCorn oil Ļ%UG8 .LOOĻ
Ø 22 hr 24 hr
Time (hr)
ĻCorn oilĻEdU Kill Ļ
Ø 22 hr 24 hr
Time (hr)
Figure 2-4 Time course of of the effects of control corn oil treatment on hepatic DNA synthesis in
male F-344/NHsd rats aged 14-15 weeks.
Two groups containing six male F-344/NHsd rats each were gavaged with 20ml/kg corn oil at time Ø
and then injected i.p after 22hr with either 100 mg/kg BrdU in 10 ml/kg PBS or 2 mg/kg EdU in 5
ml/kg PBS. The animals were then killed at 24hr.
NO. Method Dosing volume
1. Oral 20 ml/kg
2. Subcutaneous 5 ml/kg
3. Intramuscular 0.1 ml (total)
4. Intravenous 5 ml/kg
5. Intraperitoneal 10 ml/kg
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ĻCorn oil EdUĻĻCorn oil BrdUĻKillĻ
Ø 22 hr 24 hr 46 hr 48 hr
Time (hr)
Figure 2-5 Time course of procedures for treatment of rats in control vehicle group 3
Six male F-344/NHsd rats aged 14-15 weeks were gavaged with 20 ml/kg corn oil at time Ø and then
injected i.p with 2 mg/kg EdU in 5 ml/kg PBS at 22 hr, and were then gavaged again with 20 ml/kg
corn oil at 24 hr. At 46 hr the animals were injected with 100 mg/kg BrdU in 10ml/kg prior to killing
at 48 hr. The body weight was taken before every gavaging and injection treatment.
2.2.2.2 The treated groups
CiprofibrateĻBrdUĻKill
Ø 22 hr 24 hr
Time (hr)
CiprofibrateĻEdUĻKill
Ø 22 hr 24 hr
Time (hr)
Figure 2-6, A and B: Time course of effects of treatment with 50 mg/kg ciprofibrate on hepatic DNA
synthesis in male F-344/NHsd rats aged 14-15 weeks.
Two groups of six male F-344/NHsd rats each were gavaged with 50 mg/kg ciprofibrate dissolved in
20 ml/kg corn oil at time Ø and then injected i.p with either 100mg/kg BrdU (group A) in 10 ml/kg
PBS after 22 hs or with with 2 mg/kg EdU (group B) in 5 ml/kg PBS after 22 hr . The animals were
weighted before injection with BrdU or EdU. The animals were then killed at 24 hr with Dolethal
(pentobarbital) intraperitoneal in 10 ml/kg.
(A)
(B)
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Cipro. in corn oil EdUĻCipro. in corn oil BrdUĻKillĻ
Ø 22 hr 24 hr 46 hr 48 hr
Time (hr)
Figure 2-7 C: Time course of effects of treatment with 50 mg/kg ciprofibrate on hepatic DNA
synthesis in male F-344/NHsd rats aged 14-15 weeks in treatment group 3.
Six male F-344/NHsd rats were each gavaged with 50 mg/kg/day ciprofibrate dissolved in 20ml/kg
corn oil at time Ø and then injected i.p with 2 mg/kg EdU in 5 ml/kg PBS at 22 hr and then gavaged
again with 50 mg/kg/day ciprofibrate dissolved in 20 ml/kg corn oil at 24 hr. At 46 hr the animals
were injected with 100mg/kg BrdU in 10ml/kg prior to killing at 48 hr. The body weight was taken
before every gavaging and injection treatment.
(C)
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2.2.3 Measuring dual labelling of liver hepatocytes
It has been reported that the DNA synthesis begins in rat liver cells between 12 and
18 hr after exposure to a xenobiotic and then rapidly peaks between 20 and 24 hr in
vivo (Grisham 1962). Peroxisome proliferators also show high level of induction of
DNA synthesis in vitro 24 hr after dosing (Lindroos, Zarnegar et al. 1991).
Peroxisome proliferators have in addition been shown to induce high levels of DNA
synthesis in both in vivo and in vitro, with 3% and 29% respectively of cells being
found at s-phase (Plant, Horley et al. 1998). The main objective of the present study
was to determine whether the two peaks of cell division at 24 and 48 hr are related
(i.e. whether the same or different cells were involved) using the double labelling
technique with the base analogue stains EdU and BrdU. Therefore it was necessary
to check the number of dual-labelled cells arising from use of the two analogues. The
benefit of measuring the number of dual labelled hepatocytes is to find out the
proportion of liver cells that have undergone DNA synthesis and compare the results
with the number of normal liver cells that undergo DNA synthesis.
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2.2.4 Time course protocol of effects 100 mg/kg CPA
To compare previous results, which were based on male rats, female Fisher rats were
induced with 100mg/kg CPA. 20 female F-344/NHsd rats aged 14-15 weeks were
used. These were split into 4 groups: 2 × 6 rats for 24 hr kill experiment (treated and
control) and 2 × 4 rats for 3 hr kill experiment (treated and control) (Figure 2.8 and
2.9). The animals were treated, anaesthetised and killed by a schedule 1 method at
the designated establishment (BMSU, QMC at the University of Nottingham).
Experiments were designed in such a way that RNA could be extracted after 3 hr for
analysis of RNA induction by RT-PCR, whilst those killed 24 hr after treatment
could be used to determine the labelling index to compare to previous results with
male rats (Amer 2011).
Figure 2-8; A and B Time course of effects of 100 mg/kg CPA treatment on hepatic DNA synthesis in
female F-344/NHds rats aged 14-15 weeks.
Four female rats were gavaged either with 20ml/kg corn oil at time Ø (control vehicle group) or with
100 mg/kg CPA dissolved in 20mg/kg corn oil at time Ø (treated group). 3 hr later both groups were
killed with Dolethal (pentobarbital) intraperitoneal in 10 ml/kg (samples were taken at this point for
RT-PCR analysis of RNA induction of genes of interest).
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Figure 2-9, A and B time course of effects of 100 mg/kg CPA treatement on hepatic DNA synthesis in
female F-344/NHds rats aged 14-15 weeks.
Each of the six female rats were gavaged at time Ø with either 100mg/kg CPA, dissolved in 20 ml/kg
corn oil, or a corn oil control. At 22 hr the animals were injected i.p 10 ml/kg BrdU. 2 hr later they
were killed with Dolethal (pentobarbital) intraperitoneal in 10 ml/kg.
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2.2.5 Tissue processing
The animals were killed by terminal anaesthesia (pentobarbital). Immediately after
confirming death, the heart was emptied of blood by using cardiac puncture. It was
necessary to remove the remaining blood in liver because this would otherwise
interfere with the fixation process. The whole liver was taken from each animal and
weighed for comparison of body weight to liver weight ratio. A section of left lobe of
the liver and parts of colon intestinal tissue were fixed in 10% formalin. The colon
section was used as positive control for the EdU and BrdU staining procedures.
Small parts from left lobe of the liver were taken and stored directly in liquid
nitrogen and then kept at – 80 0C until use. Fixed tissues were dehydrated and placed
in a Shandon Citadel 2000 Automated Tissue Processor. The tissues underwent
processing in this machine for 15.5 hr with the following stages: 70 % ethanol for 6.5
hr then 80 %, 90 %, 95 % ethanol 1 hr for each. Then 3 hr in 100% ethanol; (an hour
in each container of ethanol). The tissues were passed through 3 containers of 100%
xylene, 1 hr each. The last stage was paraffin wax used for 2 hr which was
automatically changed to a different container after 1 hr. Tissue was removed and
embedded with paraffin and kept overnight at room temperature. The paraffin blocks
were embedded in ice for 48 hr before sectioning. The tissues were sliced at
thickness of 4.5 µm and collected on polysineTM slides and dried at 370C overnight.
All subsequent staining steps were performed in a moisture chamber.
2.2.6 Detecting DNA synthesis and cell cycle population
Observation using a Leitz WetzlarTM light microscope was used to detect hepatocyte
DNA synthesis that stained with BrdU. A DAPI filter was used to determine the
nuclei, and mCherry filter was used to detect replicative cells which stained with
click-iT EdU. All micrographs were taken using a LucaEM Camera DL-604mtvp. The
photos were taken using an exposure time of 100 ms and a medium setting was used
for binning. At least 2,000 nuclei were systematically observed in random fields to
calculate labelling indices between both staining groups of EdU and BrdU. A
magnification of 400X was used during identification and a counting while a
magnification of 200X was used to display cell population of EdU and BrdU groups.
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2.2.7 Statistics
Statistical analysis of data was performed using Prism (GraphPad Prism 5, GraphPad
Software, 2007). All values are expressed as mean ± standard deviation. The
calculated values were analyzed by student’s t-test. The T-test was used for
comparison of control and treated EdU and BrdU groups and to compare EdU with
BrdU groups. The differences were considered significant among groups if p<0.05.
2.2.8 Real – time PCR materials
2.2.8.1 Probes and primers
Real time PCR primers and probe design were obtained using the PRIMER 3
software (Rosen and Skaletsky, 2000) at: http://frodo.wi.mit.edu/primer3/. Real-time
PCR measures DNA amplification as it occurs. This technique enables one to
determine the starting concentration of nucleic acid. The primers and probes were
amplified with an endogenous control gene which has been chosen on the ground
that the gene expression would be expected to be consistent in both the control and
CPA treated samples. Quantitative real-time PCR TagMan®gene master mix was
used (from ThermoScientific) which provides a fluorescence reading of mRNA
H[SUHVVLRQGXULQJHDFKF\FOHRIWKH3&57KHDPRXQWRIPDVWHUPL[XVHGZDVȝO
LQ  ȝO RI '(&3 ZDWHU DQG WKH SULPHUV FRQFHQWUDWLRQV ZHUH  SPRȝO DQG
SPRȝORIWKHSUREHV
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2.2.8.2 Preparing the RT-PCR reaction
A high capacity RNA-to-cDNA kit was used to prepare the RT reaction mix
$E*HQHSHUȝOUHDFWLRQ7KHWRWDODPRXQWRI51$ZDVȝJSHUȝOUHDFWLRQ
as shown in Tables 2.3 – 2.5.
Table 2-3 Real time-PCR components.
Component 9ROXPHUHDFWLRQȝO
+RT -RT
2X RT Buffer 10.0 10.0
20X RT Enzyme
Mix
1.0 -
Nuclease-free
H2O
46WRȝO 46WRȝO
6DPSOH 8SWRȝO 8SWRȝO
Total per
Reaction
20.0 20.0
Table 2-4 : Real-time PCR cycle
Cycles Temperature Time
1 50 0C 2 min
1 95 0C 10 min
40 95 0C 20 sec
40 60 0C 1 min
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Table 2-5: Primer and probe sequences for qRT-PCR
Target RNA
(Rat gene)
Probe / *Primer Sequence Report dye
ȕDFWLQ 3
F
R
CAA GAT CAT TGC TCC TGA GCG
CTG ACA GGA TGC AGA AGG AG
GAT AGA GCC ACC AAT CCA CA
Cy5-BHQ2
AhR P
F
R
TAT CAG TTT ATC CAC GCC GCT
GAC ATG
GCA GCT TAT TCTGGG CTA CA
CAT GCC ACT TTC TCC AGT CTT A
Joe
CYP3A1 P
F
R
TAG AGC CTT GCT GTC ACC CA
AGT GGG GAT TAT GGG GAA AG
CAG GTT TGC CTT TCT CTT GC
FAM-BHQ1
Scd1 P
F
R
TCA TGC TGG GGC GAA ACT TT
TCC TGC TCA TGT GCT TCA TC
GGA TGT TCT CCC GAG ATT GA
Joe
Ccnd1 P
F
R
CTG GAT GCT AGA GGT CTG CGA
GCG TAC CCT GAC ACC AAT CT
GGC TCC AGA GAC AAG AAA CG
Joe
GOs2 P
F
R
CAG GCC CTG ATA GCA GAA GG
GGT GTG GTG CTC GGT CTA GT
ACA AAG TCG CCT CCT GTG TC
Cy5-BHQ2
*P, probe; F, forward primer; R,
Chapter 3 Results
70
Results3.
3.1 Validation of Methodology
3.1.1 Detection of EdU and BrdU
For the main histochemical work, either Hoechst or haematoxylin stains were used to
visualise all cell nuclei within the field of vision depending on the gene analogues to
be used. In the case of BrdU, this was always used in conjunction with haematoxylin,
whilst EdU was always used in conjunction with Hoechst dye. Standard protocols
were available for the use of haematoxylin (Schutte, Reynders et al. 1987) , so the
use of this dye did not require optimisation. However, initial work was required to
optimise the use of the Hoechst stain as follows.
3.1.1.1 Optimisation of Hoechst dye concentration
The aim of this experiment was to determine the best concentration of Hoechst dye
to use to identify cell nuclei whilst reducing the background to gain a high signal-to-
noise ratio. A range of concentrations of Hoechst dye were used, namely 50µg/ml,
10µg/ml, 5µg/ml, 1.0 µg/ml and 0.1µg/ml. It was found that a concentration of 1.0
µg/ml dye was the most appropriate (see Figure 3.1), as background fluorescence
was reduced whilst still allowing detection of nuclei. Micrograph Figure 3-1E shows
that the liver cell nuclei are clear and larger in comparison to the gut section in
micrograph Figure 3-1F, where the nuclei are smaller and irregular and reticulated
[viewed under the same magnification (200 X)]. The nucleolus decreases in size
from 7 to 1 µm2 between these cell types (Altmann and Leblond 1982).
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Figure 3-1 Optimisation of Hoechst dye staining: Paraffin sections were harvested from the liver of a
F-344 rat aged 7-8 weeks.
The rat was injected i.p with 100 mg/kg BrdU. Slides of liver sections were stained with five different
concentrations of Hoechst dye; (A) 50 µg/ml, (B) 10 µg/ml, (C) 5 µg/ml, (D) 0.1 µg/ml and (E) 1
µg/ml. Nuclei are visible after staining as indicated by the arrows. (F) Section of colon stained with 1
µg/ml Hoechst dye as a positive control. Hoechst dye was diluted in PBS solution and histochemistry
techniques were performed as described in Table 1 in the appendix section. All slides had an exposure
time = 100ms, binning level = 2, magnification = 400X.
50µm
A
50µm
C
D
50µm 50µm
E
50µm
F
50µm
B
Liver Gut
50µg/ml
Hoechst
dye
10µg/ml
Hoechst
5µg/ml
Hoechst
0.1µg/ml
Hoechst
1µg/ml
Hoechst
1µg/ml
Hoechst
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3.1.1.2 Optimisation of washing solution (PBS).
To improve the background to noise ratio, the concentration of washing solution was
optimised. The phosphate buffer solution (PBS) was modified into two different
concentrations of NaCl. Three slides were prepared for each of the washing
solutions. The slides were washed using either 0.2 M or 1 M of PBS. The results
showed that the effect of varying the NaCl concentration of the PBS gave varying
background to noise ratio when staining with Hoechst dye. Using a concentration of
0.2 M PBS was better than 1 M (Figure 3-2).
The duration of washing was also modified. 8 slides were prepared from the same
section and each 2 slides underwent one of these washing times: (5 min X2, 10 min
X2, 15 min X2 and 20 min X2). Results from these washing procedures showed that
the best time was 2X 5 min.
Figure 3-2 Optimisation of concentration of PBS washing solution for staining procedures
Liver sections were harvested from a rat aged 7-8 weeks. Two slides were prepared from the same
tissue and then stained with 1 µg/ml Hoechst dye. Slide (A) was washed in 0.2 M PBS whilst (B) was
washed in 1 M PBS. The washing time used was 2X 5 min for each section. Blue arrows indicate liver
cells. Magnification 400 X.
50 µm 50 µm
A
B
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3.1.1 3 Assessment of immunohistochemistry protocol:
BrdU is a synthetic thymidine analogue that is incorporated into DNA during the S
phase of the cell cycle. The BrdU immunohistochemistry technique has widespread
use (Muskhelishvili, Latendresse et al. 2003). However, it was still necessary to
check that the protocol worked properly. Two male F-344/NHsd rats aged 7-8 weeks
were injected i.p with 100 mg/kg BrdU 2 hr before killing. Immunohistochemistry
for the BrdU paraffin section technique (see Table 1 in Appendix) was used to stain
the liver and colon sections as follows: stain with 1:1000 µl, 1:750 µl and 1:500 µl of
primary anti-BrdU body with the diluent buffer. The same concentation of secondary
antibody (1:50 µl) was used for all the different concentrations of primary antibodies.
The results showed that using 1:750 µl of primary antibody with 1:50 µl of
secondary antibody gave the best labelling index (Figure 3.3). The protocol was able
to restrict incorporated BrdU to the cell nuclei with a good signal-to-noise ratio.
Figure 3-3 Assessment of BrdU immunohistochemistry protocol:
A; colon section and B; liver section. BrdU labelling was achieved with an immunohistochemistry
protocol utilising primary and secondary anti-BrdU antibodies (Bio-Rad) and an Amersham cell
proliferation kit.. Liver and colon sections were harvested from an animal which was injected i.p with
100 mg/kg BrdU. The concentration of primary anti-BrdU was 1:750, and the concentration of
secondary anti-BrdU was 1:50. The slides were examined under light microscope at 400X
magnification. Micrographs were taken with a LucaEM DL-604 camera. Scale bar = 50µm.
Non-labelled
A B
Labeled nuclei
50µm50µm
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3.1.2 Optimisation of the dose of EdU to monitor hepatic DNA synthesis
In order to determine the optimal dose of EdU for staining of DNA synthesis in
hepatic cells, three different concentrations were assessed. Three groups of male F-
344 rats aged 7-8 weeks were injected i.p with 2, 5 or 25 mg/kg of EdU. The colon
sections were used as a positive control alongside the liver sections. A fourth group
was injected with 100 mg/kg BrdU which was used as a negative control Figure 3-4.
As shown in Figure 3-6 below, the hepatic cells responded well with the three
concentrations of the click-iT EdU used. The EdU succeeded in identifying the
replicative DNA synthesis. All the EdU concentrations yielded acceptable results and
therefore the lowest concentration (2 mg/kg) was used in the further studies.
50
Hoechst dye 25mg/kg EdU Merge
50µm 50µm 50µm
A1 A2 A3
Gut/Hoechst MergeGut/EdU
50µm50µm50µm
Liver
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Figure 3-4 Assessment of use of different doses of EdU to evaluate hepatic DNA synthesis:
Micrographs of liver and gut were taken by a Luca
EM
DL-604 Camera at 400X magnification. Micrograph
A2; represents liver section of rat injected with 25 mg/kg EdU, B2; liver section of rat injected with 5
mg/kg EdU; and C2, liver section of rat injected with 2 mg/kg EdU. The liver and gut tissues were sliced to
4.5 µm thickness and mounted on polysine slides. All sections (liver and colon) were stained by EdU or
Hoechst histochemical techniques as described in the appendix (table 2). Micrographs A1, B1 and C2 were
stained with Hoechst, whilst A3, B3 and C3 are micrographs 1 and 2 merged using Photoshop. Gut
sections were used as a control and are shown below each row of liver sections. Arrows are used to
highlight representative stained nuclei.
B3
50µm 50µm 50µm
B1 B2
Hoechst 5 mg/kg EdU Merge
Gut/Hoechst EdU Merge
C1 C2 C3
Gut/Hoechst Gut/EdU Merge
2 mg/kg EdU
50µm 50µm 50µm
Liver
Liver
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Figure 3-5 Assessment of EdU staining in BrdU control treated tissue
Micrographs of liver and gut were taken by a LucaEM DL-604 camera at 400X magnification.
Micrograph (A) liver section taken from a rat injected with 100mg/kg BrdU and (B) gut section as a
control. Both sections were used as a negative control for the EdU stain. The liver and gut tissues were
sliced to 4.5 µm in thickness and mounted on polysine slides. All sections (liver and colon) were
stained with Click iT EdU histochemical technique. The gut section was used as a positive control for
Hoechst staining. Arrows indicate cells labelled with the Hoechst dye in liver and gut.
A B
Hoechst dye EdU
A
B
50µm
50µm
50µm
50µm
Negative control / slides
from BrdU group
Negative control / slides
from BrdU group
Gut
Liver
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3.1.3 Investigation of EdU doses to monitor hepatic DNA synthesis
The aim of this experiment was to choose between three different concentrations of
EdU, based on its ability to detect hepatic DNA synthesis, with the aim of
determining the lowest dose to reduce the severity of impact on rat cells. Eight male
F-344 rats at age 7-8 weeks were brought from Harlan. The rats were divided into 4
groups and each two of them were injected intraperitoneal (i.p) with 100 mg/kg
BrdU in PBS or 2, 5 or 25 mg/kg EdU in PBS, respectively, 2 hr prior to kill. The
rats were sacrificed 2 hr after injection and animals body weight (data not shown),
and the percentage liver weight to body weight ratio was determined (Figure 3-6).
Liver tissues were put in formaldehyde fixative with a part of colon included as a
positive control for immunohistochemistry. The results showed that all three
concentrations of EdU yielded acceptable results, with a significantly higher liver
weight to body weight ratio detected only when using the highest concentration of 25
mg/kg EdU (Figure 3-6). The average liver weight to body weight ratio (%) in the
rats dosed with BrdU was is 4.30 ± 0.04 and the average of the three dosing EdU
concentrations were 4.27 ± 0.06, 4.3 ± 0.12 and 4.65 ± 0.3, respectively.
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Figure 3-6; Liver weight to body weight ratio (%) resulting from treatment with three different EdU
concentrations.
Male F-344NHsd rats aged 7-8 weeks, were injected with either BrdU or EdU and killed after 2 hr.
All data are expressed as mean ± SD. There were no statistically significant differences between BrdU
and EdU groups. (n=2), except for the EdU 25mg/kg concentration which exhibited a significantly
different liver weight to body weight ratio (starred) compared with all other concentrations of EdU
and BrdU, according to a one way ANOVA test using Tukey’s multiple comparisons test (P<0.05).
(P<0.05).
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3.1.4 Preliminary work for dual labelling of treated cells
Initially it was aimed to sequentially stain the same liver sections, first with EdU and
then with BrdU (or vice versa). Thus it was hoped to see whether the same, or
different groups of cells, were dividing (in response to ciprofibrate treatment) by
analysis of the same individual slide. However, despite extensive experimental work
and assaying of many different conditions and sequential use of the various dyes [e.g.
Hoechst followed by haematoxylin stain (Figure 3-7) use of different dehydration
protocols (Figure 3-8) etc.] unsatisfactory results were obtained, with no reliable
staining protocol found (full data not shown). It is important to note that such
sequential use of both dyes on the same tissue sample has not, to our knowledge,
been previously reported.
Therefore in subsequent work closely aligned tissue sections were used for the dual
labelling experimental work as explained in section 2.2.3.
Chapter 3 Results
80
Figure 3-7 Assessing the effect of using Hoechst alongside haematoxylin stain:
Liver and colon sections were harvested from male F-344 rats aged 7-8 weeks which had been
injected i.p with 2 mg/kg EdU 2 hr before killing. A and B, liver and colon sections were stained with
Hoechst dye alone as a positive control for the Hoechst dye. C and D; liver and colon sections were
stained with Hoechst dye followed by Haematoxylin. E and F; liver and colon sections were stained
with Haematoxylin followed by Hoechst. Colon sections were used as positive control. The slides
were examined using light microscope with a DAPI filter. Arrows indicate nuclei. The micrographs
were taken with a LucaEM DL-604 camera at 200X magnification.
E F
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Figure 3-8 Assessing the effect of a dehydration protocol on use of Hoechst alongside haematoxylin
staining
Liver and colon sections were harvested from male F-344 rats aged 7-8 weeks which had been
injected i.p 100 mg/kg BrdU 2 hrs before killing. A and B, liver and colon sections were stained with
Hoechst dye alone as a positive control for the Hoechst dye. C and D; liver and colon sections were
stained with Hoechst dye followed by Haematoxylin. E and F; liver and colon sections were stained
with Haematoxylin followed by Hoechst. Colon sections were used as positive control. The slides
were examined using light microscope with a DAPI filter. Arrows indicate nuclei. The micrographs
were taken with a LucaEM DL-604 camera at 200X magnification.
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3.1.4 Induction of hepatic DNA synthesis by ciprofibrate in male F-
344/NHsd rats
The aim of this experiment was to test the hypothesis that ciprofibrate will induce
hepatic, replicative DNA synthesis during the process of augmentative growth in
male F-344/NHsd rats aged 14-15 weeks. 36 rats were used which were housed
randomly. These were split into three independent subset groups of 12 rats, which
were then split into 6 treated and 6 control rats i.e. a total of 6 rats × 6 groups with
three independent groupings. The three sets of 12 rats were later used either to
investigate the effects of BrdU injection, EdU injection effects or in the dual
labelling 48 hr experiment. The animals were monitored by their body weight daily
before and during the experiment [Appendix: Table 5 displays the gavaging
procedure of ciprofibrate, injection of EdU and BrdU, body weight and liver weight].
3.1.4.1 Time course protocol of effects of 50 mg/kg/day ciprofibrate
Before starting the experiment, it was necessary to monitor the animal’s health.
Figures 3-9 A-C shows the body weight of the six groups of rats used in the time
course protocol of effects of 50 mg/kg/day Ciprofibrate experiment as described in
method section 3.1.3. The body weights of the rats were measured periodically, and
results indicated that they were in a healthy state suitable for experimentation.
Figure 3-9 A shows the body weight of the rats used for the experiment when BrdU
was injected.
A
BrdU at 24 h
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Figure 3-9 Body weight of rats during laboratory adapation period. Three groups of male F-344 rats,
aged 14-15 weeks were used for the time course protocol of effects of 50 mg/kg/day Ciprofibrate.
To ensure that rats were in a suitable state of health for experimental work they were weighed
regularly both before and during the experimental work. There was no significant difference in body
weight amongst the rats. A; all rats will be used for the effects of BrdU injection. B; will be used for
EdU injection effects. C; will be used in 48 hr experiments. The animals were provided with good
conditions in terms of the temperature and relative humidity, being held at 22 ± 2 0C and 40 ± 5 %,
respectively. The animals were fed a standard lab diet with tap water add libitum. Data shown are
mean ± SD (n=6). Statistically there were no significant differences from the control group in the
body weight over 96 hr in groups (A, B and C).
B
C
EdU at 24 h
EdU and BrdU at 48 h
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3.1.4.2 Time course effects on relative liver weight to body weight of male F-344
rats aged 14-15 weeks treated with 50mg/k ciprofibrate
Six groups of male F-344 rats were used in the time course experiment to look at the
effects of 50 mg/kg/day ciprofibrate on liver weight to body weight ratio (as
described in methods section 2.2.2 above). Statistically a t-test was performed to
compare control and treated groups in each of the following injection treatments.
Figure 3-10 A: represents rats gavaged with either corn oil or 50 mg/kg ciprofibrate
at time Ø and injected i.p with 100 mg/kg BrdU after 22 hrs then killed at 24 hr. In
this case the mean liver weight: body weight ratio (%) was 3.97 ± 0.12 in control and
4.07 ± 0.25 in treated rats. Figure 3-10 B; rats were gavaged at time Ø with either
corn oil or 50 mg/kg ciprofibrate. At time 22 hr they were injected i.p with 2mg/kg
EdU, and then at 24 hr the animals were killed. The mean was 4.5 ± 0.38 in control
group and 5.2 ± 0.57 in treated group. Figure 3-10 C; rats were gavaged at time Ø
with either corn oil or 50 mg/kg ciprofibrate. At 22 hr they were injected i.p with
2mg/kg EdU, and then gavaged again with 50 mg/kg ciprofibrate. At 46 hr the rats
were injected i.p with 100 mg/kg BrdU, and then 2 hr later the animals were killed.
The mean was 3.53 ± 0.22 and 5.44 ± 0.27 control and treated rats respectively.
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Figure 3-10 Time course of effects of ciprofibrate in F-344/NHsd rats. Groups of male rats aged 14-15
weeks were dosed with either 50 mg/kg/day ciprofibrate or corn oil (vehicle).
Figures represent three groups of rats which were injected 2 hr prior to kill with either EdU or BrdU
or both. A shows liver weight to body weight ratio for the group injected i.p with BrdU 2 hr prior to
kill. B shows liver weight to body weight ratio for the group injected i.p with EdU 2 hr prior to kill. C
shows liver weight to body weight ratio for the group injected i.p with EdU at 22 hr and BrdU at 46 hr
and then killed at 48 hr.There were no statistically significant differences between control and treated
groups in groups A and B, while there was a significant difference between control and treated in
group C according to a student’s t-test (P<0.05). All data are expressed as mean ± SD (n = 6).
Statistically significant differences between the control and treated rats as indicated by an asterisk.
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3.1.5 Using base analogue stains EdU and BrdU
To test the hypothesis that ciprofibrate will induce hepatic, replicative DNA
synthesis during the process of augmentative growth in F-344 rats, two different
analogue stains (EdU and BrdU) were used. After optimisation of the EdU staining
technique, it was essential to test the EdU stain with both control and treated groups
of animals. As a negative control BrdU groups were used to ensure that the results
were not artefacts and vice versa of EdU. Figure 3-11 shows that the click-iT EdU
stain gave reliable staining, with nuclei undergoing DNA replication clearly visible
in both control (Fig 3-11 A and B) and treatment (Fig 3-11 C and D) groups, whereas
not in where BrdU control staining was used without the primary monoclonal anti-
BrdU antibody, (Fig 3-11 E and F). Meanwhile, the complete BrdU
immunohistochemistry protocol also gave clear and reliable results with darkly
staining nuclei evident (Figure 3-12).
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Figure 3-11 Micrographs illustrating the use of the base analogue stains EdU in immunohistochemical
staining.
The figure shows a series of slides prepared from male F-344/NHsd rats aged 14-15 weeks. (A and B)
Gut and liver sections, respectively, from rat gavaged with corn oil (control group) then injected i.p
with 2 mg/kg EdU. (C and D) Gut and liver sections, respectively, taken from rats treated with
ciprofibrate then injected i.p with 2 mg/kg EdU. (E and F) Gut and liver sections, respectively, taken
from a rat gavaged with ciprofibrate then injected i.p with 100 mg/kg BrdU. Micrographs numbered
(1) were stained with Hoechst stain alone, those numbered (2) were stained with EdU, those numbered
(3) are coloured merged images produced using Photoshop. The red arrows indicate replicative DNA
synthesis. The micrographs were taken with LucaEM DL-604 camera using an exposure time of 100ms
and a medium setting (2) for binning at 400X magnification.
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Figure 3-12 Micrographs illustrating the use of the base analogue BrdU in immunohistochemical
staining.
The figure shows slides prepared from male F-344/NHsd rats, aged 14-15 weeks. (G1 and G2) shows
liver and gut sections, respectively, taken from a rat treated with ciprofibrate then injected i.p with 100
mg/kg BrdU. These tissues were stained without the primary anti-BrdU antibody. (H1 and H2) shows
liver and gut sections, respectively, taken from a rat gavaged with corn oil (control vehicle) then
injected i.p with 100 mg/kg BrdU, these tissues were stained in the presence of both primary and
secondary anti-BrdU antibodies. (I1and I2), shows liver and gut sections, respectively, taken from a rat
gavaged with ciprofibrate then injected i.p with 100 mg/kg BrdU, these tissues were stained in the
presence of both primary and secondary anti-BrdU anti-bodies. The micrographs were taken with a
LucaEM DL-604 camera using an exposure time of 100 ms and setting (1) for binning at 400X
magnification.
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3.1.6 Comparison of induction of DNA synthesis by EdU and BrdU
staining
An experiment was first performed to determine whether there was any effect on the
animal resulting from staining, through calculating the liver weight to body weight
ratio and comparing the results with control group. The results obtained showed that
both histochemical markers alone had no significant effect on rats (Figure 3-13 A,
B).
It was then necessary to confirm that both EdU and BrdU staining identified a similar
number of cells undergoing DNA replication, to ensure that both stains could be used
to reliably detect any such cells to obtain reliable results. Male F-344 rats, aged 14-
15 weeks, were used. Two groups of six rats each (control and treated) were injected
i.p with 2 mg/kg EdU at 22hr. Two groups of six rats each (control and treated) were
injected i.p with 100 mg/kg BrdU at 22hr (method section 2.2.1). 2,000 nuclei were
counted for each liver tissue slide to determine the hepatic DNA labelling index.
Nuclei were labelled with click-iT EdU which gave a bright red colour (e.g. Figure
3-17 note that nuclei appear white in these images due to use of a high resolution
black and white detection camera) indicating that the cells underwent DNA division.
By contrast, nuclei labelled with BrdU gave a black/brown colour (e.g. Figure 3-16;
note that nuclei appear black in these images due to use of a high resolution black
and white detection camera). Also, non-labelled nuclei were counted. The percentage
of the labelled nuclei was then calculated. Both EdU and BrdU were shown to give
reliable results when randomly choosing an area of the tissue under a microscope, the
nuclei were systematically counted until 2,000 nuclei were reached. This was done
for both staining groups, BrdU and EdU (control and treated). Comparison of results
of the induction of DNA synthesis by BrdU & EdU showed that there was no
significant difference between EdU and BrdU stains as shown in Figures 3-13, 3-14
and 3-15 below.
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Figure 3-13: Labelling index of hepatocytes of male F-344/NHsd rats treated with 50 mg/kg/day
ciprofibrate or control (corn oil) and then injected i.p. with EdU.
Time course showing the effects of ciprofibrate treatment on groups of male rats aged 14-15 weeks
which were dosed with 50 mg/kg/day ciprofibrate or corn oil control (vehicle) at time Ø, and then
injected with EdU 2mg/kg i.p 2 hr prior to sacrifice at 24 hr. Values represent mean ± S.D, (n=6).
*Control and treated groups were statistically different from each other according to a student’s t-test
at P<0.05.
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Figure 3-14: Labelling index of hepatocytes of male F-344 rats treated with 50 mg/kg/day ciprofibrate
or control (corn oil) and then injected i.p. BrdU.
Time course showing the effects of ciprofibrate treatment on groups of male rats aged 14-15 weeks
which were dosed with 50 mg/kg/day ciprofibrate or corn oil control (vehicle) at time Ø, and then
injected with BrdU 100mg/kg i.p 2 hr prior to sacrifice at 24 hr. Values represent mean ± SD (n=6).
*Control and treated groups were statistically different from each other according to a student’s t-test
at P<0.05.
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Figure 3-15: Effect of ciprofibrate or corn oil control on labelling indices of hepatocytes in F-
344/NHsd rats, comparing groups treated with EdU and BrdU.
The diagram shows the comparison of labelling indices of groups which were injected with EdU or
BrdU against a corn oil control. Groups of six male F-344 rats aged 14-15 weeks were dosed with 50
mg/kg/day ciprofibrate or control corn oil (vehicle) at time Ø and then injected at 22 hr i.p with either
100 mg/kg BrdU or 2 mg/kg EdU prior to kill at 24 hr. Values are expressed as mean ± SD, (n=6).
Control and treated groups were statistically different from each other according to a one way
ANOVA *** Significant difference between control and both treated groups, P < 0.05.
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Figure 3-16 Immunohistochemical staining with BrdU.
The figures show slides prepared from male F-344/NHsd rats, aged 14-15 weeks. Liver and gut
sections were taken from rats either treated with ciprofibrate or from corn oil treated control groups.
They were injected i.p with 100 mg/kg BrdU. The tissues were stained by an immunohistochemistry
technique. (A and A1) shows liver and gut sections, respectively, taken from a rat gavaged with corn
oil (control vehicle group) then injected i.p with 100 mg/kg BrdU. (B and B1) and (C and C1) shows
liver and gut sections, respectively, taken from rats gavaged with ciprofibrate then injected i.p with
100 mg/kg BrdU. The slides were examined with a light microscope. The micrographs were taken
with a LucaEM DL-604 camera using an exposure time of 100 ms and setting (1) for binning at either
100X or 200 X magnifications. Red arrows indicate replicative DNA synthesis, with inserts showing
magnified images from originals of A, B and C.
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Figure 3-17 Histochemical staining with EdU.
The figure shows slides prepared from male F-344/NHsd rats aged 14-15 weeks. The figure displays
nuclei detected with Hoechst dye compared to replicative DNA synthesis detected with the click-iT
EdU protocol. (D1-3) show liver and gut sections (right and left hand sides, respectively) taken from a
rat gavaged with corn oil (control group) then injected i.p with 2 mg/kg EdU. The animal was killed
24 hr after treatment. Image D1 was stained with Hoechst, D2 with Click-iT Edu, and D3 shows a
merged colour image produced using Photoshop. (E and F) show two separate examples of liver
sections taken from a rat treated with ciprofibrate then injected i.p with 2 mg/kg EdU at 200X
magnification. Images E1 and F1 were stained with Hoechst, E2 and F2 with Click-iT Edu, and E3
show merged colour images produced using Photoshop. Finally, images G1-G3 show staining of gut
sections as a positive control, G1 was stained with Hoechst, G2 with Click-iT Edu, and G3 shows a
merged colour image produced using Photoshop. Replicative DNA synthesis shown in Click-iT
stained images as white spots, as indicated by red arrows. The micrographs were taken with a LucaEM
DL-604 camera using an exposure time of 100 ms and a medium setting (2) for binning at either 100X
or 200 X magnifications.
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3.1.7 Use of both EdU and BrdU to distinguish if the two peaks of cell
division are related
A key aim of the present project was to try and find out if ciprofibrate causes the
same cells to divide repetitively, or whether different cells divide at different
treatment times. To investigate these questions, two groups of six male -344/NHsd
rats were used as described of section 2.1.1. The animals were gavaged with either
corn oil (control vehicle group) or ciprofibrate (treated group) at time Ø. Both groups
were then injected i.p with 2 mg/kg EdU at 22 hr. At 24 hr the animals were gavaged
again with either corn oil or ciprofibrate. At 46 hr the animals were injected i.p with
100 mg/kg BrdU. At 48 hr the animals were killed. After fixation the samples
underwent tissue processing, where sections were sliced to a thickness of 4.5µm.
Then successive tissue slices were stained i.e. these were slices directly in contact
with each other, and were expected to pass through the same hepatocytes. The first of
these slices was stained with click-iT EdU and second one was stained with BrdU.
Staining was performed separately to allow for the different staining chemical
procedures, which meant that double staining of the same tissue slice was not
feasible (results not shown). The two micrographs were then superimposed together
using the program Photoshop CS4 (Adobe). This experiment was performed with
liver sections taken from both control and treated rats. Gut sections were used as a
positive control.
The results revealed the key observation that the cells which divide at 24 hr are
different from those which divide at 48 hr in both control and treated liver rat tissues
(Figures 3-18, 3-19, 3-20 and 3-21). This result was consistently obtained in at least
three independent experimental groups of animals (Figures 3.18, 3.20 and 3.21).
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Figure 3-18 Use of EdU and BrdU staining (example 1) to investigate whether the two peaks of DNA
replication at 24 hr and 48 hr (arising from treatment with ciprofibrate) occur in related or different
hepatocyte cells.
The figure shows slides prepared from male F-344/NHsd rats aged 14-15 weeks. (A) displays nuclei
detected with Hoechst dye and (A1) the same micrograph after colouration with Photoshop. (B) shows
replicative cells detected with the click-iT EdU protocol and (B1) the same micrograph after colouration
with Photoshop. (C) shows replicative cells detected with the BrdU stain. (D) Shows results of EdU and
BrdU staining merged together with Photoshop. The replicative cells detected with BrdU staining appear as
black spots, whereas replicative cells detected with the click-iT EdU protocol appear as red spots. The
animal was killed at 48 hr. The micrographs were taken with a LucaEM DL-604 camera using an exposure
time of 100 ms and a medium setting (2) for binning at 400X magnification. Red arrows indicate replicative
DNA synthesis detected by the EdU marker, blue arrows indicate replicative DNA synthesis detected with
the BrdU marker. Images to right hand side show gut (colon) section controls.
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Figure 3-19 Use of EdU and BrdU staining (example 2) to investigate whether the two peaks of DNA
replication at 24 hr and 48 hr (arising from control treatment involving gavage with corn oil) occur in
related or different cells.
The figure shows slides prepared from male F-344/NHsd rats aged 14-15 weeks. (A) Displays nuclei
detected with Hoechst. (B) Shows replicative cells detected with click-iT EdU, as indicated by red
arrow pointing to white spot. (C) Shows replicative cells detected with the BrdU stain, the replicative
cells appearing as black spots (arrowed). (D) Shows replicative cells detected with the click-iT EdU
protocol after colouration with Photoshop, replicative cells shown as red spots. (E) Shows results of
EdU and BrdU staining merged with Photoshop.,The animal was killed at 48 hr after treatment with
EdU and BrdU. The micrographs were taken with a LucaEM DL-604 camera using an exposure time of
100 ms and a medium setting (2) for binning at 400X magnification. Images F. G, H at bottom are gut
(colon) section controls.
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Figure 3-20 Use of EdU and BrdU staining (example 3) to investigate whether the two peaks of DNA
replication at 24 hr and 48 hr (arising from treatment with ciprofibrate at Ø hr and then at 24 hr) occur
in related or different cells, images taken at 200 x magnification.
The figure shows slides prepared from male F-344/NHsd rats aged 14-15 weeks. The animals were
killed at 48 hr after being gavaged with ciprofibrate at Ø hr and then at 24 hr. The animals were
injected with EdU at 22 hr and then with BrdU at 46 hr. (A) Displays nuclei detected with Hoechst
dye. (B) Shows replicative cells detected with click-iT EdU, as indicated by red arrow pointing to
white spot. (C) Shows replicative cells detected with the BrdU stain, as indicated by blue arrows
pointing to black spots. (D) Shows results of EdU and BrdU staining merged with Photoshop. The
animal was killed at 48 hr. The micrographs were taken with a LucaEM DL-604 camera using an
exposure time of 100 ms and a medium setting (2) for binning at 200X magnification.
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Figure 3-21 Use of EdU and BrdU staining (example 4) to investigate whether the two peaks of DNA
replication at 24 hr and 48 hr (arising from treatment with corn oil control at Ø hr and then at 24 hr)
occur in related or different cells, images taken at 200 x magnification.
The figure shows slides prepared from male F-344/NHsd rats aged 14-15 weeks. (A) displays nuclei
detected with Hoechst dye and (B) the same micrograph after colouration with Photoshop. (C and D)
shows replicative cells detected with the click-iT EdU protocol and (E) the same micrograph after
colouration with Photoshop. (F) shows replicative cells detected with the BrdU stain. (G) Shows
results of EdU and BrdU staining merged together with Photoshop. The replicative cells detected with
BrdU staining appear as black spots (blue arrows), whereas replicative cells detected with the click-iT
EdU protocol appear as white or red spots (red arrows). The animal was killed at 48 hr. The
micrographs were taken with a LucaEM DL-604 camera using an exposure time of 100 ms and a
medium setting (2) for binning at 400X magnification. Red arrows indicate replicative DNA synthesis
detected by the EdU marker, blue arrows indicate replicative DNA synthesis detected with the BrdU
marker).
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3.1.8 Percentage of hepatocytes labelled with EdU and BrdU after
induction with 50 mg/kg ciprofibrate
To be confident that the results obtained were reliable (showing that different groups
of cells were undergoing division at the 22 and 46 hr points of ciprofibrate
treatment), it was important to find out if the number of cells being labelled is above
or below the average number of normal liver cells undergoing staining which is 3.5%
(± 0.5). 500 labelled nuclei were counted in samples that were labelled with either
EdU or BrdU to find the average. Figure 3-22 shows that the average percentage of
cells labelled with EdU and BrdU was 3.4 ± 0.7 and 3.6 ± 0.1, respectively, and the
average of the total labelled cells with both markers was 5.5% ± 1.1, which was in
line with the expected value of 3.5% as mentioned above.
Figure 3-22 Percentage of labelled hepatocytes of F-344 liver rats following inducion with 50%
ciprofibrate.
Three groups of animals were gavaged with ciprofibrate and then injected either BrdU or EdU, or with
both EdU and BrdU (dual-labelled) at 24 and 48 hr. Paraffin liver section were prepared after 48 hr
(n=6). There was no statistically significant difference between individual EdU with BrdU staining.
However, there was a statistically significant greater number of dual labelled cells according to a one-
way analysis of variance, P<0.05. Error bars indicate mean ± SD (n=6).
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3.2 Induction of DNA synthesis induced by CPA (PRX)
It has been hypothesised that liver growth of rats resulting from treatment with non-
genotoxic carcinogens could involve some common early gene and protein
expression changes that could ultimately be used to predict chemical
hepatocarcinogenesis (Plant 2008). There are other chemicals besides PP family
toxins which might cause liver growth. Krebs (1998) reported evidence that CPA
showed genotoxic activity linked to mutagenesis and promotion of specific DNA
adducts and in rat liver cells (Krebs, Schäfer et al. 1998).
In the previous study of Amer (2011) it was found that dosing male F-344/NHsd rats
with 100 mg/kg CPA resulted in upregulation of at least 21 genes and down
regulation of at least 10 genes during the early hours of treatment at 1, 3 and 5 hr
according to analysis by microarray technology. However, despite the widespread
use of microarray technology, the use of microarray data has been challenged
regarding its reliability and reproducibility (Baker, Harries et al. 2004). Not to
mention the expensive cost for the microarray technology.
The present study had two main aims, following on from work by Amer (2011). A
first aim was to verify the observation that differences in response are evident
between male and female rats. A second aim was to make a preliminary study using
real time PCR to investigate whether genes known to show altered expression as a
result of ciprofibrate treatment were also altered in expression by CPA treatment.
Female F-344/NHsd rats aged 14-15 weeks were dosed with 100 mg/kg CPA to
confirm induction of hepatic DNA synthesis, or with corn oil (vehicle) as a control.
The experiment was performed on two different occasions as described in section
2.2.2 (Figures 2-8 and 2-9). The first time point was 3 hr; as the mice were gavaged
at time Ø and then killed, in order to extract RNA for RT-PCR work. The second
time point was 24 hr, with rats being injected intraperitoneally (i.p) with 100 mg/kg
BrdU 2 hr before killing in order to confirm induction of DNA synthesis by
histochemical means. Liver samples extracted 3 hr after initial treatment were kept at
– 80 0C until use for RNA induction analysis with real time PCR to compare changes
in gene expression with livers from earlier time points of male Fisher rats, by dosing
F-344 rats with CPA and comparing the labelling index between male and female
rats at 24hr.
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3.2.1 Effect of CPA (PXR) ligands on hepatic DNA synthesis in female
Fischer rats
CPA had been used as a positive control to ciprofibrate in previous work at
Nottingham (Bell pers comm). During such work it was inadvertently found that
dosing male F-344 rats with 100 mg/kg CPA gave only a 6% labeling index, whilst
CPA gave a 50% labeling indices in female rats at 24hr (Amer 2011). This suggested
that female rats could be used as a better model system to study gene induction.
In order to confirm the high level of induction of DNA synthesis in hepatocytes, 12
female F-344/NHsd rats aged 14-15 weeks were bought a week before use, so they
could acclimatize to their environment before giving them more stress of dosing and
handling. The rats were grouped into 2 X 6 and gavaged with 100 mg / kg CPA at
time Ø hour, which was dissolved in corn oil, and injected with BrdU i.p 2 hr prior to
killing, as described in section 2.2.2 (Figure 2-9). The rats were weighed every other
day (before and after the dosage) to ensure that they were healthy. Anti-primary and
secondary BrdU antibodies were applied to detect hepatocytes proliferation after 24
hr. The aim of this experiment was to investigate the effects of CPA activation of
liver growth and cell division. Labeling indices of BrdU detection in female rats
were compared with that obtained from male rats at 24hr by Amer (2011) under the
same conditions.
Data obtained showed that the liver weight to body weight ratio was significantly
different between the control and treated groups (Figure 3-24, A and B). The control
value was 3.6 ± 0.07% compared to the treated group 4.2 ± 0.09% at 24hr. The
results indicated that the labeling index of treated female rats showed a very high
level of 38.8 ± 7.9% in comparison with the control group where the value was 1.2 ±
0.3% (Figure 3-23). In summary the immunohistochemistry results using BrdU
labelling showed that hepatocytes proliferation is markedly higher in treated than in
control female rats, and that labelling in female rats (labeling index of DNA
synthesis of 38.8% ± 7.9%) was markedly higher than in previous studies by Amer
(2011) involving male rats (only 5.0% ±1.0).
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Figure 3-23 Effects of CPA on hepatic DNA synthesis in female F-344 NHsd rats as detected by
BrdU stating.
Groups of female rats were gavaged with 100 mg/kg CPA and DNA replication detected by BrdU
staining at 24 hr. (A) Liver tissue of control animal. (B) Liver tissue of CPA treated animal. Sections
were labelled with an anti-BrdU antibody (DNA replication indicated by dark black nuclei) and
counterstained with haematoxylin. (C) Gut section of treated animal, used as a positive control for
BrdU staining. The micrographs were taken with a LucaEM DL-604 camera at 200X magnification.
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Figure 3-24 Effects of CPA on hepatic DNA synthesis in female F-344 NHsd rats as determined by
labelling index of BrdU staining.
Group of female F-344 rats aged 14-15 weeks were dosed at time Ø hr, with either corn oil (control
vehicle) or 100mg/kg CPA. At 22 hr they were dosed intraperitoneally (i.p) with BrdU and killed at
24 hr. (A) shows liver weight to body weight ratios of different treatments. (B) shows BrdU labelling
index at 24 hr of different treatments. All data expressed as mean ± SD (n=6). There were statistically
significant differences between control and treated groups according to a student t-test (P<0.05), as
indicated by an asterisk.
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3.2.2 Early induction of DNA synthesis by CPA in female F-344 /NHsd
rats
It has reported that cyproterone acetate (CPA) can induce liver tumours in rats, with
a higher incidence in female than males (Lake, Renwick et al. 1998, Otteneder and
Lutz 1999, Brambilla and Martelli 2002). However, it is noteworthy that in order to
induce liver tumours in female rats higher dosage levels had to be used. Meanwhile,
CPA treatment very rarely gives rise to liver cancer in human patients (Kasper 2001).
As previously mentioned (section 1.3.10), it has suggested that some common
genetic mechanisms regulating DNA replication and cell division might be activated
by both PPs (e.g. ciprofibrate) and other chemicals such CPA (Wallenius, Wallenius
et al. 2000). It is therefore of great fundamental and medical interest to try to identify
any common genetic pathways. Work has previously been undertaken by Amer
(2011) to identify genes induced by both ciprofibrate and CPA, using microarray
technology. The results concerning ciprofibrate treatent were followed up by RNA
seq analysis, but not the results of the CPA analysis. It was apparent that genes
related to DNA synthesis in male rats in were induced to a much higher level in
female rats following CPA treatment. This result was confirmed by the present study
where a labeling index of DNA synthesis of 38.8% ± 7.9% was found for female rats
compared to only 5% ±1 found previously in male rats (Amer 2011) (section 3.2.1).
Work in the present study therefore focussed on genes induced in female rats.
Group of female F-344/NHsd rats at age 14-15 weeks were gavaged with either corn
oil (control vehicle) or 100 mg/kg CPA dissolved in corn oil at time Ø hr. The
animals were anaesthetized and killed 3 hr later by schedule 1 method. The animals
were weighed and after killing the livers were removed and weighed. Analysis of
results with student’s t-test showed no significant difference between liver to body
weight ratio for control (3.2±0.04%) and treated group (3.0±0.08%) (Figure 3-25).
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Figure 3-25 Effects of CPA or corn oil control on liver growth in female F-344NHsd rats CAP after 3
hr.
Graph shows liver weight to body weight ratio of female F-344 rats aged 13-14 weeks which were
dosed with either 100mg/kg CPA or corn oil (vehicle) at time Ø and killed after 3 hr. All data
expressed as mean ± SD (n=4). There was no statistically significant difference between control and
treated groups according to a student’s t-test (P<0.05).
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3.2.3 Real time PCR results of CPA induction
Previous microarray studies had identified a series of genes related to early stages of
cell division which were induced by ciprofibrate treatment. It was therefore of great
interest to investigate whether any of these genes were also induced by cyproterone
acetate (CPA) as this might indicate shared pathways relating to cell division and
carcinogenesis and it is of major medical interest to identify such genes. Unlike
previous work, the real time PCR method rather than microarray was used.
Both previous and work from the current study had shown that gene expression
responsible for induction of liver cell response is much higher in female rats than in
male rats. Therefore studies were undertaken with female rats. Samples from female
F-344 rats treated with 100 mg/kg CPA and control vehicle corn oil for 3 hr was
analysed with this technique as shown in section 2.2.2. Primers and probes were
designed for selected genes on grounds of the previous study to allow comparison
between them at the same time point with two different techniques. In this
preliminary study target genes were chosen on the basis that they were involved in
the cell cycle, so had possible links to carcinogenesis, and were found to show highly
altered gene expression (e.g. be highly induced) by RNA seq. analysis for samples
dosed with ciprofibrate (Amer 2011).
The genes chosen were CYP3A1, Scd1, Ccnd1, and G0s2 together with two genes
AhR and ȕDFWLQ which were used for normalization. Amer (2011) found that G0s2,
Ccnd1 and Scd1 were up-regulated when male rats were treated with ciprofibrate at 1
and 3 hr after dosing, but not at 24 hr. The G0s2 and Ccnd1 genes are involved in the
cell cycle pathway, whilst Scd1 is involved in PPAR signalling pathway
(Zandbergen, Mandard et al. 2005).
In this study real time PCR was used to compare and confirm the results in both
studies at one time point, namely 3 hr. The mRNA of male rats for all experiments
was obtained from my colleague Abeer Amer to compare the induction between
genders. Real time PCR was performed for male and female samples during the same
RT-PCR experimental run.
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3.2.3.1 Standard curves for genes of interest
A relative standard curve method was utilized to study expression levels of genes of
interest whereby standard cDNA (complementary DNA) dilutions are required in
order to quantify relative concentrations of the target and reference gene in the
samples. The standard curves represent the amplification efficiency and regression
coefficient for the genes, CYP3A1, Ccnd1, Scd1, G0s2, AhR and ȕDFWLQ. The
amplification efficiency for real-time PCR reaction should be 100% ± 10% and the
regression coefficient (r2) should be so close to 1 (Fraenkel, Wallen et al. 1993,
Bustin, Benes et al. 2009).
All genes studied showed efficient amplification, with the results of the regression
coefficient (r2) values being close to 1, meaning that all target genes are within ~ 9%
of 100% and 0.99 ± 0.007of the r2. The regression and efficiencies were as follows:
the CYP3A1 (r2 = 0.99 & 101.2% of the efficiency), the Scd1 (r2= 0.99 & 11.3%
efficient), the Ccnd1 (r2= 0.99&101.1% efficient), the G0s2 (r2= 0.99 & 101.3 %
efficient), the AhR (r2= 0.99 & 101.1 % efficient) and the ȕDFWLQ (r2= 0.99 & 98.9%
efficient). Figure 3-26 shows the standard curves of these genes.
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AhR, r2 = 0.99 Eff% = 101.119. Ccd1 r2 = 0.995 Eff% = 103.056
GOs2, r2 = 0.993 Eff% = 101.393 Scd1, r2 = 0.993 Eff% = 115.339
Figure 3-26 Standard curve to determine the RT-PCR efficiency. The efficiency is based on the r2
value, with the regression correlation coefficient value r2 determined as shown above.
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3.2.4 Effects of CPA on CY3A1 gene expression
This experiment was conducted to investigate the possible induction of CYP3A1
mRNA in male and female rats which were treated with 100mg/kg CPA at time Ø hr
and were then killed 3 hr later.
The results for the treated samples with CPA showed a statistically significant
induction of CY3A1 expression both in treated female rats compared to the control
group, and also between male and female treated rats at this relatively early induction
of DNA synthesis (Figure 3-27). It is noted that a literature review revealed that the
3;5 DJRQLVW SUHJQHQDORQHĮFDUERQLWULOH FDQ DOVR KLJKO\ LQGXFH CYP3A1
expression (Mikamo, Harada et al. 2003, Bailey, Gibson et al. 2011).
Figure 3-27 Effect of CPA or corn oil control treatment on CYP3A1 mRNA expression in liver cells of
female and male F-344 rats.
Figure shows the effects of treatment of either 100 mg /kg CPA or a corn oil control vehicle
on CYP3A1 mRNA expression, for both female and male rats treated at Ø hr and assayed at
3 hr. Expression was assessed using real-time PCR. Statistically significant differences were
evident between the control and treatment groups, and male and female groups, as indicated
by an asterisk. All data expressed as mean ± SD (n=3). Statistical analysis according to a
one-way analysis of variance (Tukey’s multiple comparison test), P<0.05.
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3.2.5 Effects of CPA on sterol-coenzyme A - desaturase 1 (Scd1) gene
expression
This experiment was performed to investigate the induction levels of Scd1gene
expression in both male and female samples following CPA treatment. The aim was
to find out the level of induction between control and treated rats and compare the
results with female rats to those of previous male samples.
Although the treated females showed an increase in Scd1 mRNA compared to the
control rats, the difference was not significantly different at this early 3 hr stage of
induction of DNA synthesis (Figure 3-28). Interestingly, the difference between
treated female and treated male rats was statistically significant, and there was a
significant difference between control male and treated female rats (Figure 3-28).
Figure 3-28 Effect of CPA or corn oil control treatment on Scd1 mRNA expression in liver cells of
female and male F-344 rats.
Figure shows the effects of treatment of either 100 mg /kg CPA or a corn oil control vehicle
on Scd1 mRNA expression, for both female and male rats treated at Ø hr and assayed at 3 hr.
Expression was assessed using real-time PCR. Statistically significant differences were
evident between male and female groups, as indicated by an asterisk, but there were no
statistically significant differences between control and treated female and male rats. All data
expressed as mean ± SD (n=3). Statistical analysis according to a one-way analysis of
variance (Tukey’s multiple comparison test), P<0.05.
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3.2.6 Effects of CPA on cyclin D1 (Ccnd1) gene expression
This experiment was carried out to test the effects of CPA on the induction levels of
Ccnd1 mRNA at 3 hr after treatment, a gene known to be involved with control of
the cell cycle.
The expression of Ccnd1 at this early time point was extremely high in treated
female rat compared to both the female control and treated male rats (Figure 3-29).
The results for the treated female showed a statistically significant induction of
Ccnd1 after 3 hr treatment; with a > 2.6 fold change and > 5 fold change comparison
to male treated (Figure 3-29).
Figure 3-29 Effect of CPA or corn oil control treatment on Ccnd1 mRNA expression in liver cells of
female and male F-344 rats.
Figure shows the effects of treatment of either 100 mg /kg CPA or a corn oil control vehicle
on Ccnd1 mRNA expression, for both female and male rats treated at Ø hr and assayed at 3
hr. Expression was assessed using real-time PCR. Statistically significant differences were
evident between the control and treated groups in female rats, and between female and male
rat groups according to a one-way analysis of variance (Tukey’s multiple comparison test),
P<0.05. All data expressed as mean ± SD (n=3).
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3.2.7 Effects of CPA on expression of G0s2 gene involved with G0/G1
switching
This experiment was conducted to investigate the effects of CPA on induction levels
of the G0s2 gene (involved in G0/G1 switching) compared to a corn oil control in
female F-344 rats at a 3 hr time point after treatment. Results were then compared
with similar gene expression data for male rats.
The induction of G0s2 in female treated with CPA showed no significant difference
from the control, and there were also no significant differences between control and
treated male rats (Figure 3-30).
Figure 3-30 Effect of CPA or corn oil control treatment on G0s2 mRNA expression in liver cells of
female and male F-344 rats.
Figure shows the effects of treatment of either 100 mg /kg CPA or a corn oil control vehicle
on G0s2 mRNA expression, for both female and male rats treated at Ø hr and assayed at 3
hr. Expression was assessed using real-time PCR. There were no statistically significant
differences between the control and treated groups of rats groups according to a one-way
analysis of variance (Tukey’s multiple comparison test). All data expressed as mean ± SD
(n=3).
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Discussion4.
The present study had two main objectives. Firstly, to determine whether particular
liver cell populations respond to repeated treatment by the peroxisome proliferator
(ciprofibrate), or whether independent cell populations respond to treatment.
Secondly, to undertake preliminary studies to determine whether similar sets of
genes are induced in female rat liver cells by the genotoxic carcinogen cyproterone
acetate (CPA) as are induced by ciprofibrate. In order to achieve these objectives
various experimental works was undertaken as discussed below.
4.2 Rationale and method validation
4.1.1 Optimisation of Hoechst dye concentration
A histochemical approach was utilised in order to determine whether the two peaks
of cell division observed by Amer (2011) following repeated ciprofibrate treatment
(one at 24 hr and the other at 48 hr, following treatment at Ø and 24 hr) were related.
The two histochemical and immunohistochemical stains used were EdU and BrdU,
which are both base-pair analogues that stain nuclei undergoing DNA replication as a
result of incorporation into DNA during novel DNA synthesis (Cappella, Gasparri et
al. 2008). It was hypothesized that if EdU was administered to animals at 24hr which
had been pretreated with ciprofibrate at Ø hr, then this stain would be incorporated
into nuclei of dividing hepatocyte cells at 24hr. If animals were then treated with a
second dose of ciprofibrate and then allowed to live for a further day, then
administration of BrdU at 48 hr would be expected to lead to incorporation of the
latter stain into nuclei of dividing hepatocyte cells at that stage. Thus, if the same
cells are responding to ciprofibrate treatment then cells would be co-stained by both
dyes, whereas if different cells were responding then there would be little or no
double staining of hepatocyte cells.
In order to achieve a good background to noise ratio staining by Hoechst dye was
optimised before being used to reveal the total number of nuclei. Meanwhile EdU
Chapter 4 Discussion
117
was used to detect specifically cell nuclei undergoing replicative DNA synthesis.
Many studies have investigated the relative fluorescence intensity of Hoechst dye,
e.g Lalande and Miller (1979) examined concentrations from 1µg to 20µg/ml. A
reduction of Hoechst 33258 dye (Bisbenzimide) concentration to below 1µg/ml has
been linked to decreased background fluorescence (McGowan, Kurtis et al. 2002).
Hoechst dye at a concentration of 2µg/ml was found to accurately and clearly detect
nuclei in liver cells prepared from adult rats (Lamas, Chassoux et al. 2003).
In this study, 5 different concentrations were examined, from 0.1µg/ml to 50µg/ml,
to reveal the effect of these concentrations on fluorescent signal. A Hoechst dye
stock of 5µg/ml was prepared using distilled water then PBS was used to make the
five concentrations. Stock solution was stored at 4 0C and protected from light. The
experiments show that using 1.0 µg/ml dye concentration gave the best results as
background fluorescent was reduced. In order to obtain good background to noise
ratio, the washing solution (PBS) was optimised as well. The results show that a
concentration of 0.2M NaCl was better than 1M NaCl. In addition, the time of
washing was optimised concluding that 2 X 5 min gave the best results. It was also
found that Hoechst dye gave much better results in the presence of moisture so a
small chamber was designed to meet this condition (Figure 3.7).
4.1.2 Assessment of immunohistochemistry protocol
BrdU and IHC techniques are widely used as an experimental procedure to label
DNA synthesis within replicative nuclei and have been used in a variety of studies of
cell biology including investigations of cell proliferation of liver growth in vitro and
vivo (McGinley, Knott et al. 2000, Ueda, Saito et al. 2005). BrdU is incorporated
into DNA during DNA synthesis of cell proliferation during the S-phase of the cell
cycle. In this study BrdU Immunohistochemistry for the BrdU paraffin section
technique was used to stain liver and colon sections, the latter included as these
undergo much cell division so provide a suitable control for cell and nuclei staining.
Primary anti-BrdU antibodies purchased from Amersham and Sigma were assessed
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at three concentrations 1:1000 µl, 1:750 µl and 1:500 µl. The same concentration of
secondary antibody 1:50 µl was used for all the different concentrations of primary
antibodies. Primary anti-BrdU antibodies were applied to positive sections and
incubated for 45 min. Negative control section were held in 0.2M PBS during the
primary incubation. The secondary antibody (Bio-Rad laboratories) was applied to
all sections (positive and negative) and incubated for 30 min. Using 1:750 µl of
primary antibody with 1:50 µl of secondary antibody gave the best labeling index as
shown in Figure 3-12. These optimisations were concordant to several former
studies, where in most of them the secondary antibody used was the same as the
above concentration, but different results with the primary antibody were obtained
depending on the source of purchase (Connolly and Bogdanffy 1993, Constan,
Sprankle et al. 1999, Ezaki, Yoshida et al. 2009, Ross, Plummer et al. 2010).
4.1.3 Optimisation of the dose of the EdU
EdU was used as stain to detect DNA synthesis in proliferating cells during cell
division. EdU is incorporated into DNA of nuclei of proliferating cells and can be
subsequently detected by fluorescence resulting from an antibody bound copper
azide (Salic and Mitchison 2008). In particular, the click-iT EdU reaction relies on
incorporation during DNA replication – with the terminal alkyne group of EdU
containing a thymidine analogue which replaces methyl groups in DNA. Then the
terminal alkyne group can be detected via reaction with a fluorescent copper azide.
EdU staining has been utilised in a variety of different eukaryotic cells and has been
incorporated strongly into the DNA of proliferating mammalian cells. For example,
Salic et al (2007) injected EdU into an adult mouse i.p with 100µg of EdU in PBS.
This resulted in staining of cells of the small intestine, with red nuclei observed of
cells that had been in S-phase (Salic and Mitchison 2008). In this project three
concentrations of EdU were tested to establish an optimal dose of EdU. A group of
six animals was injected with 2, 5, and 25 mg/kg EdU (n=2 per dose). As shown in
Figure (3-6) all of the EdU concentrations gave acceptable staining, therefore the
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lowest concentration 2 mg/kg was used. Indeed, using the this small amount lowest
concentration of EdU showed no signs of EdU toxicity, which confirms results of
Cappella in his vivo study in adult mice (Warren, Puskarczyk et al. 2009).
4.1.4 Using base analogue stains EdU and BrdU
It was necessary to make sure that the hepatic DNA synthesis which was detected by
both EdU and BrdU with immunohistochemistry was at the same level i.e. to ensure
that these stains detected the same cells, and same number of cells, rather than
providing artifactual results. Comparisons of BrdU and EdU histochemistry showed
no statistically significant differences. Thus, click-iT EdU incorporated into DNA
synthesis of cells in the same manner as BrdU, revealing that all cells showed similar
labelling indices with both stains (Nwe and Brechbiel 2009). The EdU showed high
efficient fluorescence without the need for denaturation, unlike BrdU which required
all slides to be denaturated (Warren, Puskarczyk et al. 2009). A study by Cappella
showed that labelling with EdU gave slightly increased staining compared to BrdU
(Cappella, Gasparri et al. 2008). The finding is in disagreement with this project,
because there were no statistically significant differences between EdU and BrdU
stains. Indeed, on the contrary, the labelling with BrdU showed a slightly increased
as displayed in Figure 3-15 although this was not statistically significant.
4.1.5 Use of both EdU and BrdU to distinguish if the two peaks of DNA
replication and cell division are related
This project was initiated to test the underlying hypothesis that certain hepatocytes
might have an increased ability to divide, due for instance to increased expression of
specific genes, which might therefore make these hepatocytes, more susceptible to
carcinogens. If so these cells would be more likely to undergo division at two
different times following toxin treatment. To determine whether ciprofibrate causes
the same cells to divide repetitively, or whether different cells divide at different
times, two different stains were used. Liver and gut tissues of 4.5 µm thickness were
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prepared. The first and second slices of tissue were taken, the first slice was stained
with click-iT EdU and second one was stained with BrdU separately. The two
micrographs were then superimposed together using the programme Photoshop. This
experiment was performed with liver sections taken from both control and treated
rats. The results revealed the key observation that the cells which divide at 24 hr are
different from those which divide at 48 hr in both control and treated liver rat tissues
as displayed in Figures 18 and 19. In other words, ciprofibrate does not cause the
same cells to divide repetitively but instead different cells divided at different times.
This suggests that that there is no specific type of hepatocytes which have a
particular physiological character, such as increased expression of certain genes, that
makes them more likely to divide at the different times and be susceptible to
carcinogens. This finding is consistent with that of Gournay, 2002 who suggested
that only mature hepatocytes have the ability divide. (Gournay, Auvigne et al. 2002).
4.1.6 Percentage of labelled hepatocytes in liver
It is known that approximately 3.5% of liver cells normally undergo DNA synthesis
(Lucier, Tritscher et al. 1991), which was similar to the average number of
replicative DNA synthesis found by BrdU & EdU labeling in the present study. 500
labelled nuclei were counted in both samples that were labelled either EdU or BrdU
to find average. Single labelled cells with EdU and BrdU were calculated and results
showed that the average of dual labelled is (5.5% ± 1.1). EdU and BrdU alone have
shown 3.4 ± 0.7 and 3.6 ± 0.1 respectively.
4.2.1 Effect of PXR ligands on hepatic DNA synthesis in female rats dosed
with CPA:
In the second part of this study work was undertaken to determine whether similar
sets of genes are induced in female rat liver cells by the genotoxic carcinogen
cyproterone acetate (CPA) as are induced by ciprofibrate. This followed previous
work was done by Amer (2011). The latter studies investigated the induction of DNA
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synthesis by peroxisome proliferators (PP) alongside CPA to make a preliminary
DQDO\VLVRIZKHWKHUVXEVHWVRIWKHJHQHVLQGXFHGE\33$5ĮDQG&3$ZHUHWKHVDPH
7KLV FRXOG EH RI PHGLFDO LPSRUWDQFH DV WUDGLWLRQDOO\ 33$5Į KDV D QRQJHQRWR[LF
mode of carcinogenesis, whereas genotoxic carcinogens can bind intracellular
receptors that bind DNA at specific DNA recognition sites.
The experiment was conducted under the same conditions implemented by Amer
(2011), such as animal age, dose and BrdU concentration. However, studies were
conducted using female rats as these were more likely to show increased changes in
gene expression. Two groups of female F-344/NHsd rats were dosed with100 mg/kg
CPA or corn oil (vehicle). The rats were then injected intraperitoneally with 100
mg/kg BrdU 2 hr prior to killing either at 3 or 24 hr after initial treatment (Schulte-
Hermann, Hoffman et al. 1980, Martelli, Campart et al. 1996). The dose of the CPA
used was chosen on the basis of following the biological conditions used in the
previous experiment (Amer 2011) and which had additionally been used elsewhere in
the literature (Coleman and Best 2005, Guzelian, Barwick et al. 2006).
4.2.2 Induction of hepatic DNA synthesis by CPA (PXR)
There has been growing interest over the current decade in the role of xenobiotics
that are characteristic non-genotoxic carcinogens. There is growing concern based on
evidence implicating some xenobiotics in liver growth(Sueyoshi and Negishi 2001,
Zhang, Xie et al. 2008), the worry being whether these chemicals are safe or not?
Studies were therefore taken to try to shed light on mechanisms of action of cell
division and whether this is related to cancer. By understanding how liver growth
works, it was hoped to gain insights into mechanisms of liver cancer on the grounds
that, if it were known how these chemicals cause cell division, it would give clues as
to how liver growth occurs. Two previous studies have been carried out by Al-
Khulaifi (2008) and Amer (2011) focusing on the role of ciprofibrate (associated
ZLWK33$5Į LQ OLYHUJURZWKZLWK VHYHUDO H[SHULPHQWV FRQGXFWHGRQ WKH OLYHUVRI
mice and rats. In addition, Amer (2011) used CPA (associated with PXR) in male F-
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344 rats as a positive control to study ciprofibrate gene induction. Amer (2011)
examined effects of CPA on hepatic DNA synthesis in male F-344NHsd rats at 4
time points; 1, 3, 5 and 24 hr of dosing. CPA is thought to have a completely
different mechanism compared with ciprofibrate.
In the present study, female F-344NHsd rats rather than males were used to
investigate effects of CPA on hepatic DNA synthesis at 3 and 24 hr of dosing. The
former work of Amer (2011) was performed using microarray technique while real
time PCR was utilized here to confirm the former and current results. In male F-344
rats 6% induction of DNA synthesis in liver was observed, whereas this was ~ 39.0
% in average of hepatocyte labeled were in female F-344NHsd rats at 24 hr in the
present study. This finding was concordant with the study of Amer (2011) in which
the labeling index was approximately 50% in female rats (Amer 2011). It is also
consistent with a previous study carried out by Martelli (1996) who found that the
dosing of CPA 100 mg/kg led to a higher induction of gene expression in female
rather than male rats after 3 days treatment (Martelli, Campart et al. 1996).
4.2.3 Effect of PXR ligands on hepatic DNA synthesis in female Fisher
rats
The pregnane X receptor (PXR) is a nuclear receptor that works as a sensor to the
presence of foreign toxic elements or xenobiotics, and responds by up regulating the
expression of proteins implicated in the detoxification of such chemicals. PXR is
activated by several endogenous and exogenous chemicals including steroids,
antibiotic and many other compounds (Quattrochi and Guzelian 2001). It has been
reported that the PXR has a central role in the regulation of the CYP3A4 gene and
others involved in drug metabolism and bile acid synthesis (Goodwin, Redinbo et al.
2002, Shukla, Sakamuru et al. 2011). It was of interest in the present study to assess
whether there might be some shared mechanisms, activated by both PPs (e.g.
ciprofibrate) and CPA (linked to PXR), that regulate DNA replication and cell
division (Wallenius, Wallenius et al. 2000, El-Sankary, Gibson et al. 2001).
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Therefore studies were undertaken using real-time PCR methodology to assess
whether any down or up-regulation was evident in response to CPA treatment in 3
genes previously found to be down or up-regulated by ciprofibrate according to
findings from microarray analysis (Amer 2011). Also included in studies as a control
for gene expression was an examination of expression of the CYP3A1 gene, for
which increased expression had previously been shown in response to CPA
treatment. Overall it was found that some genes (e.g. Ccnd1) appear to be
specifically induced by either CPA or ciprofibrate with no mutual overlap, whereas
some other genes might be a common target for the hepatic DNA synthesis (e.g.
Scd1 and G0s2) as follows.
4.2.4 Effect of CPA on CYP3A1 gene expression
CPA has been shown to be a potent inducer of CYP3A1 expression in rat and mouse,
triggering binding of the PXR receptor to its cognate DNA elements as heterodimer
with RXR and activation of transcription of genes such as CYP3A1 (Figure
3.3.1)(Moore, Parks et al. 2000, Sueyoshi and Negishi 2001, Pascussi, Gerbal-
Chaloin et al. 2003). Other studies have shown that prolonged exposure to CPA
caused liver carcinogenesis in rats, but that the liver could return to a normal weight
when the administration was stopped (Pichard and Ferry 2005). In the present study,
short-term administration with CPA confirmed that CYP3A1 gene expression was
significantly induced (2.5 fold difference) in female treated compared to female
control (and from female treated to male treated) at 3 hrs following treatment with
CPA. This finding was consistent with studies of in vitro induction of CYP3A1-
mRNA in rat liver slices treated with testosterone hydroxylation, which in turn
displayed that CYP3A1 induction was more sensitive in liver from female rats than
male liver (Glöckner, Wagener et al. 2003, Hartley, Dai et al. 2004). This first
finding of increased CYP3A1 expression provided a valuable control for the real-time
PCR work as it confirmed that a gene previously known to be up regulated by CPA
treatment was indeed confirmed to be up-regulated in the present study.
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4.2.5 Effect of CPA on Scd1
The stearoyl-CoA desaturase-1 (Scd1) gene encodes an iron-containing enzyme
which stimulates a rate limiting step in the synthesis of unsaturated fatty acids.
Moreover, Scd1 plays a key role in an increase of triglyceride as a result of
accumulation of carbohydrate in the body. This in turn acts to increase Scd1 gene
expression in liver via a sterol response element binding protein (Ntambi 1995,
Hashimoto, Ishida et al. 2013).
In previous studies Amer (2011) found that the expression of the Scd1 gene was
LQGXFHGE\FLSURILEUDWHDIWHUDQGKU,WZDVVLJQLILFDQWO\LQGXFHGE\33$5Į
(ciprofibrate) after 3 hr induction (13.2 fold change). Meanwhile, microarray analysis
of male rats treated with CPA found a 2.2 fold change. Interestingly, the induction
with CPA in male rats showed that Scnd1 expression was slightly lower than the
control samples at all the time points.
In the present study by contrast, real time PCR analysis of Scd1 showed a slight up-
regulation (1 fold change) with CPA in treated compared to control female samples
after 3 hr, although no difference was found between control and treated male rats.
This result is not consistent with the findings of the Amer (2011) and does not
VXSSRUWDFRPPRQSDWKZD\IRUKHSDWLF'1$V\QWKHVLVEHWZHHQ&3$RU33$5Į
4.2.6 Effect of CPA on Ccnd1
The Ccnd1 gene encodes a protein involved in cell division. Cyclin D1, a cell cycle
protein involved in regulation of cell proliferation, is associated with several cancers
and other diseases. Previously, it was found that the expression of the Ccnd1 gene
ZDVVLJQLILFDQWO\LQGXFHGE\33$5ĮFLSURILEUDWHDIWHUKU IROGFKDQJHEXW
was then down-regulated at 5 hr time point compared in treated to control male rats
(Amer 2011). Meanwhile, microarray analysis of male rats treated with ciprofibrate
revealed up-regulated expression on Ccd1 (2.9 fold change) at 3 hr.
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It seems that this data for this gene is controversial because treatment with CPA of
male F-344 rats at 1, 3 and 24 hr had shown no significant difference when compared
with control rats, which showed significant high induction (> 2.3 fold change) at 5
hr.
In the present study in contrast, real time PCR analysis of Ccnd1 showed up-
regulation (1.5 fold changes) following CPA treatment compared to control female
samples at 3 hr. Also there was ~1.5 fold change from treated female to treated male
at 3 hr time point. Ccnd1 might be a common target for hepatic DNA synthesis, i.e. it
is possible that Ccnd1 is not specific for PPs nor the CPA. This is consistent with
Pribiri, 2001 (Severino) who found that the induction with thyroid hormone showed
high induction of Ccnd1 at early time of DNA synthesis and induced cell division in
the rat (Severino, Locker et al. 2011). Therefore Ccnd1 may be considered a gene
that is expressed in common by both ciprofibrate and CPA treatment.
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4.2.7 Effect of CPA on G0s2
The effects of CPA on the induction levels of G0s2 mRNA, involved with G0/G1
switching at 3 hr showed no significant difference between the control and treated
female Fisher rats; in addition there was no significant difference between control
and treated male rats. These results are consistent with those of Amer (2011) who
found that the induction of G0s2 in male F-344 rats showed no significant difference
in all samples treated with CPA at time points 1, 3 and 5 hr, while the induction with
ciprofibrate showed that the expression of G0s2 was significantly higher (> 5 fold
change) (Amer 2011), which suggested that G0s2 might be a target for increased
DNA synthesis (Sueyoshi, Mitsumata et al. 2010). This finding supports a previous
finding by Amer, where the G0s2LVFRQVLGHUHGVSHFLILFWRFLSURILEUDWH33$5Į
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CONCLUSION5.
Peroxisome proliferators are a class of chemicals that have diverse effects in rats and
mice including increased DNA synthesis and peroxisome proliferation. These
chemicals act through ligand activation of nuclear membrane receptors termed
‘peroxisome-proliferator-activated receptors’ (PPARs), which themselves act as
nuclear transcription factors (Heuvel, Thompson et al. 2006, Fiskerstrand, H'Mida-
Ben Brahim et al.) (Hosoe, Nakahama et al. 2005) (Yuan, Chen et al. 2010).
PPs induce a cellular process characterised by a dramatic increase in the size and
number of peroxisomes correlated with both hepatocyte hypertrophy (i.e. an increase
in the size of liver cells) and hyperplasia (i.e. an increase in the number of liver cells
during replicative DNA synthesis and cell division). Peroxisome proliferators include
herbicides, plasticisers, hypolipidemic drugs and synthetic fatty acids. However, the
mechanism of action of increased hepatocyte growth is not currently understood. It
was hoped that gaining understanding relating to the mechanism by which increased
liver growth is induced by PPs in rodents would hopefully provide insights into how
natural liver growth occurs and have medical benefits for human health if the
mechanism of PP toxicity can be overcome. Knowledge gained from the mechanism
of PP activation might also then be applied to other chemical carcinogens.
In the present study, firstly the mode of action of the peroxisome proliferators
(ciprofibrate) was investigated. Previous work had indicated that two successive
doses of ciprofibrate treatment separated by 24hr led to two rounds of liver cell
replication, but it was not clear whether the same or different hepatocyte cells were
involved in this growth response. To study this phenomenon, histochemical
experimental work was undertaken to assess whether the same or different
hepatocyte cells were stained during the two rounds of cell division following
ciprofibrate treatment. The two histochemical stains used were EdU and BrdU,
which are both base-pair analogues that stain nuclei undergoing DNA replication. It
was hypothesized that if EdU was used to stain cells at 24 hr and then BrdU at 48 hr,
that if the same cells were responding to ciprofibrate treatment then cells would be
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co-stained by both dyes, whereas if different cells were responding then there would
be little or no double staining of hepatocyte cells – instead different cells would be
stained. F-344/NHsd rats, aged 7-8 weeks, were injected with three different
concentrations of EdU to determine the amount of the EdU required to allows
measurement of the labelling index of hepatocytes. 2 mg/kg EdU was found to be an
efficient amount for detecting replicative DNA synthesis. Finally, optimised
protocols for BrdU staining were then established. Primary anti-BrdU antibodies
were purchased from two sources, Sigma and Amersham. The primary antibody
purchased from Amersham provided clear and reliable results at a concentration of
1:750 µl. The concentration of secondary anti-BrdU antibody (1:50 µl) used was the
same as in previous work.
Experimental work undertaken to determine if the same, of different hepatocytce
cells, were induced to divide during the two rounds of cell division following
ciprofibrate treatment revealed to key result that the cells undergoing division at 24
hr were not related to those that undergoing division at 48 hr. This is of medical
significance as it suggests that there are not hepatic cells that are especially sensitive
to repeated PP treatment, but that different cells can respond and therefore there is a
more general risk of increased cell division and carcinogenesis from such non-
genotoxic carcinogenic compounds.
In related studies, previous work had investigated the effects of the genotoxic
carcinogen cyproterone acetate (CPA) on hepatocyte growth of male rats treated with
100 mg/kg CPA. In the present study female rats were treated with CPA, to firstly
evaluate whether differences in labelling indices were present compared to male rats,
as indicated by Amer (2011). Female F-344/NHsd rats, aged 14-15 weeks, were
treated at time Ø with CPA and then injected i.p with BrdU at 22 hr, and rats were
killed 2 hr later. Results showed that the female rats were found to indeed have a
considerably higher labelling index (50%) compared to male rats (6%), confirming
the results of Amer (2011). This finding suggested that upregulation of gene
expression in female rats should be much higher as well, which might provide an
exciting opportunity to identify sets of genes involved in carcinogenic response, with
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overlap to those involved in PP response. To investigate this phenomenon further
another experiment was designed where the rats were gavaged at time Ø with 100
mg /kg CPA and then killed 3 hr later. In this study, the focus was on early DNA
synthesis of genes stimulation whose expression had been shown to be up- or down-
regulated in a previous study by Amer (2011) at the same 3 hr time point. This study
was conducted on female rats, compared with males in the previous study, given the
potential to detect greater differences in gene expression.
An analysis was made by real time PCR of four genes of interest as a preliminary
pilot study (Scd1, Ccnd1, and G0s2). This showed some statistically significant
differences between the control and CPA treated group, and also some significant
differences between male and female treated rats e.g. the induction of Ccnd1 in
female fisher rats with CPA was significantly higher than in control and male fisher
rats at 3 hr. However, the expression of G0s2 in CPA – treated female rats showed
no significant difference from the control and male treated rats and results with Scd1
expression were also inconsistent with those of Amer (2011). Thus overall there was
little evidence of shared pathways between CPA and ciprofibrate activity and
therefore different mechanism of cell toxicity are likely to be present, albeit with
some potential overlap as shown by the Ccnd1 gene, whose expression was
upregulated in response to exposure to both chemicals.
.
.
Part 2
The role of peroxisome
proliferators in a model of
a neurodegenerative
disorder
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Introduction - Review of Literature6.
6.1 Introduction to part two
An improved understanding of the mechanisms causing and affecting pathogenicity,
has resulted in an advance in treatment development are increasing to understanding
the reasons and mechanisms of the pathogenicity and development ways of
treatment. Proliferation of a specific cell type is a response to acute brain injury or
infection that involves activation and an increased recruitment of astrocytes and
microglia. As a result there is, increased production of cytokines, (chemokines)
(Bartholdi and Schwab 2006). Understanding the causes of neurodegenerative
diseases is necessary, given that in many cases, the inflammatory response remains
unclear. Researchers have begun to address some of the problems that may the cause
nervous system degeneration, such as oxidative stress or dysfunction of the
proteasome system (Emerit, Edeas et al. 2004, Halliwell 2006).
This study aims to shed some light on the process of astrocyte proliferation in such
diseases as Parkinson’s or Alzheimer. The activation of astrocytes has been tracked
in order to understand the mechanisms and speed of development of
neurodegenerative disorders. For example, Lewy body Dementia is a
neurodegenerative disorder affecting the motor system. Lewy bodies are the
abnormal accumulation of protein inside nerve cells resulting in PD (Goedert,
Clavaguera et al. 2010). A number of studies have investigated the causes of
neurodegenerative disorders, some of which have focused on the role of the ubiquitin
system (Di Napoli and McLaughlin 2005). Thus, one of the important steps in the
emergence of neurodegeneration is the dysfunction of the ubiquitin proteasome
system (Hara, Nakamura et al. 2006). Currently, inhibiting the proteasome system is
one of methods used in the preparation of neurodegeneration models. Therefore, a
26S proteasome of mouse cortical brain tissue has been inhibited to represent 26S
proteasomal dysfunction of neurodegenerative disease (Petrucelli and Dawson 2004,
Bedford, Hay et al. 2008). This mouse neurodegeneration model (Psmc1fl/fl;
&D0.,,Į&UH KDV EHHQ XVHG DORQJVLGH PRGHOV RI ZLOGW\SH SXSV 3VPF1fl/fl;
&D0.,,Į:W7KHPDLQIRFXVRIWKHSURMHFWLVWRH[SODLQWKHVSHFLILFUROHRI
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astrocytes in the inflammatory response as well as to attempt to reverse any
detrimental changes. Currently, there is growing interest in the importance of
peroxisome proliferators in the treatment of brain inflammation (Bernardo and
Minghetti 2006, Klegeris, McGeer et al. 2007, Saavedra, Sánchez-Lemus et al.
2011). There is growing evidence that peroxisome proliferator-activated receptors
may be useful as a therapeutic target for neurologic disease and CNS injury as their
activation affects pathologic mechanisms. Therefore, PPAR activation has beneficial
effects in many pre-clinical models of neurodegenerative diseases and CNS injury
(Mandrekar-Colucci, Sauerbeck et al. 2013).
7KHSHUR[LVRPHSUROLIHUDWRUDFWLYDWHGJDPPDUHFHSWRU33$5ȖKDVEHHQVKRZQWR
be involved in immune differentiation as well as playing a key role in the immune
response during the inhibition of the inflammatory response. New evidence has
LQGLFDWHG WKDW WKHSUHVHQFHRI33$5ȖDJRQLVWVHLWKHUYLD  IRRGRUGUXJV DUHPRVW
likely beneficial to human health by acting as anti-inflammatory molecules (Martin
7KLV VWXG\ KLJKOLJKWV WKH LPSRUWDQFH RI 33$5Ȗ DJRQLVWV LQ UHGXFLQJ
DFWLYDWHG JOLRVLV XVLQJ URVLJOLWD]RQH 33$5Ȗ DJRQLVWV WR LQKLELW DVWURF\WH
proliferation in a mouse model representing the neurodegenerative disorder.
To study astrocyte proliferation, organotypic slice culture systems have been utilized
in vitro. Organotypic cultures have the advantage that they are open to a variety of
experimental manipulations. To ensure comparability of the in vitro model with
animals, in vivo paraffin sections were used alongside for identification of astrocyte
populations. Confocal and light microscopy were used to observe the astrocytes in
the organotypic brain culture, cryostat and paraffin sections.
6.1.1 The nervous system
The nervous system is divided into two main sections, the central nervous system
and the peripheral nervous system (Dahlstrand, Lardelli et al. 1995, Nieuwenhuys,
Voogd et al. 2007). The central part consists of the brain and spinal cord, and the
peripheral of sensory neurons, ganglia which are neurons providing connections
between different neurological structures of the nervous systems, and nerves.
Neurons and glial cells make up both the peripheral and central nervous systems, the
Chapter 6 Introduction
133
neurons being the main building unit of the nervous system (Pakkenberg and
Gundersen 2011). Glia is a Greek word meaning ‘glue’ or ‘sticky’. Glial cells are
important in preserving homeostasis, and myelin integrity, as well as providing
support and protection for neurons in the brain. However, glial cells do not
participate directly in the transfer of the neuronal signals. Glial cells outnumber
neurons by about 10:1 depending on the brain region (Hilgetag and Barbas 2009). As
well as supporting neurons, glial cells act as insulation for electric charges between
neurons and neurotransmitters (Oligodenrocytes in the CNS and Schwann cells in the
PNS, and supply neurons with vital nutrients. They also aid disposal of dead and
damaged cells, and secrete factors for the growth of neurons (Jessen and Mirsky
2005).
This study focused on glial cells, especially astrocytes, which are the biggest glial
cells in size. The following diagram summarizes the structure of the nervous system
(figure 6-1).
Figure 6-1 Diagram shows the components of the central and peripheral nervous system
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6.1.1.1 The cortex
The cerebral cortex is neural tissue that surrounds the brain, representing the grey
area of brain. The cerebral cortex is divided into left and right hemispheres, and is
responsible for higher brain functions where information processing occurs (Smith,
Fries et al. 2009). This region plays a key role in memory, attention, and integration
of ideas in addition to language development, perception and awareness (Del Cul,
Dehaene et al. 2009). It is a layered structure consisting of either three or six layers.
The three layered areas, such as the olfactory cortex and hippocampus, represent
phylogenetically older parts of the brain (Archicortex) while the neorcortex the most
recently developed part consists of six layers, each of which has a different structure
in terms of neurons and connectivity. The human cerebral cortex has a much larger
surface area than other primates and ranges in thickness between 2–4 mm (Fischl and
Dale 2000).
The cortical layers are called grey matter due to the fact that the brains in preserved
material tend to be grey in colour, and consist of neurons and their unmyelinated
fibers. Below this layer is the white matter, which is made up of myelinated axons.
These connect neurons in the cerebral cortex with each other, as well as to nerve
cells in other parts of the central nervous system.
The surface of the cerebral cortex is characterized by extensive folds. These folds or
gyri are separated by grooves, called "sulci". The cortex can be split into several
layers called phylogenetically, the neo-cortex (called iso-cortex), is distinguished
into six horizontal layers. The hippocampus is one of the oldest parts of the cortex
(also called archi-cortex), it has three cellular layers, and is divided into subfields.
Neurons in various layers connect vertically to form small microcircuits, called
columns. Different neocortical architectonic fields are distinguished by variations in
the thickness of these layers, their predominant cell type and other factors such as
neurochemical markers, Figure 6-2 shows the hippocampus and cerebral cortex in
both human and mouse (Abeles 1991, Semendeferi, Armstrong et al. 2001).
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Figure 6-2 Diagram of the brain structure, illustrating differences in neuroanatomy between mice and
humans.
Figure Shows hippocampus and cerebral cortex in both human and mouse.
www.nature.com/nrd/journal/v4/n9/fig_tab/nrd1825_F2.html
6.1.1.2 The biology of the hippocampus:
The hippocampus is a major component of vertebrates and human brains, in
particular. The term was derived from its curved shape in coronal sections of the
brain, where the term contains two Greek words; (hippos) meaning ‘horse’ and
(kampi) meaning ‘curve’. It plays an important role in linking information from
short-term memory to long-term memory. It has extensive links with the cerebral
cortex (Bliss and Collingridge 1993, Piekema, Kessels et al. 2006). Moreover, it is a
fore brain structure, located under the cerebral cortex in mammals. In primates, the
hippocampus is located in the medial temporal lobe, below the cortical surface. It
contains two main interlocking parts; Ammon's horn and the dentate gyrus. In the
dentate gyrus (DG), CA1 and CA3 fields are often referred to as the hippocampus
proper. Both hippocampus and the dentate gyrus are representing the main parts of
forebrain (Figure 6-3). Based on previous research, it is evident that the hippocampus
is part of the brain system responsible for spatial memory and navigation (Gluck,
Meeter et al. 2003, Kullmann 2011). Therefore, the hippocampus is a major target
for research to find explanations for diseases of the central nervous system and
neurodegeneration in particular.
Cerebral
cortex
Thalamus
Amygdala
Hippocampus
Hypothalamus
Human brain
Mouse brain
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Figure 6-3 Scheme of hippocampal with dentate gyrus layers in rodents.
Schematic illustration of the three layers of dentate gyrus area. The sub-granular zone of the dentate
gyrus houses transit amplifying progenitor cells. These cells mature into neuroblasts, which migrate
into the granule cell layer (GCL) and differentiate into granule neurons (Mature Granule Cell). The
newly generated granule neurons allow interconnections by extending axonal projections along the
mossy fiber towards the CA3, and into the molecular layer Mature. Cells receive glutamatergic inputs
from the entorhinal cortex; GABAergic inputs from the interneurons and provide glutamatergic inputs
to the CA3 neurons. The diagram adapted from from (Abrous, Koehl et al. 2005, McCaffery, Zhang et
al. 2006).
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6.1.1.3 Dentate gyrus
The large number of small blood vessels that lie within the dentate gyrus give it a
toothed appearance, thus called the dentate gyrus (DG) (Van Praag, Shubert et al.
2005). The dentate gyrus is part of the hippocampus, which is believed to be
responsible for forming new memories (Neves, Cooke et al. 2008). It is characterized
by its granular layer and it has three layers; molecular layer, granular layer (which
gives granular shape to the DG and polymorphic layer. The CA3 pyramidal cells
operate as a single auto-association network to store new episodic information. The
dentate gyrus is important, mainly during learning, to help to produce a new pattern
in the CA3 cells. Namely, the zone from the DG to CA3 is essential for the process
of learning (Gilbert, Kesner et al. 2001). Therefore, some studies have been
conducted to determine the ability of hippocampus to store new information as well
as how quickly the CA3 auto-association system is operating during recall using
modified synapses in pathways from the hippocampus to the cerebral cortex (Kesner
2007).
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6.2.1 Neuroglia (glial cells)
Historical accounts indicate that neuroglia were described for the first time in 1856
by the German pathologist Rudolf Virchow (Norman, Urich et al. 1958). His first
drawings of glia were unlike the modern image of an astrocyte, but similar to an
activated microglial cell. Virchow was the first to introduce the concept of neuroglia.
Pio del Rio-Hortega (1882–1945) is also one of the first who described glial cells
(Kettenmann, Hanisch et al. 2011). Neuroglia are glia cells that have great capacity
to protect neurons in the brain. Neuroglia, contain two types of cells (microglia and
macroglia) andboth have diverse functions (Figure 6-4). Microglia have essential
developmental and phagocytic roles in the brain, and are embryologically derived
from the mesoderm. Macroglia are large cells comprising of oligodendrocytes and
astrocytes. Astrocytes provide important structural, metabolic and trophic support to
neurons. Neuroglial cells comprise about half the total volume of the cells that make
up the brain and spinal cord. Their ratio differs from one part of the brain to another.
For example, in the cerebral cortex most of the glia are oligodendrocytes (75.6%);
astrocytes account for 17.3% and microglia (6.5%). Humans are known to have the
most abundant and largest astrocytes of any animal. Moreover, the amount of brain
tissue that is made up of glial cells in human brain contains 90%, compared to 65%
in a mouse. (Bartus and Dean III 2009).
Figure 6-4 Classification of glial cells and how they differ.
www.mananatomy.com/basic-anatomy/glial-cells-neuroglia
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6.2.1.1 Microglia
Microglia represent the first line of immune defense in the central nervous system.
They account for 20% of the total glial population, and are the macrophages of the
brain and spinal cord (Olson, Zamvil et al. 2003, Hauwel, Furon et al. 2005).
Microglia recognizes foreign bodies, engulf them, and are extremely sensitive to
small pathological changes in the CNS (Yang, Han et al. 2010). Microglia are
activated in the spinal cord after acute injury and in chronic disease and it is
suggested that these cells have an innate immune memory of tissue injury and
degeneration. Namely that inflammation is associated with a decline in function of
microglia leading to neurodegenerative disease (Hanisch and Kettenmann 2007).
6.2.1.2 Astrocytes
Astrocytes differ from neurons in terms of form and functions in the brain.
Astrocytes can be divided into two kinds based on their location and morphology.
Protoplasmic astrocytes are most abundant in the grey matter and have branched
processes. The second type, called fibrous astrocytes have long and fibre-like
processes and are located in the white matter (Nedergaard, Ransom et al. 2003,
Sofroniew and Vinters 2010). As there are significantly more astrocytes in the brain
than neurons (Figure 6-5) they are vital for normal neurotransmission to occur
(Volterra and Meldolesi 2005). Astrocytes also have a key role in stabilizing, and
modulating synaptic activity. Moreover, they are implicated in the pathological states
of reactive gliosis and glial scar formation that accompany injury, and may be
associated with brain tumour development, including glioblastomas. Functions of
astrocytes include physical and metabolic support for neurons, detoxification, and
guidance during migration, regulation of energy metabolism, electrical insulation,
transport of blood-born material to the neuron, control of fluid movements between
the intracellular and extracellular space and reaction to injury. In addition, astrocytes
are predominantly important in determining the tissue response to ischemia and CNS
trauma. They are responsible for reducing excitotoxicity, whereby nerve cells
Chapter 6 Introduction
140
become damaged and die as a result of excessive stimulation from neurotransmitters
e.g. glutamate. (Volterra, Bezzi et al. 2006).
This study focused on the presence of astrocytes in the two main regions, cortex and
hippocampus, where it has been reported that on average, astrocytes make up about
18% of the total neuroglial cell population. Astrocytes perform many functions in the
cortex such as regulating blood flow and influencing neuronal responses (Peters,
Leahu et al. 1994). Glial cells can be identified by their expression of the main
intermediate filament, glial fibrillary acidic protein (GFAP).
Figure 6-5 Illustration of the glia cells.
A; Astrocyte (in green colour) processes make contact with the neuronal synapses and the blood
vessel. B; Astrocyte under confocal microscope. Astrocytes are in contact with both neurons and the
small blood vessels. Astrocytes serve to alter blood flow in response to neuronal activity. (Allen and
Barres 2009, Egolf 2012).
A
B
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6.2.2 Fundamental functions of astrocytes
Some anatomical studies suggest that astrocytes in mice are about 2.5 times smaller
than in humans (Kimelberg and Nedergaard 2010). Studies have indicated several
vital functions of the astrocytes which can be summarized into eight points that allow
neurons in the brain to function optimally (Figure 6-6).
Figure 6-6 Diagram summarizes the most important functions of astrocytes
Astrocytes maintain and regulate glycogen as energy reserves, as well as serving several other
functions. They support neurons through the availability of glucose, and play a vital role in the
regulation of K+ and H+ ions and water transport (via astrocytic end feet). Glutamate uptake by
astrocytes prevents an *excitotoxic glutamate rise in the extracellular space. Astrocytes can also
produce neuro-trophic factors, and are involved in the metabolism of neurotransmitters.
http://missinglink.ucsf.edu/lm/introductionneuropathology/Response%20_to_Injury/Astrocytes.htm
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6.2.3 Gliosis
Gliosis is an accumulation of astrocytes in damaged regions of the CNS. This
proliferation of astrocytes occurs as a result of two processes, hypertrophy and
hyperplasia. The activation of astrocytes is an indication of damage to the nervous
system due to stroke, trauma, growth of a tumor, or neurodegenerative disease,
which is one of the most common of sources of damage e (Pekny and Nilsson 2005).
Gliosis is a reactive cellular process leading to scar formation in the central nervous
system, as a result of injury. This action creates a dense fibrous network of neuroglia
in areas of damage. Glia scar formation identifies a reactive cellular process
including astrogliosis that follows the brain injury, which usually leads to death and
disappearance of the neurons, known as gliosis (Djebaili, Guo et al. 2005, Bignami
and DAHL 2008).
6.2.4 Mechanism of action of gliosis (proliferation of astrocytes)
Gliosis can be defined as proliferation of astrocytes resulting in an increase of
astroglia in the damaged areas of the central nervous system (Logan, Berry et al.
2006). It is believed that astrocytes help to retain the structure of cells in addition to
the main function of holding neurons together in a 3-D matrix. They also serve
many other functions such as maintenance of the extra cellular environment and
stabilization of cell–cell communications in the CNS (Bear, Connors et al. 2006).
Astrocytes become active and start proliferating in response to injury such as trauma,
tumor brain growth or neurodegenerative disorders (Buffo, Rolando et al. 2010).
Due to brain injuries, astrocytes undergo physiological changes which lead to
increased synthesis of glial fibrillary acidic protein (GFAP), which astrocytes
express. The expression of GFAP occurs in astrocytes. GFAP is an important
intermediate filament (IF) protein that allows the astrocytes to initiate synthesis of
more cytoskeletal supportive structures (Franke, Krügel et al. 2003) .
Astrocytosis; (astrogliosis) is defined as an increase in the number of astrocytes due
to the damage of adjacent neurons (Barbeito, Pehar et al. 2004). Due to an injury,
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astrocytes become activated , which resulted in triggers molecules produced at site
drive of further brain injury. This process is called astrogliosis (cell hypertrophy) and
is followed by up-regulation of intermediate filaments (IF) and increased cell
proliferation. At this stage; the astrocytes migrate towards the injured area to create
the glial scar (Figure 6-7 E), and release factors mediating the tissue inflammatory
response (Blackburn, Sargsyan et al. 2009). It has been reported that the reactive
astrocytes can repopulate stem cell numbers after damage. The reactive process of
astrocytosis is followed by hypertrophy as mentioned earlier, and then up-regulation
of the intermediate filament (IF) protein, whereas the stem cells contain Nestin a
member of the intermediate filament (IF) protein family that is especially abundant
in neuroepithelial stem cells. There is also expression of vimentin, and GFAP. The
cells enter the stage of cell proliferation, while astrocytes can continue to divide and
migrate to form the glial scar, and release factors mediating the tissue inflammatory
response. The next schematic (Figure 6-7) illustrates the active mechanisms of
astrogliosis (glial scar formation).
Figure 6-7 Schematic drawing illustrating astrogliosis (astrocyte proliferation).
A: Production of growth factors step (cytokines) and release of nucleotides and toxic compounds. B);
Astrogliosis; (cell proliferation). C): Migration towards the lesion. D). Reactive astrocytes contribute
in glial scar formation. (Buffo, Rolando et al. 2010).
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6.2.5 Role of astrocyte in promotes neuronal survival
Many studies indicate that astrocytes are the supporting cells for neurons in the
nervous system (Zhang, Li et al. 2009). Astrocytes provide structural support for
neurons. In addition, they are responsible for maintaining the homeostasis of the
brain tissues. However, a high activation of astrocytes and microglia is an indication
of uncontrolled inflammation, predominantly resulting in neuronal cell death. Thus,
astrocytes are stimulated to trigger cell proliferation , as a reaction to the destruction
of adjacent neurons because of CNS trauma (Song, Stevens et al. 2002, Luna-
Medina, Cortes-Canteli et al. 2005).
6.2.6 Reactivation of astrocytes during CNS injury
Reactive gliosis is distinguished by cellular hypertrophy and proliferation of
astrocytes. Proliferating microglia form a bordering glial scar around the damaged
area. Reactive gliosis is a natural reaction that occurs during brain injury, and the
formation of the glial scar protects the brain, despite also causing inhibition of
neuronal regeneration. The brain is exposed to varying intensities of injury, both
moderate and high grade. Moderate astrogliosis occurs after mild trauma, whereby
the combination of molecular changes and impact on functional activity leads to
cellular hypertrophy. In severe astrogliosis, scar formation generally occurs and
continues along cellular borders, causing tissue damage and/or inflammation. Glial
scars tend to persist for long periods of time and act as barriers to inflammatory cells.
This in turn protects intact tissue from nearby accumulations of inflammatory cells
(Buffo, Rolando et al. 2010, Allaman, Bélanger et al. 2011).
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6.3 Neurodegenerative diseases
‘Neurodegenerative’ refers to the pathological changes in the brain, resulting from
loss of neurons, ultimately leading to deterioration of brain function. At a cellular
level, neurodegeneration is seen as a gradual loss of structure or function of neurons
leading to neuronal death. Many neurodegenerative diseases including Parkinson’s,
Alzheimer’s, multiple sclerosis, Als lateral sclerosis and Huntington’s disease occur
as a result of neurodegenerative disorders (Minagar, Shapshak et al. 2002, Pryce,
Ahmed et al. 2003, Romero and Rodríguez Luque 2011). The hallmark of many
neurodegenerative diseases is the accumulation of intracellular or extracellular
protein. Some studies in vitro and in vivo have provided new visions into
neurodegeneration disorders, furthering understanding of the mechanisms regulating
protein processing, specifically neurodegenerative disease proteins. The
understanding of such disorders facilitates the development of therapies, that may
prevent occurrence of severe memory loss, communication problems or the
aforementioned diseases (Zecca, Youdim et al. 2004). These types of diseases belong
to the category of dementias which result in cognitive deficits (loss of cognitive
ability as a result of a brain injury (Dementia and MCI , Robinson 1998, Schneider,
Wilson et al. 2003).
6.3.1 Anti-Inflammatory role of PPARs in neurodegenerative disorders
Recent studies point towards the role of peroxisome proliferator activated receptors
in protecting against inflammation, particularly in the central nervous system. New
evidence has shown a beneficial effect of targeting peroxisome proliferators
DFWLYDWHG UHFHSWRU JDPPD 33$5Ȗ WR LPSURYH WKH RXWFRPHV RI QHXURGHJHQHUDWLYH
GLVHDVH 6HYHUDO UHFHQW VWXGLHV KDYH VKRZQ WKDW 33$5Ȗ DJRQLVWV LQKLELW QHXURQDO
GHJHQHUDWLRQ )RU H[DPSOH RUDO WUHDWPHQW ZLWK SRWHQW 33$5Ȗ DJRQLVWV VXFK DV
telmisartan, provides neuro-protection against cell death and neuro-inflammation
(Shoelson, Lee et al. 2006, Akaike, Takada-Takatori et al. 2010).
.
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6.3.2 Neuro-inflammation in parkinsons’ disease (PD), Alzheimer (AD)
and Sclerosis
0RVWRI WKHVWXGLHVSHUIRUPHGRQWKH33$5ȖUHFHSWRUKDYHEHHQLQUHODWLRQWRWKH
microglia, to understand its role during inflammation. Studies on astrocytes are less
abundant (Carta and Pisanu 2012). The present study focuses on the role of
astrocytes, and understanding how they are activated to proliferate, ultimately
resulting in neurodegenerative disorders.
6.3.2.1 Alzheimer disease and microglial phagocytic role
Studies suggest that Alzheimer's disease (AD) is associated with age, gender and
varies between brain regions. The cause and progression of Alzheimer's disease is
not well understood. Alzheimer’s disease involves glial inflammation associated with
amyloid plaques in the grey matter of the brain. This would lead to abundance of
microglia, and astrocytes, leading to progressive neuronal degeneration and
ultimately death (Lipton 2005). The role of the microglial cells in the AD brain is
controversial, as it remains unclear whether the microglia form the amyloid plaques
or react to them in a macrophage-phagocytic role. Some evidence has shown the role
of phagocytosis by microglia in the brain, although there is also evidence that
microglia show differential selection to specific types of amyloid plaque in the AD
brain. This may explain why microglia are sensitive to the presence of foreign
bodies (McGeer, Itagaki et al. 1988, Wyss-Coray and Mucke 2002).
6.3.2.2 Parkinson's disease
Parkinson's disease is a degenerative disorder in the central nervous system
characterised by loss of dopaminergic neurons in the extrapyramydal motor system.
7KHSDWKRORJ\RIWKHGLVHDVHLVFKDUDFWHUL]HGE\WKHJDWKHULQJRIDSURWHLQFDOOHGĮ
V\QXFOHLQ LQWR/HZ\ERGLHV LQQHXURQV7KHĮV\QXFOHLQJHQHZDV LGHQWLILHGDV WKH
main element of Lewy bodies. Lewy bodies (LBs) cause gradual degeneration of
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neurons progressing to full Parkinson’s disease. The ubiquitin proteasome system
(UPS) became the most important way to verify the mechanism of PD. The UPS is a
highly regulated and controlled system, thereby avoiding protein degradation in the
brain (Olanow, Kieburtz et al. 2008).
6.3.2.3 Ubiquitin Proteasome System
Proteasomes are very large protein complexes, found inside all eukaryotes and
archaea, and in some bacteria. In eukaryotes, they are located in the nucleus and the
cytoplasm. The cells of organisms work hard to maintain the healthy balance of
proteins. The main function of the proteasome is to degrade unwanted or damaged
proteins by proteolysis, a chemical reaction that breaks peptide bonds. Enzymes that
carry out such reactions are called proteases. Their important regulatory role is
carried out by the ubiquitin proteasome system (UPS). Proteasomes are part of a
major mechanism by which cells regulate the concentration of particular proteins and
degrade misfolded proteins. The degradation process yields peptides of about seven
to eight amino acids long, which can then be further degraded into amino acids, to be
used in synthesizing new proteins. In a sense, the UPS is responsible for detecting
destroyed or faulty proteins. Proteins are tagged for degradation with a small protein
called ubiquitin, (Figure 6-8). The tagging reaction is catalyzed by enzymes called
ubiquitin ligases.
Ubiquitin is a small regulatory protein that has been found in almost all tissues of
eukaryotic organisms. Among other functions, it directs protein recycling. Ubiquitin
binds to proteins and labels them for destruction. The ubiquitin tag directs proteins to
the proteasome, which is a large protein complex in the cell that degrades and
recycles unwanted proteins. Once a protein is tagged with a single ubiquitin molecule
(monoubiquitination) or many (polyubiquitination), this is a signal to other ligases to
attach additional ubiquitin molecules. The result is a poly-ubiquitin chain that is
bound by the proteasome, allowing it to degrade the tagged protein (Rogers, Paine et
al. 2010).
Chapter 6 Introduction
148
Therefore, the UPS can be over-active, whereby useful proteins are destroyed, or
underactive, causing harmful proteins to build up to toxic levels. Homeostasis
requires the right amount a specific protein at the right time (Kimura and Tanaka
2010). Failure of the ubiquitin proteasome system can result in diseases such as;
Alzheimer’s disease, infectious diseases, some cancers and inflammatory diseases
such as Rheumatoid (Oddo 2008, Moreau, Luo et al. 2010).
Figure 6-8 Diagram of the 26S proteasome structure.
The 26S proteasome system composes of two sub-complexes: a 20S core particle that carries the
catalytic activity, and a regulatory 19S regulatory particle. Ubiquitination and degradation processes
undergoing three steps to degrade misfolded proteins. (E1) activates and binds to ubiquitin. The
activated ubiquitin is transferred to a cysteine group, an ubiquitin-conjugating enzyme (E2). Then, the
ubiquitin is transferred to the substrate by the action of an ubiquitin ligase enzyme (E3). Depletion of
26S proteasomes in mouse brain neurons showes 26S proteasomal dysfunction caused
neurodegeneration (Ciechanover 2005).
Chapter 6 Introduction
149
6.4 Peroxisome proliferator-activated receptors (PPARs) in the brain
As referred to in Chapter one, peroxisomes are organelles found in almost all
eukaryotic cells. In 1978, Arnold describes the peroxisome proliferators in both
neurons and glia (Cristiano, Bernardo et al. 2001). It became known that astrocytes
contain high levels of peroxisomes (Moreno, Farioli-Vecchioli et al. 2004).
Peroxisome proliferator-activated receptors are ligand-activated transcription factors,
as part of the steroid/thyroid hormone category, in the superfamily of nuclear
receptors. Other studies showed that PPAR transcription factors are pharmaceutical
drug targets in inflammatory degenerative diseases (Stuchbury and Münch 2005).
7KH WUDQVFULSWLRQ IDFWRUV LQFOXGH WKUHH LVRIRUPV WKDW KDYH EHHQ LGHQWLILHG 33$5Į
15&33$5ȕ15&DQG33$5Ȗ15&HQFRGHGE\GLIIHUHQWJHQHV7KH
ODWWHULQFOXGHVWZRLVRIRUPVQDPHO\33$5Ȗ	33$5Ȗ<X0DWVXVXHHWDO
Aleshin, Grabeklis et al. 2009). PPARs heterodimerize with RXR receptors and bind
to specific DNA sequences, termed peroxisome proliferator response elements
(PPREs).
33$5V DUH IRXQG LQ WKH QHUYRXV V\VWHP GXULQJ URGHQW HPEU\RJHQHVLV 33$5ȕ
UHSUHVHQWV WKH PRVW DEXQGDQW RI WKH WKUHH LVRIRUPV ZKLOH 33$5Į DQG 33$5Ȗ
decrease in the postnatal brain. The three isoforms were detected in the hippocampal
DUHDZLWKKLJKFRQFHQWUDWLRQVRI33$5ȕIRXQGLQWKHGHQWDWHJ\UXVDQG&$UHJLRQ
FRPSDUHGWR33$5ȖZKLFKLVPRUHFRQFHQWUDWHGWRWKH&$UHJLRQ/XQD0HGLQD
Cortes-Canteli et al. 2007, Yi, Park et al0RUHRYHU33$5ȖLVVKRZQKLJKO\
expressed in most other brain areas, especially cortex.
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5RVLJOLWD]RQH33$5ȖDJRQLVW
33$5ȖLVRIRUPLVDVXEIDPLO\RIWKHQXFOHDUKRUPRQHUHFHSWRUQDPHGSHUR[LVRPH
proliferator-activated receptor gamma. Thiazoledinediones (TZDs) belong to a group
RI33$5ȖDJRQLVWVDQGURVLJOLWD]RQHLVRQHRI WKH7='VXVHGLQWKHWUHDWPHQWRI
type 2 diabetes. The mechanism of the agonist involves binding to the PPAR
receptors in fat cells (Malinowski and Bolesta 2000, Culman, Zhao et al. 2007).
7KHFXUUHQWHYLGHQFHVXJJHVWV WKDW33$5ȖPD\EH LQYROYHG LQ UHGXFLQJEUDLQFHOO
inflammation and inhibiting glial cell proliferation (Bernardo and Minghetti 2006,
Hirsch, Breidert et al. 2006, Schintu, Frau et al. 2009, Carta 2013). Moreover, other
HYLGHQFH KDV HPHUJHG VXJJHVWLQJ WKDW 33$5Ȗ DJRQLVWV ZKHWKHU QDWXUDO RU
synthetic, may regulate brain disorder by inhibiting several functions associated with
glial cells and microglial activation (Bernardo and Minghetti 2006).
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6.5 Aims of project part 2
The main aims of this project are to understand the role of astrocyte proliferation and
its relation to neural insult this may contribute to fundamental understanding of how
pathological changes come about in the CNS. Recent evidence suggests neuroglia-
mediated inflammatory mechanisms may stimulate disorders in the mouse brain
(Gavériaux-Ruff and Kieffer 2007). To test the hypothesis that the number of
astrocytes increase in both cortex and hippocampus in vivo, the brains of mice aged
2-6 weeks were dissected and immunohistochemistry was performed. Pups aged 1-5
days, were used for brain culture purposes in vitro. L. Bedford’s lab has created a
mouse model (Psmc1fl/fl; &D0.,,Į&UH), whereby the mice do not survive for longer
than 3-4 months. The main goal is to follow the evolution of pathology through the
ages from 2 weeks to 6 weeks of culturing, and then try to improve or reduce the
GLVHDVHXVLQJ33$5ȖDJRQLVW
The hypotheses
1. Astrocyte proliferation contributes to the neuropathology seen in a mouse model
of dementia (Psmc1fl/fl).
2. Rodent organotypic slice cultures can be used to further understand
neurodegenerative diseases.
1. Peroxisome proliferators such as rosiglitazone can be used to inhibit astrocyte
proliferation in a mouse model
The aims
1. Characterize the temporal and spatial aspects of astrocyte proliferation in the
Psmc
1fl/fl. mouse model and compare to age matched controls.
2. Evaluate the use of organotypic slice cultures system, to observe the progression
of astrocyte proliferation and determine whether this progression is comparable in
vivo.
,QYHVWLJDWHWKHHIIHFWVRID33$5ȖDJRQLVWRQDVWURF\WHSUROLIHUDWLRQLQGHPHQWLD
with a lewy body disease model.
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Materials and method7.
7.1Materials
7.1.1Animals
A mouse model of neurodegeneration with 26S proteasome dysfunction was used. It
pathologically represents dementia with Lewy bodies disease (Psmc1fl/fl;CaMKII-
Cre) (Bedford, Hay et al. 2008). This mouse model depends on a system known as
Cre-loxP recombination, which allows the DNA modifications to be targeted to a
specific cell type (Kuhn and Torres 2002). Cre is a 38 kDa recombinase protein
derived from bacteriophage P1, which has the ability to cut and recombine DNA
between two similarly orientated loxP sites, reference to Figure 7-1.
It was reported that 26S proteasome function is essential for normal neurological
function in mice. In a previous experiment in Bedford’s lab, it was shown that these
mice are more anxious in open-field analysis and displayed obvious spatial learning
deficits in the Morris water maze task at 6 and 8 weeks, respectively. These animals
have a short lifespan; they die when aged 3–4 months, as a result of lacking interest
in locating food.
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)LJXUH  'LDJUDP VKRZV FRQGLWLRQDO GHOHWLRQ RI 3VPFO LQ PRXVH VSHFLILFDOO\ ZLWK WKH &D0.,,Į
SURPRWRUFDOFLXPFDOPRGXOLQGHSHQGHQWSURWHLQNLQDVH,,Į
Expressed cells have 26S proteasome dysfunction, and therefore Ub accumulation pathologically
resembling neurodegeneration that occur in Parkinson's’ disease and LBD.
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7.1.2 Immunohistochemistry materials
Glial fibrillary acidic protein (GFAP) primary antibodies from thermo scientific were
used to identify the astrocytes. GFAP is a common marker used to distinguish
astrocytes via intermediate filament proteins (Takamiya, Kohsaka et al. 1988,
Miguel-Hidalgo, Baucom et al. 2000).
7.1.3 Culture mediums
Hanks’ Balanced Salt solution containing sodium bicarbonate, without phenol red,
sterile-filtered, PH 7.1-7.5, glucose concentration 0.9 - 1.1 g/l from Sigma was used
as a basic salt solution in all sterile procedures. Culture medium was Dulbecco’s
Modified Eagle Medium (D-MEM) - 1X, liquid (containing 4500 mg/L; D-glucose),
sodium pyruvate, L-glutamine and 25 mM HEPES buffer, Sodium Bicarbonate (PH
7.2) but without sodium pyruvate or phenol red.
7.1.4 Chemicals and instruments
Normal goat serum was purchased from Vector, bovine serum albumin (BSA) from
sigma. Three types of slide were used; cavity slides (depression slide) for
organotypic slices, coated slides (APES) for paraffin embedded sections and chrome
gelatinised slides for cryostat sections. The slide sizes were 1.0-1.2 mm; Slides were
purchased from Fisher. Paraffin embedded sections were prepared using Microtome-
LEICA RM2145. Cryostat sections were prepared on a Cryostat CM1900 and
McILWAIN tissue chopper was used to produce the organotypic brain slices. Brains
were processed in a Leica-TP 1020 tissue processor prior to paraffin embedded
sections being prepared. The organotypic slices were incubated in Galaxy S Co2
Incubator. Axiovert 25 PCR machine was used for amplification of DNA from the
brains isolated from the pups.
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7.1.5 Inserts and slide types
7UDQV:HOO SHUPHDEOH VXSSRUWV  ȝP SRO\HVWHU PHPEUDQH ±  PP LQVHUWV 
well plates was used for organotypic brain slice cultures (Corning Incorported-
Coring, NY 14831 the USA). See section 7-2-3. Micro-plate 96 well purchased from
IWAKI / EZ-BirdShut®.
Three types of slides were used in the study: cavity slide, APES (2% 3-
aminopropyltriethoxysilane) and gelatin-coated (gelatinised) slides.
7.1.6 Mounting medium
To cover the slides, DABCO (1-4-Diazabicyclo-2-2-2-octane) in 90% glycerol in
phosphate buffered saline (PBS) was used after mounting the fluorescent brain
tissue. (100 mg of DABCO in 5 ml of PBS and then add 45 ml of glycerol and max
well, and store at 40C).
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 3HUR[LVRPH SUROLIHUDWRUDFWLYDWHG UHFHSWRU JDPPD 33$5Ȗ
agonist and antagonist
Peroxisome proliferator activated receptor gamma agonists have been used to
investigate the effect of reducing astrocyte activation on neurodegenerative
GLVRUGHUV5RVLJOLWD]RQH33$5ȖDJRQLVWDQGWKHDQWDJRQLVW7ZHUHXVHG
in this study, both purchased from sigma.
7DEOH6WUXFWXUHRI5RVLJOLWD]RQHDQG733$5ȖDQWDJRQLVW
Systematic *IUPAC Name 3D Structure structure
Rosiglitazone
(RS)-5-[4-(2-[methyl(pyridin-2-
yl)amino]ethoxy)benzyl]thiazolidin
e-2,4-dione
733$5ȖDQWDJRQLVW
EORFNV33$5ȖIXQFWLRQ
*IUPAC (International Union of Pure and Applied Chemistry).
7.1.8 Microscopes
The DMRB Fluorescence Microscope LeicaEM was used to capture fluorescent
images of tissues. These were detected by using DAPI (wavelength 350/50 –
460/50), mCherry filters; (480/40 – 535/50) and Rhodamine RedTM (TRITC, 545/20
– 610/75). The Leica DM4000B light microscope fitted with MicroPublisher 3.3RTV
camera was used for pictures. Images were captured on a Confocal Microscope
(Leica TCS SP2) and analysed off line on a workstation equipped with Volocity
software.
7.1.9 Statistics
One way and two-ways ANOVA, followed by a post hoc student t-test were
performed for statistical analysis, where P values <0.05 were considered significant.
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7.2 Methodology
7.2.1 Sample preparation
For whole brain fixation, mice were injected with Heparin, then anesthetized using
isoflurane inhalation, and perfused transcardially. Perfusion was initiated by washing
out the blood with 0.9 % saline solution at 370C until the perfusate became clear.
This was then followed by perfusion of 4% paraformaldehyde (Bustin, Benes et al.)
in 0.1 M PBS, PH 7.4 at 40C. The brains were dissected out and stored in Eppendorf
tubes containing 4% PFA overnight for post-fixation.
In vitro, brains from postnatal pups aged 1-5 days were used to prepare organotypic
VOLFHVDWWKLFNQHVVȝPDQGFXOWXUHGIRUSHULRGVRIDQGZHHNV)RU
fixation, slices were washed 4 times in PBS and then fixed for 20 minutes in 4%
PFA. The inserts of the organotypic slices were embedded in paraffin prior to being
sectioned. Slices were stored in 40C until required for immunohistochemistry with
either rhodamine red or DAB stains. The slices were labelled with fluorescent
rhodamine red.
Chapter 7 Materials and methods
158
7.2.2 Determination of area of interest using a box dividing protocol
To determine the specific areas of interest (i.e. within the cortex and hippocampus) a
box dividing slice technique was used for both mutant and control pups to match
paraffin embedded sections with the organotypic slices.
Figure 7-2 Method of box-dividing a brain into 1mm sections.
Brain is placed onto divider and the same section is taken to preparing the paraffin embedded brains to
look at the same area of interest. after fixation overnight mouse brain dissected into 1 mm using box
dividing of gel agarose.
www.mbl.org/atlas165/atlas165_frame.html
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7.2.3 Organotypic Slice Culture
Postnatal slices can be maintained in culture from weeks to months, which is the
reason for the use of new-born C57 black 6 modified (Psmc1fl/fl&D0.,,Į&UH) and
wild-type (Psmc1fl/fl &D0.,,Į:W) mice aged 1-5 days, in this study.(Gähwiler,
Capogna et al. 1997).
The experiments were performed in accordance with protocols from the Scientific
Procedures (Act 1986) and the Home Office recommendations with regards to killing
by schedule 1 method, at the designated establishment (BMSU, QMC at the
University of Nottingham). Mouse pups were decapitated, the brain removed and cut
into 200, 300 and 325µm thick tissue slices using a Mcilwain Tissue Chopper. The
various thicknesses were checked to select the best for long term survival in culture.
Chosen slices were transferred to a sterile petri dish containing Hanks’ Balanced Salt
solution then dissected slices were detached from each other under the microscope
using sterile needles and carefully transferred to the transwell membrane inserts.
Organotypic slice cultures were grown for periods of 2, 3, 4, 5 and 6 weeks in culture
harvested from control and mutant pups. 1 or 2 brain slices were placed into each
transwell insert with 500µl medium (Dulbecco's Modified Eagle Medium) in the
base of a 12 multi-well plate. The tissues were strictly controlled in terms of
sterilization, temperature and rate of carbon dioxide availability and the media was
changed regularly. Therefore, the slices were incubated at 36-370C in 5% CO2 and
the medium changed every second day. The culture medium contained the following
components: 89 ml DMEM, 10 ml FCS and 1 ml glutamine. All procedures were
carried out under strict sterile conditions.
The diagram below (7-3) illustrates how the brain slices were cultured in vitro.
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Figure 7-3 Diagram of organotypic slices system materials and method.
$  ȝP WUDQVZHOO LQVHUWV ZHUH SODFHG LQ HDFK ZHOO RI WKH  ZHOO SODWHV 7R DYRLG GDPDJLQJ RI
slices, two types of slide were used - cavity slide and normal slide, provided with frame. B; The brain
tissue must be centrally placed on the membrane during the immunohistochemistry protocol. C
Gaskets prevent any pressure on the brain slices when being coverslipped.
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7.2.4 Tissue fixation of organotypic slices
The cultured slices were washed in PBS and fixed in 4% paraformaldehyde for 20
minutes. Organotypic slice cultures were grown for periods of 2, 3, 4, 5 and 6 weeks
in culture, once harvested from control and mutant pups. Organotypic slices cultures
were re-washed three times in PBS. The slices were immersed in PBS and stored at
40C until required for use. Storage time was kept to a minimum to avoid loss of
immunogenicity of the samples. Details of storage time for the slices are mentioned
in results section.
7.2.5 H&E staining
The paraffin embedded sections were deparaffinised in xylene twice, for 10 minutes
each. Slides were then washed in 100% ethanol For 10 minutes three times, followed
by 90 % ethanol, 70%, and 50% respectively for 5 minutes each. Once washed in tap
water for 5 minutes slides were submerged in freshly filtered haematoxylin for 5
minutes. After being washed in running tap water until it ran clear, they were dipped
in 1% acid alcohol then rinsed again in water. After a minute wash in Scott’s tap
water, slides were immersed in eosin for 5 minutes. Subsequent dehydration involved
washing in running tap water, 50%, 70%, 95% ethanol and 3 different containers of
100% ethanol, followed by xylene. Slides were coverslipped with DPX and left to
dry. (See appendix). Positive staining showed cell nuclei as blue, and cytoplasm as
pink.
Chapter 7 Materials and methods
162
7.2.6 Distinguishing between a mutant and control animals using
DNAreleasy technique to release gDNA
An ear or tail biopsy was taken from the mouse and placed in an Eppendorf tube.
20µl DNAreleasyTM was added (Anachem) to cover the tissue then placed in the
PCR machine. The samples were run on a PCR programme, entitled ‘lysis 20’ as
shown below. This programme cycles the sample through various thermal
conditions.
Primers were used for genotyping the DNA, which distinguished between control
and mutant mice used in the study.
Table 7-2Thermal cycle to release the DNA
NO Temperature cycle Time
1. 650C 15 mins
2. 960C 2 mins
3. 650C 4 mins
4. 960C 1 mins
5. 650C 1 mins
5. 960C 30 sec
6. 200C hold
Note: DNAreleasy- lysate can be used directly in PCR (DNA releasyTM can be made
up to 40%) and stored at -20 0C for future use.
DNA was prepared from the animals after the genomic DNA has been extracted from
the biopsy sample, where 2µl of DNA is needed for each sample. Positive and
negative controls were included. The preparation will be for x + 2 samples to avoid
any shortage.
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7.2.6.1 Running the samples in PCR
The DNA samples were prepared to detect homozygote and heterozygote pups,
mutant (Psmc1fl/fl; &D0.,,Į&UH) and wild-type pups (Psmc1fl/fl; &D0.,,Į:W). The
table below shows primers and nucleotides (dNIPs) of the Cre and S4 genes.
Table 7-3 primers and nucleotides of the Cre and S4 genes preparation
NO S4 gene components Cre gene components
1. dNIPs 1µl x n = x µl dNIPs 1µl x n= x µl
2. 10X 1µl x n = x µl 10X 1µl x n= x µl
3. D130 0.5µl x n = x µl Cres 0.5µl x n= x µl
4. LB3 0.5µl x n = x µl Creas 0.5µl x n= x µl
5. X316 0.5µl x n = x µl Taq 0.05 X n= x µl
6. Taq 0.05 X n = x µl
7. Total x1 µl Total x1 µl
8. DNA 2 µl for each sample DNA 2 µl for each sample
10. dH2O x2 µl /x2 = 100- x1 dH2O x2 µl /x2= 100- x1
Table 7-4 PCR temperature cyle for genotype detection
NO Temperature cycle Time
1. 94.0 0C 3 mins
2. 94.00C 15 sec
3. 64.0 0C 15 sec
4. 72.0 0C 30 sec
5. Go to 2 REP 34
6. 72.0 0C 3 mins
7. T = 94.0 0C 3 mins
8. Hold at 15.0 0C Enter
Run 3% gel agarose and check the results.
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7.2.7 Immunohistochemistry
Immunohistochemistry has been used with both fluorescence and DAB stains for
whole brain sections, as well as sections from organotypic brain slices. Rhodamine
red goat anti-mouse as a fluorescent secondary antibody was used in paraffin
embedded, organotypic slice culture and cryostat sections. DAB stain was used in
vivo and in vitro whereas organotypic slices were prepared for paraffin sectioning
embedded for all target age groups.
7.2.7.1 Mouse on mouse (M.O.M
TM
) immuno-detection kit.
The Vector® M.O.M. immunodetection kit for mouse tissues has the advantage of
very low background staining, which has been a problem in other studies (Chang
2009). Paraffin-embedded brain sections from mice aged 2-6 weeks were de-waxed
through xylenes and rehydrated with different concentrations of ethanol 100 %, 95%
and 70% respectively for 10 minutes each, then rinsed for 5 minutes in tap water. 10
mM sodium citrate buffer pH 6 was employed as antigen retrieval, which was
necessary to uncover hidden antigen sites. For endogenous peroxide, slides were
incubated in 3% H2O2 (hydrogen peroxide) for 5 minutes, then immersed in tap
water for 5 minutes. Blocking reagent was applied (block endogenous peroxidase
activity) to block non-specific binding. Sections were washed three times for 5
minutes in PBS, and then in working solution of M O MTM diluent. The sections
were incubated with primary antibody raised against the antigen of interest. Labelled
secondary antibody was added, which is biotinylated anti-mouse M O M IgG
Reagent, for 30 minutes. To perform Avidin/Biotin blocking, the avidin of
biotinylated enzyme complex (ABC) is then added, which binds to the biotinylated
secondary antibody (Figure 7-4). The incubation with a substrate for the enzyme
generates a brown color resulting from DAB breakdown. Table 1 in the appendix
summarizes the immunohistochemical process used for the paraffin embedded
sections.
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Figure 7-4 A diagram to illustrate the DAB reaction and how a labelled secondary antibody reacts
with a primary antibody bound to a tissue antigen.
Immunohistochemical staining of paraffin sections (mouse on mouse kit – vector labs PK-2200).
Incubation of brain tissue with primary antibody overnight at 40C is followed with a secondary
antibody conjugated with a peroxidase enzyme for 1 hour. The ABC complex was added to tissue
sections followed by DAB which is oxidized; the generation of brown color can detect under the light
microscope. Longer incubations may result in an increase in background staining.
The diagram is adapted from php.med.unsw.edu.au/cellbiology/index.php?title=Group_3_Project-
_Immunohistochemistry.
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7.2.7.2 Immunohistochemistry technique for rhodamine-red fluorescent
organotypic slice cultures
Organotypic slice cultures were fixed in 4% PFA for 20 minutes and then washed
with PBS three times, for 5 minutes each. Slices were immersed in PBS and stored at
40C until required, which was be within two weeks of fixation. Slices were rewashed
with PBS, and permeabilized by incubation with 0.5% Triton X-100 in PBS, in a
humidity chamber at room temperature. Non-specific protein binding was blocked
with 10% bovine serum albumin (in 0.5% Triton X-100 in PBS) for 2 hours at RT,
and then washed with PBS. Slices were incubated overnight at 40C in primary
antibody 1 µl:150 µl (anti-GFAP) in solution of 0.5% triton-X100 in PBS, then
washed with PBS for 20 minutes. Rhodamine- conjugated secondary antibodies –
(goat anti-mouse,1 µl:400 µl) in 0.5% triton-X100 in PBS was applied and incubated
for 3 hours at room temperature. The tissue was then washed with PBS four times for
20 minutes, and finally incubated with DAPI stain for 20 minutes at room
temperature. After washing in PBS 4 more times for 20 minutes, mounting medium
was added to the slide and then cover slipped and sealed with nail varnish.
7.2.7.3 Immunohistochemistry technique for paraffin sections and
organotypic slice cultures
Immunofluorescent and immunohistochemical staining were performed on both
whole brain sections and organotypic brain slices. Organotypic slice cultures were
fixed with 4% paraformaldehyde in PBS for 20 min at room temperature and
immuno-fluorescent staining was conducted. Tissues were permeabilized with 0.5%
Triton-X-100 in PBS for 1 h at room temperature. Nonspecific binding sites were
blocked with 10% bovine serum albumin (BSA, Sigma) with 0.5% Triton-X-100 in
PBS. Organotypic slices were incubated with anti-GFAP antibody (1:150 µl) in
solution of 10% normal goat serum with 0.5% Triton-X-100 in PBS overnight (16-18
hrs) at 40C in a humidity chamber. Secondary antibody: Rhodamine red goat anti-
mouse IgG (1:200 µl) in 10% normal goat serum with 0.5% Triton-X-100 in PBS
was added to the slides and incubated for 3 hours in the humidity chamber at room
temperature.
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After washing with PBS, the slices were incubated with DAPI stain for 20 minutes at
room temperature.
After dewaxing in xylene, the slides were immersed in three different concentrations
of ethanol as follows: 100%, 95% and 70% and washed gently in running tap water.
The sections were washed with PBS twice for 10 minutes in each container. The
most important step is antigen retrieval, which involves steaming the sections for 40
minutes. This step was optimised several times to get the best result. The slides were
left to cool for 20 minutes then blocked with 5% normal goat serum dissolved in
0.25% Triton X-100 in PBS for 2 hours in a humidity chamber at room temperature.
The sections were then washed twice with PBS and incubated with primary antibody
1: 150 µl GFAP with 5% normal goat serum in PBS overnight, at 40C in a humidity
chamber. The sections were again washed with PBS and incubated with rhodamine
red- secondary antibody 1: 500 µl with 5% normal goat serum in PBS for I hour in
the humidity chamber at room temperature. The sections were washed several times
with PBS and then incubated with DAPI nuclear stain for 20 minutes. After washing
with PBS 4- 5 times, slices were finally mounted in DABCO and coverslipped and
sealed with nail varnish.
7.3.1 Image-J program for calculating the number of astrocytes
7RHYDOXDWHZKHWKHURU QRW URVLJOLWD]RQH 33$5ȖDJRQLVW KDVSRVLWLYH HIIHFWV E\
reducing brain disorders seen in the mutant mice, there was a requirement to
accurately count the number of astrocytes. Unbiased stereological methods had been
used since 1984 and recently, a more modern software, Image-J is commonly used
(Lalancette-Hébert, Gowing et al. 2007, Sadeghi, D'Haene et al. 2008). Image-J has
the ability to convert coloured cells to black and white, making it easier to calculate
the number of labelled cells. All images were counted at the same magnification. An
objective lens was used at 20 X with a unified frame for counting all slides. The
counting frame size was 400X360 µm. The standard was computed by counting the
number of astrocytes in the region of tissue that appeared between the grids. Three
sections per mouse were used for the analysis. All astrocytes shown in the cortex and
hippocampal regions were counted (Figures 7-5 and 7-6). The data was averaged and
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analysed by a two-tailed unpaired Student’s t test and one way ANOVA; post-hoc
tests included Dunnett’s multiple comparison test. Data are expressed as mean ± SD.
Figure 7-5 Using Image-J program for calculating the number of astrocytes in cortex region.
Images of the slices containing the cortex were captured at 20x and 40 x magnifications. A: illustrates
the grid that the programme places over the image. B: Colour changes are applied to make the
astrocytes more easily visible. C: At high magnifications and appropriate colour contrasts, the
astrocytes in each grid were counted.
A
B
C
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Figure 7-6 Using Image-J program for calculating the number of astrocytes in hippocapus region.
Brain tissue slices in the hippocampal region (CA1 zone) were captured at magnification X 20 and 40
X. Images A; the CA1 area before and after using Image-J to input a grid. B; same images undergo
colour contrast changes to clarify astrocytes. C; same images at high magnification and different
background to show astrocytes body.
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7.4.1 Resazurin cell viability assay
Resazurin is a reagent that is not toxic to cells and is stable in culture medium. It is
used to provide a quantitative measure of cell viability and allows the user to
measure cell proliferation in vitro, via redox reaction that releases a fluorescent
signal. Resazurin is a blue dye and non-fluorescent, also known as (alamarBlue
Reagent). The colour change from blue to red is characteristic of this assay and
causes the cells to become fluorescent. This assay was conducted to investigate
ZKHWKHUWKH33$5ȖKDVWR[LFHIIHFWVRQEUDLQWLVVXH6DUNHU1DKDUet al. 2007). The
Fibroblast 3T3 cell line was used as the standard for toxicity testing, as they are fast
growing cells, and are highly sensitive to toxic materials (Seiler, Visan et al. 2004).
3T3 cells were grown into two 96 well plates for 24 and 72 hours prior to addition of
WKHIOXRUHVFHQWUHDJHQW5HVD]XULQȝ0VROXWLRQDQGSKHQROUHGIUHH+%66&D2+
and Mg2+) were needed to prepare stock solution. The concentration was 12 mg of
Resazurin dissolved in 100ml HBSS. A stock solution contains 10% of resazurin
mixed with 90% of culture medium of use. After growing cells for 24 hours and 72
hours, the media was aspirated from the wells and replaced with resazurin working
solution. Results were analysed for both plates and in a several time points 1, 2, 4, 6
and 24 hours of incubation. The results have been translated to graphical forms and
can be found in the results section 8-6-3.
(IIHFWRI33$5ȖDJRQLVWURVLJOLWD]RQHRQWKHUHGXFWLRQRIDVWURF\WH
proliferation
Organotypic slices from the cortex and hippocampal areas were cultured separately.
7KHFRQFHQWUDWLRQVRI733$5ȖDQWDJRQLVWXVHGZHUHDQG0
733$5ȖDQWDJRQLVWZDVXVHGVHSDUDWHO\DQGZLWKDQDJRQLVWDVDQHJDWLYH
control. In this assay 4 controls were used, which are DMSO vehicle, T0070907
alone, free drug medium, and agonist followed with antagonist. Organotypic slices
were grown up to the fifth week. On the first day of the sixth week, experiments
were conducted as outlined in the following diagram. The medium was changed
every 2 days. Figure 7-5 shows time course of treating organotypic slice culture with
33$5ȖDJRQLVW	DQWDJRQLVWDQGYHKLFOHV
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Figure 7-7 Schematic diagram indicates the time courses of treating the organotypic slice culture with
33$5ȖDJRQLVW	DQWDJRQLVW'062YHKLFOHDQGIUHHGUXJPHGLXP
The slices which were treated with agonist alongside antagonist were pre-treated
with the antagonist alone, for 6 hours. The organotypic slices were allowed to grow
for 5 weeks, and treatment started at the end of the fifth week for a week. The
medium was changed every second day. Organotypic slices were prepared from the
cortex and hippocampus of both the mutant and wild-type pups.
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Results8.
This chapter is divided into two parts; validation of materials & methods and
LQYHVWLJDWLRQRIWKHUROHRI33$5ȖLQSUHYHQWLQJDVWURF\WHDFWLYDWLRQ7KLVVWXG\KDV
provided further understanding of this receptor’s influence in the reduction of
neuronal cell death in the CNS.
8.1 Immunohistochemistry validation
8.1.1 Validation of GFAP marker to stain astrocytes of paraffin sections
The aim of this study was to detect astrocytes in vitro, using an organotypic slice
culture. To achieve this, it was important to ensure that astrocytes are detected
reliably in vivo and then in vitro using a Glial Fibrillary Acidic Protein (GFAP)
marker. Paraffin-embedded brain tissues of mice and rats were prepared for this
experiment. The rat brain sections have been employed as a positive control. A
technical challenge was to improve the captured image, and to improve the access of
the primary antibody into the cell, by varying the temperature to 25oC Celsius during
this process. The underlying mechanism can be described as antigen retrieval, which
facilitates the break of protein cross-links that have been formed by formalin during
tissue fixation; thereby uncovering hidden antigenic sites. Result shows that GFAP is
detectable with good signal-to-noise ratio in Figure 8-1.
Triplicate paraffin embedded sections were incubated at room temperature and
compared to triplicates of paraffin embedded brain sections incubated at 40C
overnight. The results showed that this temperature difference had an impact on the
detection of GFAP. There is increased intensity and clarity of astrocytes, as referred
to (Figure 8-1, B) which represents incubation at 40C overnight. This is in addition to
a difference in the detection number of astrocytes which were more numerous, in
favor of 40C. To verify the integrity of the results, Figure 8-2 is showing a negative
control staining in the presence and absence of primary antibody in rat brain paraffin
section stained for GFAP (Thermo scientific).
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Figure 8-1 Rat brain paraffin section stained with GFAP (Thermo scientific).
A, B and C illustrate slices that were treated with a GFAP antibody and incubated over night at 40C.;
D and E: Slices were treated with a GFAP antibody and incubated over night at room temperature.
The arrows refer to GFAP+ cells Magnification X63, scale bar 25 µm.
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Figure 8-2 Verification of the negative control staining in the presence and absence of primary
antibody in rat brain paraffin section stained for GFAP (Thermo scientific)..
The slides were incubated overnight with primary antibody at 40C. A, B and C: slices were treated
with a GFAP antibody and a fluorescent stain. D, E and F represent negative control of
immunohistochemistry staining. Brain tissue stained without primary antibody show negative results
0DJQLILFDWLRQ;VFDOHEDUȝP
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8.1.2 Optimising GFAP primary antibodies to stain astrocytes of rat and
mouse paraffin sections
Previously, difficulties using immunohistochemistry in detecting astrocytes by using
anti-GFAP have been experienced. Therefore, it was important to optimise the
protocol by varying the source of primary antibodies to detect GFAP. The anti-GFAP
reagents (GFAP - Astrocyte Marker from Abcam and GFAP antibody from Thermo
Scientific) were purchased and checked. Three concentration ratios (1:100, 1:150 and
1:200) of the two reagents have been investigated. The incubation with the primary
DQWLERG\ ZDV SHUIRUPHG DW Û& DQG WKH WLPH RI LQFXEDWLRQ ZLWK SULPDU\ DQWLERG\
was restricted to 18 hours. Paraffin embedded sections of rat brain tissues were used
as a positive control. The anti-GFAP antibody from Thermo Scientific showed good
results with a dilution ratio of 1:150 (Figure 8-3; A, B and C) whilst the antibody
from Abcam required a 1:100 dilution to detect the astrocytes (Figure 8-3; D, E and
F). However, using a dilution of 1:200, both antibodies gave rise to non-specific
binding and false-positive results (data not shown). The primary antibody from
Thermo Scientific gave a brighter fluorescent signal compared to the antibody from
Abcam. This experiment also revealed that the antigen retrieval time must be not less
than 40 -45 minutes.
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Figure 8-3 Rat brain paraffin embedded sections, illustrating astrocytes stained for GFAP from either
Thermo scientific or Abcam.
The slides A, B and C represent astrocytes detection after overnight incubation (18 hr) at 4oC with
primary antibody from (Thermo scientific). D, E and F show astrocytes detection after overnight
incubation with primary antibody from (abcam). Arrows refer to differences in astrocytes brightness.
The tissues were stained with GFAP antibody by fluorescent immunohistochemistry staining.
Micrographs have been captured with DMRB microscope Magnification X63, scale bar = 100 pixels
(1 pixel = 0.3 µm).
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8.1.3 Examining the impact of gasket thickness on clarity of image
resolution for organotypic slice cultures
To avoid coverslip pressure damage to the organotypic slice cultures during
mounting for microscopy, it was necessary to use a gasket that serves as a bridge
between the coverslip and the organotypic slice to protect it from damage. It was
necessary to discover the exact gasket thickness that would provide protection and
still retain a minimal working distance from the objective lens. Paraffin embedded
brain sections were prepared with and without the gasket to investigate the effect of
the gasket on micrograph clarity. As in Figure (8-4; B), immunohistochemistry
protocols gave clear and reliable results without gaskets. With gaskets the astrocyte
resolution was lower as you can see in Figure (8-4; A). However, to avoid any
chance of altering the slice morphology by coverslip pressure it was decided to use
gaskets of thickness 0.25 mm. A justification of this decision is that the slice thins
down from 300 µm to approximately 150 µm after the culture period.
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Figure 8-4 Examining the impact of gasket thickness on clarity of image resolution.
The figure shows slides prepared from male C57 black 6 mouse brain aged 1-2 days. The figure
displays nuclei detected with DAPI and the astrocytes detected with Rhodamine TM red. The
micrographs revealed a fluorescent image with and without use of the gasket. Column A shows
astrocytes in the presence of the gasket; the cells can be seen, but with less clarity. Column B shows
astrocytes without a gasket, and the cells can be seen in a good resolution , with more refined
micrographs. Arrows refer to GFAP+ cells. The micrographs were taken with DMRB florescence
HAMAMATUS digital Camera C4742-95, magnification X40.
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8.2.1 The differences between the staining of astrocytes in the brains of
mice between fluorescent with fluorescent Rhodamine and DAB markers
Preliminary results obtained when the astrocytes were stained with fluorescent
Rhodamine red revealed the difficulty in counting the astrocytes, especially in the
dentate gyrus of hippocampus. This is in addition to the already mentioned loss of
clarity due to gasket thickness. Paraffin embedded sections of brain tissues were
prepared from either wild-type or mutant 2 week old mice. The reason for using
these age groups in particular, is that the astrocyte proliferation still low between
wild-type and mutant pups, which might facilitate the comparison. The slides were
stained either with M.O.MTM kit followed by DAB, or rhodamine red. After
incubation the sections were incubated in primary antibody against GFAP, and then
secondary antibody – a biotinylated anti-mouse IgG. The avidin of the biotinylated
enzyme complex (ABC) was then added, which bound to the biotinylated secondary
antibody. The incubation with a substrate for the enzyme generated a brown color,
resulting from DAB breakdown (Figures 8-5; B & 8-6; B). For Rhodamine red, a
fluorescent marker conjugated to a secondary antibody was applied after the primary
GFAP antibody for 1 hour followed by washing several times with PBS to remove
unbounded antibodies. DAPI stain was added then washed with PBS then 5µl
mounting medium was added, and the slide sealed with nail varnish (Figures 8-5; A
& 8-6; A). Both protocols are more fully described in the appendices. The results
revealed that both staining regimes are acceptable, but it was decided that the DAB
stain was more appropriate, as it made it easier to identify astrocytes in the
hippocampal area, particularly the dentate gyrus. The staining is also more stable
after the procedure. Figure 8-6 displays the comparisons of the two stains in three
different areas of interest. Astrocytes labeled with DAB are more clearly
distinguishable in the cortical areas.
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Figure 8-5 Comparing astrocyte detection by using fluorescence and DAB stains in the CA1 layer of
hippocampus.
There is a less clearly defined border of astrocytes in micrograph A, while it is clearly defined in
micrograph B. Both micrographs were captured at magnification X20.
A
B
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Figure 8-6 Comparison of astrocytes detection by using fluorescence or DAB stains in three different
regions.
Paraffin embedded brain tissue sections were harvested from wild-type 2 week old mice that. 3 slides
were used with each stain. The arrows point to labelled astrocytes with the two different stains.
Micrograph C: slides underwent the immunohistochemistry protocol without primary antibody.
Micrographs were captured with DMRI fluorescent microscope and light microscope. The
magnification is X20
A B
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8.3.1 Determining the genotype of mouse pups
Before proceeding with culturing the organotypic slices, it was necessary to identify
mutant and wild type pups, using PCR analysis. The genomic DNA from the tails of
the mice was extracted using DNAreleasyTM and the lysis 20 PCR program. This was
followed by PCR amplification (see materials and methods section 7-2-6). 9 µl of
PCR product was taken from each sample and loaded onto 3% agarose gels, which
were run at 145 V and 400 mA for 30 minutes. PCR bands for Cre recombinase and
S4 proteasomal subunit genes were detected by using a UV trans-illuminator (Figure
8.7). The gels revealed a single band of both genes for the animals, indicating a
floxed S4 gene, which could be targeted and inactivated by Cre recombinase in the
forebrain region i.e. animals numbered 2, 6 and 7 are mutants, while the others are
wild type and used as a controls.
Three control and mutant pups were used for organotypic slice cultures; they were
scarified and their brains were dissected immediately.
Figure 8-7 Representative image of Psmc1 and Cre genotyping, following agarose elelctrophorasis.
Bands were detected using a UV trans-illuminator.
Tissue biopsies were obtained from the mouse tails for the DNA genotyping of 9 pups.
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8.4.1 Astrocyte detection in organotypic slice cultures technique
The antibodies used against the GFAP antigen in the paraffin embedded sections
were successful, allowing easy detection of the astrocytes. This was an important
step before commencing immunohistochemistry in vitro. Organotypic slice cultures
ZHUHSUHSDUHGDWHLWKHURUȝPIURPQHZERUQSRVWQDWDOPLFHDJHGWKUHHWR
five days old. The brain tissue slices were cultured for two to six weeks, according to
the protocol in Materials and Methods section 7-2-3. Slices were observed daily with
the medium changed every 48 hours. Figure 8-8 shows that the maintenance of slice
integrity remained unaffected. After 24 hours of culture, the cells were in healthy
condition, which continued after two weeks of culture. The organotypic slices were
derived from mutant and wild-type pups.
Figure 8-8 Maintenance of slice integrity remains unaffected for up to 2 weeks.
Organotypic slice cultures were harvested from postnatal wild-type and mutant pups. The slices were
cultured for up to 6 weeks. A & B organotypic slice cultures after 24 hours of culturing. C &D: the
slices were fixed at 2 weeks of age before immunohistochemistry was performed. The medium was
changed every 48 hours, and the images show the organotypic slices in good health. The micrographs
are captured with Olympus CKX41 camera. Magnification X 10.
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The purpose of this experiment was to detect astrocytes and as a result, find the most
suitable of the two thicknesses tested. After two weeks of culture, the slices of the
first age group were fixed for 20 minutes in 4% PFA, followed by four gentle
washings with PBS to avoid separation of brain tissue from the membrane. All
following steps were performed in cavity slides as shown in section (7-2-3). The
slices underwent permeabilisation and were then blocked in 5% BSA for 2 hours at
room temperature, as described in the materials and methods (7-2-4). The cavity
slide was changed for a normal slide at the last stage of the protocol, provided with
gaskets (frames) of 0.25 mm thickness 0.25 mm. Frames were used as gaskets for
protection of the organotypic slices against pressure of the coverslips. Results show
that astrocytes are detectable at 300 µm thickness in both wild-type and mutant
animals at two weeks of age, viewed in Figure 8-9. It is worthwhile to mention that
after a few weeks in culture the slices thinned down to less than the gasket thickness
of 250 µm. Although both thicknesses can be used to detect astrocytes, less thickness
gives better clarity (data not shown). It is clear that astrocytes appear contracted in
the wild-type slices (Figure 8-9; B), while astrocyte processes appear longer and
more branched in the mutant brain slices (Figure 8-9; E).
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Figure 8-9 Detection of astrocytes using immunohistochemistry in slices cultured for 2 weeks.
Confocal images of organotypic slice cultures were taken of both wild-type and mutant pups. B;
White arrows indicate contracted astrocytes in brain tissue of wild-type animals. E; blue arrows
referred to long processes of astrocytes in mutant animals. The micrographs were captured with
confocal DMIRE microscope (Leica SP2). Magnification X 20.
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8.4.2 Optimisations to improve immunohistochemical protocol
In order to enhance the morphological characteristics of organotypic slice cultures,
several optimisations have been conducted. The stages of the optimisation can be
summed up in three points: permeabilisation, blocking non-specific binding and the
thickness of slices. To amend the permeabilisation step, the concentration of
TritonX-100 was changed from 0.1% to 0.5%. In addition, the time of incubation
was extended, from two hours to overnight. Originally, 5% bovine serum albumin
with 0.1% TritonX-100 in PBS was used in the blocking procedure, which was
changed to 10% of BSA with 0.5% Triton X-100 in PBS and incubated overnight,
rather than for two hours. The optimal thickness of slice culture was 200- 250 µm.
Following the above protocol precisely resulted in good quality images as seen in
Figure 8-10. The result confirmed that the detection system works with good signal-
to-noise ratio. The astrocyte and their nuclei are clear; however there is no difference
in astrocytes number between control and mutant slices, which was expected in this
early age.
Figure 8-10 Immunohistochemical detection of GFAP after amended permeabilization and blocking
stages.
Organotypic slice cultures of wild-type and mutant pups were prepared from animals at age 4-5 days
and cultured for 2 weeks. The slices were fixed in 4% PFA, and then immunohistochemistry
performed. Arrows indicate some nuclei of astrocytes, each one of them representing a single
astrocyte body. Micrographs were captured with DMRB Fluorescence Microscope Luca EM,
magnification X63, scale bar 25 µm.
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8.4.3 Validation of the use organotypic slice cultures to observe astrocytes,
and detect proliferation.
To assess pathological injury in the brains of mice, and ultimately investigate
whether the development of gliosis was comparable in vitro and in vivo, organotypic
brain slices were cultured for 2, 3, 4, 5 and 6 weeks. The slices were harvested from
brains of mutant and wild-type postnatal mice aged 3-4 days. Brain tissues were
sliced at 250 µm thickness and cultured then fixed with 4% PFA for 20 minutes
according to target ages. Immunohistochemistry was performed using anti-GFAP
antibody and Rhodamine Red. The results showed that at all ages, gliosis was
detectable under both ordinary fluorescent or confocal microscopy. Interestingly, it
was observed that nuclei from the astrocytes in the mutant brains were different from
those in the control animals. The astrocyte nuclei in the controls looked smaller in
weeks 2, 3, and 4, but became identical during the fifth and sixth week. Additionally,
they adopted an oval form in the mutants while remaining spherical in the wild-type
slices (it can be seen in Figures 8-11 to.8-15).
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Figure 8-11 Organotypic slice cultures of mutant and wild-type mice at 2 weeks of age.
A1; Brain slices from mice at two weeks of age were grown in an organotypic slice culture system.
Slices were fixed and left for 24 hours in PBS at 40C, and immunohistochemistry performed using
anti- GFAP antibody. Two different microscopes ordinary fluorescent (A) and confocal (A2) were
used to see if there was any difference in the cells. Use of the ordinary microscope was suggested. A1;
Micrographs were captured by ordinary fluorescent microscope. The blue arrows indicate examples of
single body’s of astrocytes and its nucleus in control animals, while white arrows represent the same
cells in mutant slices (magnification 63X). A2 shows the same slices under examination using a
confocal microscope, GFAP in red and DAPI in blue at magnification X40.
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The following micrographs (Figure 8-12) show that after three weeks of culture,
astrocytes are detectable. Note that the nuclei in wild-type brain slices are circular
and appear almost twice size of those in the mutant brain slices ( blue circle; Figure
8-12) which are small in size and are oval in shape (white circle; Figure 8-12).
Figure 8-12 Organotypic slice cultures of mutant and wild-type mice at 3 weeks of age.
B; Mouse brain sections were grown in an organotypic slice culture system. Immunohistochemistry
was performed using anti-GFAP and Rodamine Red marker. In the third week, it is difficult to note
whether there is a difference in the number of astrocytes between mutant and control cultures.
Micrographs were captured by ordinary fluorescent microscope at magnification 63X, scale bar 25µm.
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Astrocytes were detectable after week four of culture. In wild-type slice cultures,
nuclei were still round in shape and larger (see blue circle in Figure 8-13) than those
in mutants slice cultures (see white circle in Figure 8-13). At this age of culture it
suggests that the number of astrocytes is increasing in the mutant cultures.
Figure 8-13 Organotypic slice cultures of brains from mutant and wild-type mice at 4 weeks of age.
C; Mouse brain sections at four weeks of age were grown in an organotypic slice culture system.
Immunohistochemistry performed using anti-GFAP antibodies and Rodamine Red marker. As you can see in the
merged micrographs, the numbers of astrocytes increased at this age of culture in mutant slices, compared to
control cultures. Micrographs were captured by ordinary fluorescent microscope at magnification 63X.
Chapter 8 Results
191
Astrocytes during the fifth week of culture were also detectable, as the difference in
the size of the nuclei between mutant and wild type slices still exists. The differences
however, do slowly decline (Figure 8-14).
Figure 8-14 Organotypic slice cultures of brains from mutant and wild-type mice at 5 weeks of age.
D; Mouse brain sections at weeks five of age were grown in an organotypic slice culture system.
Immunohistochemistry performed using anti-GFAP antibodies and Rodamine Red marker. The
micrographs show that there is still a difference in the size of the nuclei between the mutant and wild-
type sections, although the magnitude of this difference is declining. Micrographs were captured by
ordinary fluorescent microscope at magnification 63X.
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One of the most important goals of the study was to investigate whether the slice
culture of mutant mice can be cultured up to six weeks (Figure 8-15). Interestingly,
by the end of culture week six the nuclei of both mutant and control cultures were
found to be of similar size and shape, contrary to what was seen at five weeks in
culture.
Figure 8-15 Organotypic slice cultures of brain from mutant and wild-type mice at 6 weeks of age.
E; Mouse brain sections at six weeks of age were grown in an organotypic slice culture system.
Immunohistochemistry was performed using anti-GFAP antibodies and Rodamine Red marker. Micrographs
show comparisons between the nuclei in control and mutant samples, where the nuclei are similar in size and
shape. Micrographs were captured by ordinary fluorescent microscope at magnification 63X.
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8.5.1 Creating cryostat and paraffin sections from organotypic slice
culture
After seeding the organotypic slice cultures for 2 – 6 weeks and fixing at target ages,
paraffin and cryostat sections were prepared from control and mutant samples. 5 - 8
slides were obtained, at a section thickness of 8 µm, from each organotypic slice.
Immunohistochemistry was performed using anti-GFAP antibodies and Rhodamine
Red marker. Astrocytes are clearly detectable in the cryostat sections. The number of
astrocytes gradually increased over the period from 4 to 6 weeks (Figure 8-16 & 8-
17). However at weeks two and three the difference in astrocyte density is not clear
between wild-type and mutant cultures (see Figure 8-16).
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Figure 8-16 Cryostat and paraffin sections of brains created from organotypic brain slice cultures from
mutant and wild-type mice at ages 2 and 3 weeks.
Slices were fixed after 2 and 3 weeks of culture. Astrocytes were labeled with Rhodamine RedTM-
using the immunohistochemistry technique. Micrographs A & C represent cryostat sections created
from organotypic slices were harvested from wild-type mice. B & D show micrographs illustrating
sections that were harvested from mutant mouse brains. Blue arrows show examples of astrocytes that
were detected in the control samples, while white arrows indicate astrocytes detected in mutant
samples. The differences between the astrocyte density is not clear between control and mutant
sections at both week 2 and three of the cultures. Magnification is X20.
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Figure 8-17 Cryostat sections of mice brains were created from organotypic slice cultures at 4, 5 and 6
wks.
Slices were fixed after 4, 5 and 6 weeks of culture. Micrographs E, G and I represent cryostat sections
generated from organotypic cultures from wild-type mouse brain. F, H and J were harvested from
mutant mouse brain organotypic slice cultures. Blue arrows indicate examples of astrocytes detected
in the control samples, and white arrows indicate astrocytes found in mutant samples. There is a
higher astrocyte density in the mutant samples, compared to the control samples.Magnification is X20.
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Paraffin sections were created from organotypic slice cultures to see whether it was
possible to improve the detection of astrocytes using a chromogenic stain. This was
particularly important, to enable quantification of astrocyte density from the images,
as the fluorescent stain is labile. Paraffin sections were prepared from slice culture
from mice aged 2 weeks, stained and labelled with DAB (Figure 8-18). Figure A
represents brain tissue of a wild-type mouse. Figure B represents brain tissue of a
mutant mouse. The astrocytes were labelled in brown and the nuclei in blue. The
results show that both cryostat (Figures 8-16 and 8-17) and paraffin embedded
sections (Figure 8-18) can be used. DAB labelling will be used in the next
experiments, as this staining enables a better ability to distinguish between astrocytes
morphology and their borders, especially in the dentate gyrus region.
Figure 8-18 Paraffin sections of mutant and wild-type mouse brains created from organotypic slice
cultures at 2 weeks of culture.
A; brain tissue of a wild-type mouse, B; brain tissue of a mutant mouse. The astrocytes revealed in
brown colour and the nuclei in blue. Magnification is 50 X.
A B
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8.5.2 Morphology of brain tissue in paraffin sections using haematoxylin
and eosin staining
Haematoxylin and eosin staining is commonly used in histology (Schwartz,
Bukshpan et al.). It has been used in this study to determine the structure of the
hippocampus and cortex in paraffin wax sections. 5 different thicknesses (5, 6, 7, 8
and 10 µm) were examined to determine which are the most stable on the slide, as
they are small. All thicknesses were examined (data not shown). The 8 µm thick
coronal slice was chosen as it showed good stability on APES coated slides, in
addition to illustrating sufficient penetration by antibodies and markers. All sections
were collected and every 11th section was selected for H&E staining. Approximately
16 – 20 slides were obtained for morphometric measurement. The slides were
checked under a light microscope to compare morphology between control and
mutant tissue within the same age group. Subsequent micrographs (Figure 8-19)
showed regions of the cortex and hippocampus in the brains of control and mutant
mice at 2 weeks old.
Images showed the size and area chosen, and all astrocytes in this area were counted
for each section. For all ages, immunohistochemistry was performed to obtain in vivo
results. Three random areas were counted in both the cortex and hippocampus (2
CA1, 1 CA2 and 1 CA3) and then the DG zone. Three samples from three different
animals would be used.
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Figure 8-19 Coronal heamatoxylin and eosin stained section through the cortex (CTX) and
hippocampus.
Micrographs show morphology of wild-type and mutant mouse brain slices at 2 weeks old. Red
squares indicate zones in which the number of astrocytes was counted after subsequent
immunohistochemical stain. The tissues were sliced at 8 µm thicknesses and shown at magnifications
X10, X20 and X 50.
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8.6 Neurodegenerative disease
8.6.1 Progression of neurological disease in vivo
In order to monitor the progression of disease in the brains of Psmc1fl/fl; &D0.,,Į
Cre (mutant) mice in vivo, a set of slides was prepared from each age group,
including mutant and control samples. The slides were selected according to the
results from H & E staining. An immunohistochemistry technique was used for the
detection of astrocytes. However the antigen retrieval time was altered according to
the requirements of the experiment (See Materials & Methods p164). The results
obtained showed that the number of astrocytes started to increase in the brains of
mutant animals at the third week in both the cortex and hippocampus (tables 8-1, 8-2
and 8-3). The population of astrocytes was greater in the fourth week. Therefore, the
disease was more pronounced when the mutant animal entered the fourth week of
age. It was noted that the difference in the number of astrocytes was greater in the
area of the cortex than in the hippocampus, especially at weeks 4, 5 and 6 (Figures;
8-20, 8-22 and 8-24).
In conclusion, reactive gliosis was observed by the third week of age in mutant
animals, and gradually increased to the sixth week of age, especially in the cortex.
Subsequent statistical analysis showed the results of each week separately
represented graphically.
The histograms and figures of each age group will now be analysed. Figure 8-23 is
comparison GFAP+ cells in the cortex, CA1 and dentate gyrus.
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Figure 8-20; Detection of astrogliosis in mouse brain using GFAP+ cells in the cortex.
Micrographs showing GFAP+ cells; A, C, E, G and I display coronal sections from
Psmc1
fl/fl&D0.,,Į:W (wild-type). B, D, F, H and J show Psmc1fl/fl&D0.,,Į&UH mutant mouse
brains at 2 to 6 weeks of age in cortex region. K represents negative control; arrows refer to the
GFAP+ cells. The number of GFAP+ cells increased at 3 weeks of age and was significantly greater at
4, 5 and 6 weeks of age in mutant mice. Neurodegeneration begins in the third week in this mouse
model then increasingly progressively in subsequent weeks. Micrographs were captured by a light
PLFURVFRSH6FDOHEDUȝP
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Figure 8-21 Number of astrocytes in wild-type and mutant mice between 2 and 6 weeks of ages in the
dentate gyrus.
Bar graph showing GFAP+ cells in the cortex of control and mutant mice. The mean (± SD) number of
the GFAP+ cells per control (n=3) or mutant (n=3) was determined from three coronal sections per
mouse. Asterisks refer to the results of 2-way ANOVA using original cell counts. There was an
increase in GFAP+ cells in the cortex of mutant mice. Analysis shows a statistically significant
difference using unpaired Student’s t-tests between control and mutant at 3, 4, 5 and 6 weeks of age.
P*<0.05, P**<0.001 and P***<0.0001
Table 8-1Number of astrocytes in the cortex
Age Wild-type
mean
Mutant
mean
P value
2 weeks 2.66±0.33 4.0±0.57 P<0.05 (NS)
3 weeks 3.66±0.33 8.66±0.66 *P< 0.015
4 weeks 10.6±0.3 22.3±2.0 **P< 0.004
5 weeks 14.6±1.03 29.3±0.8 ***P< 0.0004
6 weeks 17.6±1.5 26.3±1.6 **P< 0.0057
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Figure 8-22; Detection of astrogliosis via GFAP+ cells in the CA1 area of the hippocampus, in mouse brain.
Micrographs showing GFAP+ cells in the cortex. A, C, E, G and I show coronal sections from
Psmc1fl/fl&D0.,,Į:W (wild-type) mouse brain and B, D, F, H and j show coronal sections from
Psmc1fl/fl&D0.,,Į&UHmutant mouse brains at 2 weeks to 6 weeks of ages. Arrows refer to the GFAP+ cells.
The number of GFAP+ cells increased at 4 weeks of age in both mutant and wild-type mice. The number of
GFAP+ cells in the mutant sections was significantly greater at 5 weeks of age compared to control mice. Scale bar
ȝP
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Figure 8-23 Number of astrocytes in wild-type and mutant mice between 2 weeks and 6 weeks of age
in the CA1 area of the hippocampus.
Bar graph showing GFAP+ cells in the hippocampal region of control and mutant mice. The mean (±
SD) number of the GFAP+ cells in the control (n=3) or mutant (n=3) animals was determined from
three coronal sections per mouse. Asterisks refer to the results of 2-way ANOVA using original cell
counts. There was a significant increase in GFAP+ cells in the hippocampal region of mutant mice,
compared to the controls, at 4 and 5 weeks of age Where P*<0.05 and P**<0.001, respectively in an
unpaired Student’s test.
Table 8-2 Number of astrocytes in the CA1 area of the hippocampus
Age Wild-type
mean
Mutant
mean
P value
2 weeks 19.8±2.33 24.0±0.4 P< 0.15 (NS)
3 weeks 23. 7±0.88 28.66±1.8 P< 0.068 (NS)
4 weeks 18.0±1.8 25.5±1.2 *P< 0.025
5 weeks 16.6±1.1 31.3±1.4 **P< 0.0012
6 weeks 22.6±2.0 28.0±1.8 P< 0.0115(NS)
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Figure 8-24; Using GFAP + cells to detect astrogliosis in the dentate gyrus of the mouse brain.
Micrographs showing GFAP+ cells. A, C, E, G and I display coronal sections from
Psmc1
fl/fl&D0.,,Į:W (wild-type) mice. B, D, F, H and J display coronal sections from
Psmc1
fl/fl&D0.,,Į&UH mutant mice, between 2 and 6 weeks of age in the cortex. K represents
negative control. Arrows refer to the GFAP+ cells. The number of GFAP+ cells increased at 3 weeks
of age and was significantly greater at 4, 5 and 6 weeks of age in mutant mice, compared to control
PLFH6FDOHEDUȝP
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Figure 8-25 Number of GFAP+ cells in wild-type and mutant mice between 2 weeks and 6 weeks of
age in dentate gyrus area.
Bar graph showing GFAP+ cells in the cortex of control and mutant mice. The mean (± SD) number of
GFAP+ cells in control (n=3) or mutant (n=3) mice was determined from three coronal sections per
mouse. Asterisks refer to the results of 2-way ANOVA using original cell counts. There was an
increase in GFAP+ cells in the cortex of mutant mice, whichis significantly different to control mice at
4 and 5 weeks of age, where P*<0.05 and P**<0.001 using an unpaired Student’s test.
Table 8-3 Number of astrocytes in the DG area of the hippocampal
Age Wild-type
mean
Mutant
mean
P value
2 weeks 18.6±0.33 20.0±0.67 P< 0.21 (NS)
3 weeks 20. 7±1.4 23.0±1.8 P< 0. 25 (NS)
4 weeks 23.60±1.4 33.0±1.5 *P< 0.010
5 weeks 23.7±1.5 35.0±1.6 **P< 0.0067
6 weeks 24.5±1.5 25.7±1.8 P< 0.63(NS)
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Comparison of GFAP+ cells in the cortex, CA1 and dentate gyrus
Figure 8-26; Comparison of the number of GFAP+ cells in the cortex, CA1 and dentate gyrus, in wild
type and mutant mice up to 6 weeks of age.
A; GFAP+ cells in the brains of Psmc1fl/fl&D0.,,Į:W wild-type mice in three different areas of the
brain B; GFAP+ cells in the brains of Psmc1fl/fl&D0.,,Į&UH mutant mice in three different areas of
the brain. Data is expressed as mean ± SD, based on three animals per region.
A
B
Chapter 8 Results
207
(IIHFWRI33$5ȖDJRQLVWRQDVWURF\WHSRSXODWLRQLQ'HPHQWLDZLWK
Lewy Body Model
8.6.2.1 Resazurin assay to investigate a non-toxic dose of Rosiglitazone
33$5ȖDJRQLVW
Before investigating the actual effects of the agonist, a preliminary assessment was
carried out to determine the toxic levels of the drug. This was necessary to determine
whether any potential reduction of cell number was not due to toxicity. For this
purpose, 3T3 cells (fibroblast cell line) were grown in a 96-well plate. The cells were
grown to densities of 1K, 5K, 10K, 20K and 50K. This type of cells was chosen
instead of brain tissue, for three reasons. They only require 24 hours to grow; they
grow in a uniform manner, and are highly sensitive to toxic materials. The cells were
grown in several 96-well plates for 24 and 72 hours. The medium was changed every
other day. Rosiglitazone was dissolved in DMSO at the following concentrations:
25µM, 50µM and 100 µM. The medium was removed and the cells were treated with
either Rosiglitazone, or the same concentrations of DMSO vehicle for 24 and 72
hours. Once the time points were reached, Resazurin was added and the plates were
subsequently re- incubated from 2 hours, up to 1 week. The results were analysed by
a FLUOstar Galaxy software reader Results showed that Rosiglitazone was non-toxic
at the concentrations used in this study. Subsequent bar charts represent the cell
viability after treatment with Rosiglitazone, (Figures 8.27 – 8.30).
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The Resazurin assay was performed and fluorescent cells were checked 2 h later. Results of a one way
ANOVA (post-hoc Dunnett’s multiple comparison tests) show that all three concentrations are not
toxic. Data are expressed as mean ± SD (n=6)100% DMSO positive control showed a significant
difference from the control medium, indicated with an asterisk (P < 0.05).
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Figure 8-28 Bar chart shows the results obtained when reading the plates after 2 and 24 hours (24
hours post-seeding).
Cell viability of 3T3 cells was measured after 2 and 24 hours, using the Resazurin assay, after being
WUHDWHG ZLWK 5RVLJOLWD]RQH 33$5Ȗ DJRQLVW IRU KRXUV 7ZR ZD\V $129$ VKRZV DOO WKUHH
concentrations are not toxic. Data are expressed as mean ± SD (n=6. The 100% DMSO positive
control showed significant difference from the control medium indicated with an asterisk (P < 0.001).
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Figure 8-29 Bar chart shows the results obtained after reading the plates after 2 and 4 hr, ( 72 hours
post-seeding).
Cell viability of 3T3 cells was measured after 2 and 24 hours, using the Resazurin assay, after being
WUHDWHG ZLWK 5RVLJOLWD]RQH 33$5Ȗ DJRQLVW IRU K 7ZR ZD\ $129$ VKRZV DOO WKUHH
concentrations are not toxic. Data are expressed as mean ± SD (n=6.100% DMSO positive control
showed significant difference from the control medium, indicated with an asterisk (P < 0.001).
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Figure 8-30 Bar chart shows the results of the survival of the cells after seeding for 72 hours.
Cell viability of 3T3 cells after 1 week incubation was measured using the Resazurin assay, after
EHLQJ WUHDWHG ZLWK 5RVLJOLWD]RQH 33$5Ȗ DJRQLVW IRU K 7ZR ZD\ $129$ VKRZV DOO WKUHH
concentrations are not toxic. All data are expressed as mean ± SD (n=6) 100% DMSO positive control
showed significant difference from the control medium, indicated with an asterisk (P < 0.001).
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 (IIHFWV RI 33$5Ȗ DJRQLVW RQ DVWURF\WH SRSXODWLRQ GXULQJ
astrocyte reactivation
In order to, Organotypic slice cultures of the transgenic mouse model of dementia
with lewy body disease were used to assess the effect of peroxisomal proliferation on
pathological injury in vitro (Bianco, Ridet et al. 2002).
The brains of four day old mice were sliced to a thickness of 350 µm and cultured on
membrane inserts (See materials and methods, page; 148 for details). The
hippocampus was separated from the cortex before culturing organotypic slice
cultures of the mutant and wild-type mice. Four different control brain slice cultures
were used; DMSO vehicle, antagonist (T0070907), antagonist with agonist and
untreated medium. The slices were grown for 6 weeks and treatment was started by
WKH HQG RI WKH ILIWK ZHHN 7KUHH GLIIHUHQW GRVHV RI 5RVLJOLWD]RQH 33$5Ȗ DJRQLVW
were used on the slices: (25µM, 50 µM and 100 µM) every other day for a one week.
The culture medium was changed every other. At the end of the sixth week, brain
slices were fixed and paraffin sections were prepared in preparation for
immunohistochemistry staining.
Since there is no published data on volume-dose ratio in slice culture technique, we
anticipated that 25 µM, 50 µM and 100 µM would be suitable to study organotypic
slice cultures. The doses 50 µM and 100 µM showed a positive result in the cultures,
ZKLOH WKH  0 GRVH GLG QRW :H LQYHVWLJDWHG WKH HIIHFW RI 33$5Ȗ DJRQLVW
rosiglitazone, in the cortex and hippocampal areas after a week of treatment. The
UHVXOWVVKRZHGWKDW33$5ȖDJRQLVWLQKLELWHGDVWURF\WHDFWLYDWLRQLQERWKWKHFRUWH[
and hippocampus of the mutant mice (Figure; 8-35 & 8-40). The number of GFAP
positive astrocytes was significantly decreased in mutant mice slices treated with 100
µM rosiglitazone in both areas. 50 µM rosiglitazone caused decreases in the number
of astrocytes in both the hippocampus (see histograms; 8-36 to 8-39) and the cortex,
yet was only significant compared to controls, in the cortex. (Figures and histograms
8-31 to 8-34).
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,QYHVWLJDWLQJ WKH HIIHFW RI WZR GLIIHUHQW FRQFHQWUDWLRQV RI WKH 33$5Ȗ DJRQLVW
rosiglitazone on astrocyte numbers in cortical organotypic slice cultures of wild-
type mice.
Unt
rea
ted
med
ium
Ctx
/C
M (
Ctx
/C)
P
Tre
ated
wit
h 50
M (
Ctx
/C)
P
Tre
ated
wit
h 10
0
0
5
10
15
20
N
u
m
b
e
r
o
f
G
F
A
P
+
NS
NS
Wt
)LJXUH,QYHVWLJDWLRQRIWKHHIIHFWRIWKH33$5ȖDJRQLVWURVLJOLWD]RQHRQDVWURF\WHQXPEHUVLQ
thje cortex region, using wild-type organotypic slice cultures.
The bar chart represents the varying effects of two different concentrations of rosiglitazone on
astrocyte numbers in organotypic slice cultures of wild-type mouse cortex. Data are expressed as
PHDQ6'6OLFHVZHUHWUHDWHGZLWKHLWKHUȝ0RUȝ0URVLJOLWD]RQH33$5ȖDJRQLVW7KHUH
is no significant difference between the concentrations and controls when analysed using one way
ANOVA with Post-hoc; Dunnett’s multiple comparison test, (n=3) P< 0.05.
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,QYHVWLJDWLQJ WKHHIIHFWRI WZRGLIIHUHQWFRQFHQWUDWLRQVRI WKH33$5ȖDJRQLVW
rosiglitazone on astrocyte numbers in cortical organotypic slice cultures from
mutant mice.
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)LJXUH,QYHVWLJDWLRQRIWKHHIIHFWRIWKH33$5ȖDJRQLVWURVLJOLWD]RQHRQDVWURF\WHQXPEHUVLQ
the cortex region of cultures from mutant mice.
The bar chart represents the varying effects of two different concentrations (50uM and 100uM) of
rosiglitazone on astrocyte number in organotypic slice cultures of mutant mouse cortex. Data are
expressed as mean ± SD. A statistically significant difference was seen between control treated
cultures and rosiglitazone treated cultures when analysed using ANOVA with post-hoc Dunnett;s
multiple comparison test (n=3) *P< 0.01 and ***P< 0.001.
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Figure 8-33 Immunohistochemical staining of GFAP through the cortical region of a brain slice from
a wild-type mouse, treated with 50 and 100 µM rosiglitazone.
Micrographs illustrate the differences in the number of labelled astrocytes when comparing the control
FRQGLWLRQZLWKWKHWZRFRQFHQWUDWLRQVRI33$5ȖDJRQLVWURVLJOLWD]RQH0LFURJUDSKVZHUHFDSWXUHGDW
two magnifications X20 and X50.
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Figure 8-34 Immunohistochemical staining of GFAP through the cortical region of brain slices from a
mutant mouse treated with 50 and 100 µM rosiglitazone.
Micrographs illustrate the differences in the number of labelled astrocytes when comparing the control
FRQGLWLRQ ZLWK WKH WZR FRQFHQWUDWLRQV RI 33$5Ȗ DJRQLVW URVLJOLWD]RQH LQ PXWDQW PRXVH VOLFHV
Micrographs were captured at two magnifications X20 and X50.
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Variations in astrocyte number in cortical region
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Figure 8-35 Percentages change of GFAP+ cells in the cortex of wild type and mutant mouse brain
slices after treatment with 50 µM and 100 µM of rosiglitazone.
TKHEDUFKDUWVVKRZWKHUHGXFWLRQLQDVWURF\WHQXPEHUDIWHU33$5ȖDJRQLVWWUHDWPHQWDVDSHUFHQWDJHRI
the control. Data are expressed as mean ± SD, (n=3). One way ANOVA analysis with post-hoc Dunnett’s
multiple comparison test found no significance in the wild-type animals, however both concentrations on
rosiglitazone caused a significant reduction in GFAP
+
cells compared to controls, (n=3) P< 0.05 and ***P<
0.001.
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,QYHVWLJDWLQJ WKH HIIHFW RI WZR GLIIHUHQW FRQFHQWUDWLRQV RI WKH 33$5Ȗ DJRQLVW
rosiglitazone on astrocyte numbers in hippocampal organotypic slice cultures of
wild-type mice.
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)LJXUH,QYHVWLJDWLQJWKHHIIHFWRIWKH33$5ȖDJRQLVWURVLJOLWD]RQHRQDVWURF\WHQXPEHUVLQWKH
hippocampal region of wild-type mice.
7KH EDU FKDUW UHSUHVHQWV WKH HIIHFWV RI WZR GLIIHUHQW FRQFHQWUDWLRQV  ȝ0 DQG  ȝ0 RI
rosiglitazone on astrocyte numbers in organotypic slice cultures of wild-type mouse hippocampus.
Data are expressed as mean ± SD). One way ANOVA analysis; Dunnett’s multiple comparison test,
(n=3) showed no significance.
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,QYHVWLJDWLQJWKHHIIHFWVRIWZRGLIIHUHQWFRQFHQWUDWLRQVRIWKH33$5ȖDJRQLVW
rosiglitazone on astrocyte numbers in hippocampal organotypic slice cultures of
mutant mice.
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)LJXUH  ,QYHVWLJDWLQJ WKH HIIHFW RI WKH 33$5Ȗ DJRQLVW URVLJOLWD]RQH RQ DVWURF\WH QXPEHUV LQ
hippocampal region of mutant mice slices.
7KHEDUFKDUWUHSUHVHQWVWRWKHYDU\LQJHIIHFWRIWZRGLIIHUHQWFRQFHQWUDWLRQVRIURVLJOLWD]RQHȝ0
DQGȝ0RQDVWURF\WHQXPEHUV LQKLSSRFDPSDORUJDQRW\SLFVOLFHFXOWXUHVRIPXWDQWPLFH'DWD
are expressed as mean ± SD One way ANOVA with Dunnett’s multiple comparison test (n =3)
revealed a significant difference between control and treated cultures, where *P< 0.01 and ***P<
0.001.
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Figure 8-38 Immunohistochemical staining of GFAP in the hippocampal region of slices from wild-
type mouse brain treated with 50 and 100 µM rosiglitazone.
Micrographs show the abundance of labelled astrocytes in untreated slices compared to slices treated
ZLWKWZRGLIIHUHQWFRQFHQWUDWLRQVRI33$5ȖDJRQLVWURVLJOLWD]RQH0LFURJUDSKVZHUHFDSWXUHGDWWZR
magnifications X20 (column A) and X50 (column B).
X50
A B
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Figure 8-39 Immunohistochemistry staining of GFAP in the hippocampal region of mutant mouse
brain slices treated with 50 and 100 µM rosiglitazone.
Micrographs show the abundance of labelled astrocytes in untreated slices compared to slices treated
ZLWKWZRGLIIHUHQWFRQFHQWUDWLRQVRI33$5ȖDJRQLVWURVLJOLWD]RQH0LFURJUDSKVZHUHFDSWXUHGDWWZR
magnifications X20 (column A) and X50 (column B).
A B
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Percentage difference of the number of astrocytes in the hippocampal region of wild-
type and mutant mice
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Figure 8-40 The number of GFAP+ cells expressed in the hippocampal region of wild-type and mutant
mise brains after treatment with 50 µM or 100µM rosiglitazone, expressed as a percentage of control.
TKHEDUFKDUWVKRZVWKHSHUFHQWDJHUHGXFWLRQRIDVWURF\WHQXPEHUDVDUHVXOWRI33$5ȖDJRQLVWWUHDWPHQW2QH
way ANOVA analysis; Dunnett’s multiple comparison test, revealed that although wild-type results showed no
significance, the mutant results indicate significant declines in astrocyte count compared to the controls. Data are
expressed as mean ± SD, (n=3)*P< 0.01 and **P< 0.001.
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 (IIHFW RI WKH 33$5Ȗ DQWDJRQLVW 7 RQ 33$5 Ȗ DJRQLVW
activity.
,W ZDV QHFHVVDU\ WR FRQILUP WKDW 33$5Ȗ DFWLYDWLRQ LV WKH PHFKDQLVP E\ ZKLFK
URVLJOLWD]RQH33$5ȖDJRQLVWUHJXODWHVLWVHIIHFWVLQVOLFHFXOWXUHVRIPXWDQWPLFH
7KHUHIRUH 33$5Ȗ DQWDJRQLVW 7 ZDV DGGHG WR WKH FXOWXUH PHGLXP DV
concentrations of75 µM and 150 µM), 6 hours prior to adding rosiglitazone. When
rosiglitazone was added at concentrations of 50 and 100 µM, the same
concentrations of the antagonist were added, so the slices were exposed to both
UHDJHQWV 7KH UHVXOWV LQGLFDWHG WKDW 33$5Ȗ DQWDJRQLVW KDV DWWHQXDWHG WKH HIIHFW RI
rosiglitazone. The difference in the number of astrocytes between the untreated slices
and antagonist treated slices used in this study was not significant, (Fig 8-41& 8-43).
There was a significant difference (P<0.001) in astrocyte number between the slices
treated with rosiglitazone and controls (Figure 8-42 & 8-44).
,QWHUHVWLQJO\ 33$5Ȗ DJRQLVW KDV VKRZQ D PLQLPDO HIIHFW EHWZHHQ WKH VDPSOHV
prepared from control mice. Therefore, peroxisome proliferators may be considered
as potential therapeutic agents against the disease.
Chapter 8 Results
222
,QYHVWLJDWLQJWKHDELOLW\RIWKH33$5ȖDQWDJRQLVW7LQEORFNLQJ33$5
ȖDJRQLVWDFWLYLW\UHSUHVHQWHGE\DVWURF\WHQXPEHUVLQFRUWLFDORUJDQRW\SLFVOLFH
cultures from wild-type mice.
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Figure 8-41 Bar chart representing the effects of 50 µM and 100 µM rosiglitazone treatment in control
mouse slices, compared with controls and combined agonist/antagonist treatment.
Data are expressed as mean ± SD The number of astrocytes is similar in all four controls.
Rosiglitazone caused no significant difference in GFAP+ cell number, when one way ANOVA
analysis with Tukey’s multiple comparison test, (n=3) was performed, P< 0.05.
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,QYHVWLJDWLQJWKHDELOLW\RIWKH33$5ȖDQWDJRQLVW7LQEORFNLQJ33$5
ȖDJRQLVWDFWLYLW\UHSUHVHQWHGE\DVWURF\WHQXPEHUVLQFRUWLFDORUJDQRW\SLFVOLFH
cultures from mutant mice.
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Figure 8-42 Bar chart represents the effects of 50 µM and 100 µM rosiglitazone treatment in mutant
mouse slices, compared with controls and combined agonist/antagonist treatment.
Data are expressed as Rosiglitazone caused significant decreases in the number of GFAP+ cells at both
concentrations. Administration of the antagonist alongside the agonist, showed no reduction in GFAP+
cell number, indicating that the antagonist blocks the agonist effects. One way ANOVA analysis;
Tukey’s multiple comparison test, (n=3) *P< 0.01 and **P< 0.001 .
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Figure 8-43 Comparison of astrocyte number in the cortex of paraffin sections created from control
and mutant mouse organotypic slice cultures.
Micrographs represent labelled astrocytes in wild-type and mutant mouse brains. Sections were either
untreated or treated with a DMSO control, or with a combination of agonist and antagonist. Slices
were stained with DAB that reacted positively for GFAP+ cells. The images were captured at two
magnifications X20 and X50.
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Figure 8-44 Comparison of astrocyte number in the cortex of paraffin sections created from treated
organotypic slice cultures from wild type and mutant mouse brain.
Micrographs represent labelled astrocytes in wild-type and mutant mouse brains. Sections were
treated with a PPAR-gamma antagonist, or with either 50 µm or 100 µm rosiglitazone. Micrographs
were captured at two magnifications X20 and X50.
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8.6.3 Expressing astrocyte numbers as a percentage of the controls
The number of astrocytes counted in each condition was expressed as a percentage of
the controls (drug free medium). Results were analysed using a one way ANOVA,
with an unpaired student’s t-test.
The results showed that in the mutant mouse slices, there was a dose-dependent
decline in the number of astrocytes compared to controls, when treated with
rosiglitazone, in both the cortex and hippocampus (Figure 8-48). The drugs had no
effect on astrocyte number in the wild-type mouse slices (Figure 8-47).
In the cortex of wild-type mice, the percentage reduction of astrocytes was 4.7 ± 2.1
 DQG     IRU WKH  0 DQG  0 33$5Ȗ DJRQLVW UHVSHFWLYHO\ ,Q
contrast, in mutant slices there was a significant decline in the number of astrocytes;
DQGIRUWKH33$5ȖDJRQLVWDWFRQFHQWUDWLRQVRI0
and 100 µM, respectively (Figure 8-41).
In the hippocampus of wild-type mice, number of astrocytes decreased by 3.0 ± 1.1
 DQG     IRU WKH  0 DQG  0 33$5Ȗ DJRQLVW UHVSHFWLYHO\ ,Q
contrast, the number of astrocytes was significantly lower in the mutant mice; 15.1 ±
DQGIRU WKH33$5ȖDJRQLVW0DQG0 UHVSHFWLYHO\
(Figure 8-42). (Figure 8-42).
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Effect of rosiglitazone on astrocyte number, expressed as a percentage of control in
the cortex and hippocampus of wild-type and mutant mice
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Figure 8-45 The change in the number of GFAP+ cells in 50 µM and 100 µM rosiglitazone treated
mutant and wild-type mouse brain slices, compared to controls.
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Figure 8-46 The change in the number of GFAP+ cells in 50 µM and 100 µM rosiglitazone treated
wild-type and mutant mouse brain slices.
Chapter 8 Results
228
Figure 8-47 Effect of two different concentrations of rosiglitazone on the expression of astrocytes in
the cortex and hippocampus in the brains of wild-type mice.
The micrographs represent immunohistochemistrcayl staining of GFAP+ cells (astrocytes) in the
cortex and hippocampus of wild-type mice after treatment with either 50 µM or 100 µM
URVLJOLWD]RQHLQYHVWLJDWLQJ WKH UHGXFWLRQ RI DVWURF\WHV QXPEHU 7KH 33$5Ȗ DJRQLVW FDXVHG D
reduction in astrocytes number in the cortical areas at a concentration of 100 µM but showed very
little effect in the hippocampus in wild-type brain mice with no effect seens at a concentration of
50µM. Magnification is X20.
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Figure 8-48 Effect of two different concentrations of rosiglitazone on the expression of astrocytes in
the cortex and hippocampus in the brains of mutant mice.
The micrographs represent immunohistochemical staining of GFAP+ cells (astrocytes) in the cortex
and hippocampus of mutant mice after treatment with either 50µM or 100 µM rosiglitazone. The
33$5Ȗ DJRQLVW KDV D SRWHQW HIIHFW RQ DVWURF\WH QXPEHU DW  0 LQ ERWK WKH FRUWH[ DQG
hippocampus. Magnification is X20.
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Discussion9.
9.1 Methodology validation
9.1.1 Assessment of the use of immunohistochemistry to detect astrocytes
There is an increasing number of studies investigating the involvement of astrocyte
proliferation in neurodegenerative disorders (McGeer and McGeer 1995, Bolaños,
Almeida et al. 1997, Chiarugi and Moskowitz 2003). This study has evaluated the
UROHRI33$5ȖDJRQLVW5RVLJOLWD]RQH LQ LQKLELWLQJDVWURF\WHSUROLIHUDWLRQ7R WKLV
end, it was necessary to optimise the tools and materials of the experiments:
- Validating the GFAP in staining the astrocytes.
In this process, several steps were optimised. These include determining the
thickness of the paraffin sections of brain tissues, of which 5, 6, 7, 8, and 10 µm,
were tested. 8 µm was the most suitable, as it showed better stability on the slide
during immunohistochemical staining. Furthermore, this thickness enabled thorough
penetration of the primary and secondary antibodies, particularly the fluorescent
marker, Rhodamine red. If thinner slices were used, such as 5 µM, the brightness of
the fluorescent marker was compromised after a week. A previous study cut 7 – 10
µM slices, which were double-stained successfully using immunohistochemistry. In
this study a 10 µm was used for a double staining which provided enough penetration
(Dickson, Farlo et al. 1988).
- The procedure required an optimised concentration of the GFAP primary antibody,
to yield a good signal-to-noise ratio, prior to Rhodamine Red labelling. The ratio of
the GFAP antibody (Thermo Scientific) to diluent used was 1:150, and this enabled
better detection of astrocytes when compared to another GFAP antibody (Abcam)
whereby the ratio was 1:100. The former yielded better results at a lower cost than
that of the latter. The diluent ratio of 1:150 for the GFAP antibody (Thermo
Scientific) is identical to that used by Ferriero and Aurora (Bergeron, Ferriero et al.
1997, Flax, Aurora et al. 1998). It was different to that of Zhang (2001) who used a
ratio of 1:100.others used 1:50 concentration from Sigma. The use of normal goat
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serum to prevent nonspecific binding was more effective at concentrations of 10%
than 5% if, incubated for 1 hour for paraffin sections. Previous studies indicate
varying concentrations of blocker have been used with paraffin sections. Clark et al.
(2001) used between 3% - 50%, and concluded that concentrations between 3% and
10% were most suitable (Zhang, Wernig et al. 2001, Kaneko, Kawakami et al. 2006;
Ozzello, De Rosa et al. 1987, Clark, Ding et al. 2001). The incubation time was
extended to 3 hours in organotypic slice cultures using 10% bovine serum albumin in
PBS (pH 7.4) to enable better penetration. Three concentrations were used in this
study; 5, 10 and 15%. Of these 10% was the most effective, supported by Gulubova
and Vlaykova (2008) who used 8%(Gulubova and Vlaykova 2008).
It was necessary to use antigen retrieval reagents to break the protein cross-links
formed by fixation, to uncover hidden antigens. This procedure was optimised by
increasing the vapour exposure time from 20 to 45 minutes. Longer exposure times
resulted in a greater improvement in the clarity of the micrograph. Although Fiala,
Liu et al. (2002) heated paraffin brain tissue sections for 25 mins, their tissue
sections were at a thickness of 6 um which could account for the difference in vapour
exposure time (Fiala, Liu et al. 2002).
9.1.2 The development of neurodegenerative diseases in vivo
A transgenic mouse model of neurodegeneration with 26S proteasome dysfunction
was used. The model depends on a system known as Cre-loxP recombination which
allows the DNA modifications to be targeted to a specific cell type. This model
represents Lewy Body Dementia (LBD) in humans.
Paraffin sections were prepared from the brains of Psmc1f1/f1 &D0.,,Į &UH
(mutant) (Ardley and Robinson) and Psmc1f1/f1 &D0.,,Į:W (control) mice.
Immunohistochemistry was performed for GFAP, to determine at which age
astrocyte activation is triggered, following 26S proteasome dysfunction. This is the
hallmark of the onset of neurodegeneration.
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Identification of the age of disease onset was vital so that it could be correlated with
start of drug administration. There was a gradual increase in number of astrocytes in
the mutant mice, compared to the control mice at three weeks of age which became
significant at four and six weeks. This correlates well with the reports of Bedford,
Hay et al. (2008) who used the same mouse model to study 26S proteasomes in
neurodegeneration (Bedford, Hay et al. 2008).
9.1.3 Evaluating the use of organotypic slice cultures study
neurodegenerative diseases
Organotypic slice cultures proved to be a useful tool for understanding aspects of
neurodegenerative disorders. The major advantage is that the glia cell grows in a 3-D
configuration, helping to maintain both microcircuitry connections and relationships
between neurons, glia and the extra cellular matrix (ECM). It closely resembles the
in vivo state and is a relatively simple to prepare. However, the slices need to be
treated carefully to avoid damage to the slice when transferring to the trans-well
inserts.
9.1.3.1 Establishing the optimal conditions when conducting organotypic
Slice Culture
The organotypic slice culture technique is fast becoming the favoured technique to
study many CNS disorders, including neuronal death and other neurotoxic effects,
such as oxidative stress. Nevertheless, slice culture studies present several
difficulties. For example, some researches have experienced issues with secondary-
antibody stimulated neurotransmitter release from astrocytes (Hamilton and Attwell
2010). When comparing the numbers of astrocytes in wild-type and mutant mice,
there was still reliable detection of astrocytes (Section 8.4.2).
In order to determine the most appropriate slice culture conditions, many options
have been considered, as shown in the results chapter (section 8.4.1). Postnatal
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derived slice cultures are commonly used in the study of neurodegenerative disorders
(Zimmer, Kristensen et al. 2000). In this study, slice cultures were derived from early
postnatal mice (P1-P5) which helps to conserve the cytoarchitectural state of the
slice, so that arrangement of cell bodies in their tissue is similar to that of the whole
brain, in vivo (Gähwiler, Capogna et al. 1997)
In the current study, slices were cultured in two different inserts, of which the
membranes were 0.4 µm and 3.0 µm in diameter. The 0.4 µm inserts provide
sufficient oxygen and medium to the slice, as well as providing sufficient adhesion
for the tissues compared to 3.0 µm pore. This is consistent with earlier studies, such
as Lein, Barnhart et al. (2011) who provided the protocol of preparing hippocampal
slices using the same system , and A. Alshehri (2010) who used an organotypic slice
system (PhD thesis 2011) (Lein, Barnhart et al. 2011).
In terms of thickness, it was found that a typical thickness of 200 µm was optimal for
detecting nerve cells under confocal microscope. However, for paraffin or cryostat
sections from organotypic slice cultures, a thickness of 325-350 µm is preferred.400
µm was not ideal, due to hypoxia of the slices, which resulted in the loss of in long-
term cultures. Muller, (1996) reported that long-term culturing requires specific
PHGLXP DQG D ORZHU WHPSHUDWXUH RI LQFXEDWLRQ ZKHUHE\ Û& LV UHFRPPHQGHG
(Muller, Wang et al. 1996).
Others have found 400 µm sections acceptable but it depends on the period of
FXOWXUH 3DUN  UHFRPPHQGHG VOLFHV EHWZHHQ  DQG  ȝP WKLFNQHVV
harvested from rat for ideal conditions for up to three weeks successful culture. In the
present study the period of culture was six weeks, which would limit the use of 400
µm thick slices (Cho, Park et al. 2009).
The above circumstances have led to better survival of tissue culture in older
animals. Nevertheless, the use of neonatal pups instead of adults remains the
favourable option. However in situations where an adult brain slice (neuronal cell
bodies) is desirable then it would be possible to use these specialised conditions.
Cryostat sections were created at thickness 8µm using coated glutamate slides, which
was ideal for this study, while others used 12µm thickness (Gao, Stieger et al. 1999).
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9.1.3.2 Astrocytes nuclei modification in organotypic slice cultures
As another aspect of this work, it was observed that nuclei in the astrocytes of the
brains of mutant animals were smaller and more oval, compared to those in the wild-
type animals, which were larger and round. It was hypothesised that the astrocytes in
mutant mouse brain should have undergone hypertrophy and hyperplasia. It has been
suggested that cell division is dependent on nuclear size (Webster, Witkin et al.
2009). Villena et al., (1997) suggested that nuclei did not shrink, but rather adapted
to conditions, causing small nuclei to grow faster, until a suitable ratio is achieved
(Villena, Diaz et al. 1997). In reference to Figure 8.13 the nuclei return to their
normal size in the fifth week. An extra week was required in the organotypic slices
cultures (Figure 8.14). This finding may support the notion raised by Bedford. Hay et
al. (2008), noting that brains of mutant pups were smaller than those of the control
pups (Bedford, Hay et al. 2008).
Chapter 9 Discussion
235
3HUR[LVRPHSUROLIHUDWRUDFWLYDWHGUHFHSWRUȖDJRQLVWV
5RVLJOLWD]RQH3HUR[LVRPHSUROLIHUDWRUDFWLYDWHGUHFHSWRUȖDJRQLVW
may be effective in the treatment of human diseases
Evidence indicates that astrocyte activation is implicated in the pathogenesis of some
neurodegenerative disorders. Astrocytes undergo changes during the process of
neurodegeneration, including altered morphology, gene expression and cellular
function. These can be collectively encompassed by the term ‘reactive astrogliosis’.
However, it is s still not fully understood when and how proliferation arises in the
developmental course of a neurodegenerative disorder (Sun, Xu et al. 2004).
$EROLVKLQJWKHDFWLRQVRID33$5ȖDJRQLVW
Many studies have implicated the T0070907 antagonist, as it potently abolishes
33$5ȖDFWLYLW\7KH33$5ȖDQWDJRQLVW7KDVWKHRSSRVLWHHIIHFWWR33$5
Ȗ DJRQLVWV DV LW FDXVHV DQWLSUROLIHUDWLYH GRVHUHVSRQVH HIIHFWV 0RVW UHVHDUFKHUV
emphasize that it is necessary to have a higher antagonist concentration than agonist,
in order to acquire a revoked effect (Burton, Goldenberg et al. 2008). The antagonist:
agonist ratio is dependent on several conditions: the site of administration (i.e. oral or
i.p dose), whether the study is in vitro or in vivo, and the origin of the tissue/cells.
In this study, the ratio of antagonist: agonist was (1:0.7) which was effective in
reversing the effects of the agonist. Antagonist T0070907 abolished the effect seen
with rosiglitazone treatment alone. The concentration used is lower than that in
another study in vivo, whereby the ratio was 0.1:1.5 (Adabi Mohazab, Javadi-Paydar
et al. 2012).
,WKDVEHHQUHSRUWHGWKDW±0RIWKH33$5ȖDQWDJRQLVWZHUHXQDEOHWRLQKLELW
WKHDQWLLQIODPPDWRU\HIIHFWVVHHQZLWK0RIWKH33$5ȖDJRQLVWURVLJOLWD]RQH
(Brody, Mandelkern et al. 2004, Ray, Akbiyik et al. 2006).
Lee et alLGHQWLILHGDSRWHQWRI33$5ȖIXQFWLRQZLWK7DV33$5Ȗ
antagonists. She found that effects of rosiglitazone were blocked by 50% upon
administration of T0070907
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For optimal effects, an antagonist should be given prior to the agonist, however this
is also subject to tissue/cell type. For example, in isolated glia cells in vitro, the
T0070907 antagonist was added 30 minutes prior to the agonist; to be effective in
vivo, it was necessary to add the antagonist 24 hours earlier (Ou, Zhao et al. 2006).
As the organotypic slice cultures were thicker in this study, the antagonist was added
6 hr prior to the agonist, as well as using agonist treatment.
'RVHGHSHQGHQWHIIHFWVRIURVLJOLWD]RQHD33$5ȖDJRQLVW
,W ZDV QHFHVVDU\ WR IRFXV RQ WKH UROH RI 33$5Ȗ DJRQLVWV LQ UHGXFLQJ DVWURF\WH
proliferation, as this may contribute to knowledge for the future therapy of
QHXURORJLFDO GHJHQHUDWLRQ 5RVLJOLWD]RQH LV DQ DJRQLVW RI 33$5Ȗ DOVR NQRZQ DV
thiazolidinedione (TZD). It is classified as a non-steroidal anti-inflammatory
compound and is widely used in recent neurodegenerative experiments. Few studies
have addressed the development of therapeutic strategy, with regards to inhibiting
astrocyte activation in an attempt to reduce inflammation and neurotoxic effects in
the CNS.
0RUH UHFHQWO\ 33$5Ȗ DJRQLVWV KDYH EHHQ VKRZQ WR DIIHFW  SURGXFWLRQ RI SUR
inflammatory molecules by primary microglia and astrocytes (Lovett-Racke, Hussain
HWDO6WRUHU;XHWDO/LNHZLVH33$5ȖDJRQLVWVKDYHDOVREHHQVKRZQ
to reduce disease pathology in animal models that previously presented
neurodegenerative disorders (Racke and Drew 2008).
The mouse model chosen for this study has a proteasome deletion that causes
neurodegeneration. In this model, astrocyte number increases in response to the
neurodegenerative disorder. In this study, the finding that astrocyte activation was
high at week 4 was interpreted as proteasome deletion in neurons, causing neuronal
death. This is consistent with the findings of Bedford, (2008).At week 4, the neurons
may send a signal to astrocytes, causing them to enter proliferation (Bedford, Hay et
al. 2008). Another possibility is that as a result of neuronal death, the astrocytes
increase in number to fill the gaps left by the neurons.
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Three different concentrations of rosiglitazone were administered. The high
concentrations (50 µM and 100 µM) have shown significant reduction in astrocyte
DFWLYDWLRQLQPXWDQWDQLPDOV,WLVNQRZQIURPWKHOLWHUDWXUHWKDW33$5ȖUHJXODWHV
gene transcription heterodimers with the retinoic acid receptor (RXR), by binding to
a precise site of DNA sequences, termed peroxisome proliferator response elements
335(V7KHPHFKDQLVPRI33$5ȖDJRQLVWVUHO\RQWKHLQFUHDVHLQWKHELQGLQJRI
33$5ȖWR335(¶VUHVXOWLQJLQHQKDQFHGWUDQVODWLRQDODFWLYLW\RI33$5Ȗ<L3DUN
et al. 2007).
It was expected that rosiglitazone would reduce proliferating cell number in brain
slices, as shown by GFAP+ cells staining. Rosario Luna et al. (2005) reported that
33$5Ȗ UHFHSWRU SOD\HG D YLWDO UROH LQ WKH UHJXODWLRQ RI FHOOXODU SUROLIHUDWLRQ DQG
inflammation. The majority of the results from the present study agreed with this, as
it showed that rosiglitazone did alter proliferation in the hippocampus. This may be
consistent with another finding, that a 50 µM dose did not cause a reduction in
proliferation in the hippocampus, while increasing the dose to 100 µM, caused a
significant effect. The number of astrocytes was decreased and statistically different
in mutant brains, compared to wild-type brains in both the cortex and hippocampus.
However, lower doses of 25 µM had no effect on the astrocyte number in mutant
mice in either regions (Luna-Medina, Cortes-Canteli et al. 2005).
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9.3 Conclusion
Peroxisome proliferator-activated receptor gamma is protective against
neurodegeneration, by its action in preventing astrocyte proliferation. Rosiglitazone
DFWVDVDQDJRQLVWIRU33$5ȖDQGLQKLELWVVHFUHWLRQRISURLQIODPPDWRU\PROHFXOHV
(Sastre, Klockgether et al. 2006). This effect could be reversed by administration of
the antagonist T0070907. In the current study, it was hypothesized that treatment
ZLWK WKH 33$5Ȗ DJRQLVW URVLJOLWD]RQH FRXOG EH XVHG WR LQKLELW DVWURF\WH
proliferation, and therefore enhance neuro-protection against neurodegenerative
disorders. Organotypic slice cultures were treated with 25 µM, 50 µM and 100 µM
doses of Rosiglitazone after five weeks of culture for 7 days. This experiment
VKRZHG D WKHUDSHXWLF HIIHFW RI URVLJOLWD]RQH DIWHU LW ZDV ERXQG WR 33$5Ȗ
Rosiglitazone is capable of reducing astrocyte proliferation, which could reduce the
effects of neurodegeneration in this particular model. The current study produced
VLPLODUILQGLQJVWRVWXGLHVWKDWKDYHDOVRXWLOL]HGWKLV33$5ȖDJRQLVW)RUH[DPSOH
rosiglitazone has also been shown to prevent cognitive impairment by inhibiting
astrocyte activation and oxidative stress in a rat epilepsy model of neurodegenerative
disease (Chuang, Lin et al. 2012). Similar to the current study it was concluded that
WKH 33$5Ȗ DJRQLVW FDXVHG GHFUHDVHG QXPEHUV RI LPPXQH FHOOV DVWURF\WHV
oligodendrocytes, neurons and microglia and may therefore be effective as a
therapeutic drug used to inhibit neurodegeneration (Chuang, Lin et al. 2012).
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General discussion10.
Peroxisome proliferators are a class of chemicals that have diverse effects in rats and
mice including the induction of increased DNA synthesis and peroxisome
proliferation. These chemicals act through ligand activation of nuclear membrane
receptors termed ‘peroxisome-proliferator-activated receptors’ (PPARs), which
themselves act as nuclear transcription factors. This project focused on an
investigation of the biological roles of PPs, covering two aspects: a follow on from
previous work to investigate the role of the PPs in the liver growth, and investigation
of the role of this chemical class in the treatment of neurodegeneration. This
ironically involved an examination of both the detrimental aspects of PPs in causing
disease, but also the beneficial aspects in their possible use for medical treatment.
10.1 Role of peroxisome proliferators in liver growth
Peroxisome proliferators include herbicides, plasticisers, hypolipidemic drugs and
synthetic fatty acids. However, the mechanism of action of increased hepatocyte
growth is not currently understood. It was hoped that gaining understanding relating
to the mechanism by which increased liver growth is induced by PPs in rodents
would hopefully provide insights into how natural liver growth occurs and have
medical benefits for human health if the mechanism of PP toxicity can be overcome.
Knowledge gained from the mechanism of PP activation might also then be applied
to other chemical carcinogens. Experimental work was undertaken to determine if
the same, of different hepatocytce cells, were induced to divide during the two
rounds of cell division following ciprofibrate treatment revealed. The two
histochemical stains used were EdU and BrdU, which are both base-pair analogues
that stain nuclei undergoing DNA replication.
The results showed that the cells undergoing division at 24 hr were not related to
those that undergoing division at 48 hr following repeat treatment with ciprofibrate.
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This is of medical significance as it suggests that there are not hepatic cells that are
especially sensitive to repeated PP treatment, but that different cells can respond and
therefore there is a more general risk of increased cell division and carcinogenesis
from such non-genotoxic carcinogenic compounds.
In related studies, previous work had investigated the effects of the genotoxic
carcinogen; cyproterone acetate (CPA) on hepatocyte growth of male rats treated
with 100 mg/kg CPA. In the present study female rats were treated with CPA, to
firstly evaluate whether differences in labelling indices were present compared to
male rats. Female F-344/NHsd rats, aged 14-15 weeks, were treated at time Ø with
CPA and then injected i.p with BrdU at 22 hr, and rats were killed 2 hr later. Results
showed that the female rats were found to indeed have a considerably higher
labelling index (38.9%) compared to male rats (6%), confirming the results of Amer
(2011). This finding suggested that upregulation of gene expression in female rats
should be much higher as well, which might provide an exciting opportunity to
identify sets of genes involved in carcinogenic response, with overlap with those
involved PP response, including those of possible low transcript number.
This study then made a preliminary investigation of whether genes induced by
chemical treatment are largely the same or different between ciprofibrate and CPA
i.e. whether they might share some underlying mechanisms of action. This followed
previous work undertaken by Amer (2011) at Nottingham who used microarray
analysis to identify global sets of genes that are upregulated by CPA and ciprofibrate
treatment. Due to time restriction only preliminary work could be undertaken using
real-time PCR methodology to study changes in expression in three target genes,
Scd1, Ccnd1 and G0s2 (together with the CY3A1 control) previously identified by
Amer (2011). Of these genes, only Ccnd1 showed a similar pattern of induction
between CPA and ciprofibrate. Thus, overall there was little evidence of shared
pathways between CPA and ciprofibrate activity and therefore different mechanism
of cell toxicity are likely to be present, albeit with some potential overlap as shown
by the Ccnd1 gene. So to conclude, although ciprofibrate and CPA are chemicals
which both cause liver growth and possible cancer, they appear to do so by
completely difference mechanisms.
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10.2 Role of peroxisome proliferators in neurodegenerative disorders
The second part of research project presented in this thesis aimed to use a mouse
model to investigate the role of peroxisome proliferators (primarily rosiglitazone) in
causing neurodegenerative disorder, using Parkinson's disease (PD) as an example.
Organotypic slice cultures were used to discover whether rosiglitazone is involved in
inhibiting astrocytes activation. To this end, a series of experiments were performed
to optimise the tools and materials for the experiments in order to test the hypothesis
that PPs have the ability to reduce astrocyte proliferation.
Studies were made using an organotypic slice system, an animal model system which
allowed neurodegeneration progression to be monitored in vitro in particular, this
system enabled a closed study to be made of the effect of rosiglitazone in reducing
the progression of disease, by tracking the evolution of astrocytes activation. Given
that PPARs bind DNA as heterodimers with RXR, it was considered possible that
WKHUHIRUH 33$5Ȗ DFWLYDWLRQ E\ DQWLLQIODPPDWRU\ GUXJ OLJDQGV PLJKW UHJXODWH WKH
activation of macrophages and astrocytes.
Preliminary results showed that development of disease was apparent at 4, 5 and 6
weeks of growth in organotypic slice cultures harvested from brain mutant pups.
Based on this disease progression it was decided to commence drug treatment of the
agonist rosiglitazone at 5 weeks of age, with the drug being given for 7 days. This
was found to result in extensive astrogliosis activity in both areas of interest, namely
the hippocampus and cortex.
From the literature review chapter, it is known that the dementia with lewy bodies is
DVVRFLDWHG ZLWK SURWHDVRPH 6 GHOHWLRQ 2QH SRVVLEOH VFHQDULR LV WKDW 33$5Ȗ
agonists might alter/enhance proteasome 26S activity in such a way that this results
in a reduction in proliferation of astrocytes in both the hippocampus and cortex
regions, compared to wild-type mice. This was consistent with observations from the
present study that treatment with rosiglitazone resulted in a significant reduction in
the number of astrocytes at concentrations of both 50 and 100 µM. This finding
suggests that the PP rosiglitazone can be considered for potential use as a therapeutic
drug to inhibit neurodegeneration.
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Future work11.
11.1 Studies on PP and CPA toxicity and mode of action
Due to time restrictions and changes in supervision, only a very limited pilot study of
changes in expression in three target genes (together with the CY3A1 control) in
response to CPA treatment was made. But ideally a far larger number of genes
should be assayed to determine whether similar sets of genes are induced in female
rate liver cells by the genotoxic carcinogen cyproterone acetate (CPA) as are induced
by ciprofibrate. This work might be achieved for instance by RNA seq studies.
Should it then be found that particular genes were identified with clear differential
expression following treatment by both carcinogens, then this raises the question of
what is their function and how do they work? Is the protein associated with the
RNA? To investigate these questions it would be worthwhile exploring the
possibility of using a knock out mouse which lacks that gene to determine possible
physiological effects (Aleshin, Grabeklis et al. 2009).
11.2 Studies on role of PPs in neurodegenerative disorders
In this part of study we wished to use in vitro methods, due to the benefits of this
technique in reducing the number of animals used and increasing the ability to
control experimental parameters. It is also important to compare the results with
those in vivo to confirm the relevance of the results in a whole animal
In this work, we have demonstrated the neuroprotective potential of a peroxisome
proliferator activated receptor gamma agonist, rosiglitazone in an ex vivo model of
dementia with lewy body model. It would be beneficial to further these studies by the
administration of rosiglitazone to mice in vivo and assess its beneficial effects. In
addition, it would be important to include other neurodegenerative disease models
such as Alzheimer disease, which will also benefit from rosiglitazone treatment
where the focus is on inflammatory processes, such as microgliosis.
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)XUWKHUVWXGLHVDUHUHTXLUHGWRHOXFLGDWHWKHPROHFXODUPHFKDQLVPE\ZKLFK33$5Ȗ
agonist attach to the proliferation sites of astrocytes.
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Appendixes13.
Table(1) Immunohistochemistry technique for BrdU paraffin sections.
No. Solution Time if the number of the slides are small
you may
give them less timing at stage 17-30
1- Xylene I 5 min after heating in microwave
(40°C
for 2 min)
2- Xylene II
3- ethanol 100% 8 min.
4- ethanol 70% 4 min.
5- ethanol 50% 3 min.
6- Distal H2O 2 min.
7- H2O2 ( 1) 15 min.
8- PBS (2) 5 min.
9- PBS 5 min.
10- Citric acid (ph 6)(3) 10 min. at 3 (warm)
11- PBS 5 min.
12- BSA 5% (4) 15min.
13- Primary antibodies (5) 45 min.1ml lab dilute+1 µL anti-pri
BrdU14- Distal H2O 5 min.
15- Secondary antibodies(6) 30 min. 2 µL:100 µL
16- PBS * 9 min.
17- Staining solution DAB(7) 8 min.
18- Distal H2O 3 min.
19- Haematoxyline sol.(8) 30 sec.
20- Tape water 3 min.
21- Acid alcohol(9) 5 sec.
22- Rinse in running Tape water 1 min.
23- Ammonia in water(10) 1 sec.
24- Tape water 3 min.
25- ethanol 50% 2 min.
26- ethanol 70% 2 min.
27- ethanol 95% 2 min.
28- ethanol 100% 2 min.
29- Xylene 2 min.
30- Mount with DPX
31- Put cover slide
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Table (2) Histochemistry technique for Hoechst dye and EdU paraffin sections.
No. Solution Time if the number of the slides
are small you may give them less
timing at stage 17-30
1- Xylene I 5 min after heating in microwave
(40°C for 2 min)
2- Xylene II 5 min
3- Ethanol 100% 8 min.
4- ethanol 70% 4 min.
5- ethanol 50% 3 min.
6- Distal H2O 2 min.
7- H2O2 ( 1) 15 min.
8- PBS (2) 5 min.
9- 1 X Hoechst (500-1000) µL per slide - in dark 5 min.
10- PBS 5 min
11- PBS 5 min.
12- H2O distal 3 min
13- ethanol 50% 1 min.
14- ethanol 70% 1 min.
15- ethanol 95% 1 min.
16- ethanol 100% 1 min.
17- Xylene 1 min.
18- Mount with DPX
19- Put cover slide
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Table (3) Immunohistochemistary technique for BrdU paraffin sections and histochemistry
for EdU paraffin section.
No. solution Time if the number of the slides are
small
you may give them less timing at stage
1- Xylene I 5 min after heating in microwave (40°C
for 2 min)2- Xylene II
3- ethanol 100% 8 min.
4- ethanol 70% 4 min.
5- ethanol 50% 3 min.
6- Distal H2O 2 min.
7- H2O2 ( 1) 15 min.
8- PBS (2) 5 min.
9- PBS 5 min.
10- Citric acid (ph 6)(3) 10 min. at 3 (warm)
11- PBS 5 min.
12- BSA 5% (4) 15min.
13- Primary antibodies (5) 45 min.
14- Distal H2O 5 min.
15- Secondary antibodies(6)* 30 min.
16- PBS ** 9 min.
17- Staining solution DAB(7) 8 min.
18- Distal H2O 3 min.
19- Haematoxylin sol.(8) 30 sec.
20- Tape water 3 min.
21- Acid alcohol(9) 5 sec.
22- Rinse in running Tape water 1 min.
23- Ammonia in water(10) 1 sec.
24- Tape water 3 min.
25- PBS 5 min
26- 3% BSA in PBS(1) use pipette 10 min
27- Click-iT reaction cocktail (250µl/ 1 slide) 30 min (room temp.) in dark
28- 3% BSA in PBS(II) wash use pipette 5 min
29- PBS I 5 min
30- I X Hoechst dye (250 µl per slide) 30 min (in dark)
31- PBS I 5 min
32- PBS II 5 min
33- H2O distal 3 min
34- Mount with DPX
35- Put cover slide Over night
*remove the mark at this point 5 hrs
**put on a shaker
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Table (4): Immunohistochemical staining of paraffin sections. Mouse primary
antibody; mouse on mouse (M.O.M) kit-Vector labs PK-2200
No. Solution Time
if the number of sides are small you may give them
less timing -At stage 17-30
1- Xylene I 15-20 min before de-wax and rehydrate
in oven or heating in microwave (40 º C
for 2 min)
2- Xylene II
3- Ethanol 100% 10 min
4- Ethanol 95% 10 min
5- Ethanol 70% 10 min
6- Running water (gently) 10 min
7- Place in hot antigen retrieval solution at~100 ºC (PH 6) 20 min
8- Remove beaker to a shaker set 20 min
9- Wash in running water (gently) 10 min
10- Incubate in 3% H2O2 (5ml H2O2+45ml methanol) in a coplin jar 5 min
11- PBS** 5-10 min
12- I drop of M O M Ig blocking reagent in 1.25ml PBS 30 min-1 hrs incubate in humid chamber
13- PBS** X3 5-10min
14- Working solution of M O M diluent 5 min
15- Primary antibody 1 µ1/100 µ1 of M O M diluent 30min-1hrs in humid chamber
16- PBS** X3 5-10 min
17- Secondary antibody (1 µ1/250 µ1 of M O M diluents) 30min-1hrs in humid chamber
18- PBS**X3 5-10 min
19- ABC reagents (1 drop of A to 1.25ml PBS mix gently then
add 1 drop of B and mix gently)
15 min in humid chamber
20- PBS** 5-10 min
21- DAB reaction (3, 3’ diaminobenzidine) 30 sec-10 min / in coplin jar
22- Running water (gently) 10 min
23- Harris haematoxylin 5 min
24- Rinse in running water until water runs clear -
25- Dip in 1% acid alcohol (Hcl in 70% ethanol) 15 sec
26- Rinse in running water tape water 5 min
27- Dehydrate: 70% ethanol 10 sec
28- Ethanol 95% 10 sec
29- Ethanol 100% 10 sec
30- Ethanol 100% 10 sec
31- Xylene 5 min
32- Mount with DPX 1 min
33- Put cover slide
* Remove the mark at this point
* * put on a shaker
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Table (5): Immunohistochemical staining of paraffin section anti-GFAR with fluorescent
rhodamine red tm – X goat anti-mouse igG: marken
NO. Solution Time
1- Dewax and rehydrate -
2- Xylene I 10 min
3- Xylene II 5 min
4- Ethanol 100% I 8 min
5- Ethanol 100% II 4 min
6- Ethanol 95% 5 min
7- Ethanol 70% 5 min
8- Running water (gently) 5 min
9- Wash in PBS I 5 min
10- Wash in PBS II 5 min
11- Wash with PBS (use pipette gently) 1-2 min
12- * Antigen retrieval steamer 40 min+20 min cool down
13- **Block with 5% normal goat serum (NGS) with 0.5%
triton X-100 in PBS
2 hrs incubate in humid
chamber at room temperature
14- PBS X 2 5-10 min
15- PBS (use pipette gently) 1-2 min
16- ***Incubate primary antibody 1 µl/100 µl in solution
of 2% (NGS) in PBS
Overnight (18 hr) at 4oc in
humid chamber
17- PBS X 2 5-10 min
18- PBS (use pipette gently) 1-2 min
19- Incubate secondary antibody , Rhodamine red goat
anti-mouse 1µ /1000 µl of 2% (NGS) in PBS
1 hrs in humid chamber at
room temperature. (with little
boiling water)
20- PBS X 3 5-10 min
21- PBS (use pipette gently) 1-2 min
22- Incubate with DAPI stain 20 min at room temperature
23- Wash in PBS X 2 5 min
24- PBS (using pipette gently) 1-2 min
25- Wash with sterile distal water 2 min (in hood)
26- Drop of mounting -
27- Cover slip -
28- Sealed with nail varnish -
*cooking pot with water and place the beaker of antigen retrieval in it until it reaches the temperature of antigen
retrieval solution up to 100oc then places the slides for 40 min as above.
**Prepare 0.25% triton in PBS mix well the add 5% of NGS.
***2 µl of NGS in 982 µl of PBS (100 µl total)
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Table (6): immunohistochemistry staining of paraffin section. Mouse primary antibody;
mouse on mouse (M.O.M) kit-vector labs PK-2200. 14.08.12
NO. Solution Time
1. Xylene I 10 min
2. Xylene II
3. Ethanol 100% 10 min
4. Ethanol 95% 10 min
5. Ethanol 70% 10 min
6. Running water (gently) 10 min
7. Place in hot * antigen retrieval solution at~100o c
(PH6)
20 min
8. Remove beaker to a shaker set 20 min
9. Wash in running water (gently) 20 min
10. Incubate in 3% H2O2 (5ml H2O2+ 45ml methanol)
in coplin jar-wash in tap water running
5 min
11. PBS** 5-10 min
12. 1 drop of M.O.M Ig blocking reagent in 3.6µl in
100 µl 1.25 PBS /150µl/9µl
30 min- 1hrs incubate in
humid chamber /125µl
400µl PBS + 14.5µl
13. PBS** X3 5-10 min
14. ** working solution of M O M diluent 5 min
15. Primary antibody 1 µl/100 µl of M O M diluent 1hrs in humid chamber
16. PBS** X3 5-10 min
17. Secondary antibody
(1 µl/250 µl of M O M diluents)
1hrs in humid chamber
18. PBS** X3 5-10 min
19. ABC reagents (1 drop of A to 1.25ml PBS mix
gently then add 1 drop of B and mix gently)
30 min
in humid chamber
20. PBS** 5-10 min
21. DAB reaction (3,3’ diaminobenzidine) 30 sec-10 min/in coplin jar
22. Running water (gently) 10 min
23. Harris haematoxylin 5 min
24. Rinse in running water until water runs clear -
25. Dip in 1% acid alcohol (HCL in 70% ethanol) 15 sec
26. Rinse in running tap water 5 min
27. Dehydrate: 70% ethanol 10 sec
28. Ethanol 95% 10 sec
29. Ethanol 100% 10 sec
30. Ethanol 100% 10 sec
31. Xylene 5 min
32. Mount with DPX 1 min
33. Put cover slide
*sodium citrate retrieval/ 10mM sodium citrate buffer PH 6:
2.35g sodium citrate in 800 ml of water - add 400 µl of tween-20 (0.05%).
**prepare enough M O M diluent for primary and secondary antibody steps [80 µl of protein concentrate in1ml
PBS]
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Table (7): Immunohistochemical staining of organotypic slice cultures
No. Solution Time
1. Wash with PBS (use pipette) 10 min
2. Permeabilize in 1% triton X-100 in PBS Overnight at 4ºc
3. Wash with PBS (use pipette) 10 min
4. Block with 20% bovine serum albumin with 0.1% triton
X-100 in PBS
1.30hrs incubate in humid
chamber at room temperature
5. PBS X2 5-10 min
6. Incubate primary antibody 1µl/100µl in solution of 1%
(NGS) with 0.1% triton X-100 in PBS
Overnight (16-18hr) at 4ºc in
humid chamber
7. Wash with PBS 1-2 min
8. Incubate secondary antibody red goat anti-mouse
(1µl/400µl of 5% (NGS) with 0.5% triton -100 in PBS)
3hrs in humid chamber at room
temperature
9. PBS (use pipette gently) 10 min
10. Incubate with DAPI stain 45 min at room temperature
11. Wash with PBS (use pipette gently) 10 min
12. Drop 5µl of mounting medium -
13. Cover slip -
14. Sealed with nail varnish -
15. Stored in the dark At 4ºc for 12hr
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Table (8): Immunohistochemical staining of organotypic slice cultures
No. Solution Time
1. Wash with PBS X3 10 min
2. Permeabilize in 0.5% triton X-100 in PBS 1hr incubate in humid chamber
at room temperature
3. Block with 10% bovine serum albumin with 0.5% triton
X-100 in PBS
Overnight at 4ºc
4. PBS X3 5-10 each time
5. Incubate primary antibody 1µl/150µl of 10% (NGS) with
0.5% triton-X100 in PBS (200µl for each well) 100µl/1ml
(NGS)
Overnight (6-18hr) at 4ºc in
humid chamber
6. Wash with PBS 20 min each time
7. Incubate secondary antibody-rhodamin red goat anti-
mouse (1 µl/200 µl of 10% (NGS) with 0.5% triton-X100
in PBS)
3hrs in humid chamber at room
temperature
8. PBS X3 20 min each
9. Incubate with DAPI stain 20 min at room temperature
10. Wash in PBS X3 10 min each time
11. Drop 5 µl or so of mounting medium -
12. Cover slip -
13. Sealed with nail varnish -
14. Stored in the dark At 4ºc for 12hr
15. All steps from 1-10 will perfume in wells inserts -
